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1.1. THE STEROID HORMONE RECEPTOR FAMILY 
Steroid hormones are widely distributed, cholesterol-derived, small hydrophobic molecules. 
They mediate a variety of biological functions, including tissue development, differentiation 
and homeostasis. Mammalian steroid hormones (androgens, glucocorticoids, 
mineralocorticoids, estrogens and progestins) exert their function by binding to the 
corresponding intracellular steroid hormone receptor. This binding triggers a complex set of 
molecular events, including protein-protein and protein-DNA interactions. 
H 
o 
CYTOPLASM 
NUCLEUS 
~-~+-----~ ~ 
HR ~
HRE / 
RNA /' " 
PROTEIN 
Figure 1.1. A basic model for activation of gelle expressio1l by steroid hormoJles. H: steroid 
hormone, HR: steroid hormone receptor, HRE: hormone response elemellf, TIC: transcription 
illUiatioJl complex. 
As early as 29 years ago, Jensen et aJ. (1968) proposed a model for the action of steroid 
hormones, that is basically still valid today. According to this model (see Figure 1.1), 
circulating steroids enter target cells by diffusion through the cell membrane. In the cell they 
interact with their cognate receptors. UpOll ligand binding the receptor is activated and 
converted into a tight nuclear binding state. In the nucleus it regulates transcription by 
binding to the hormone response element (HRE) in the regulatory region of target genes, 
thereby activating RNA polymerase II in the transcription initiation complex (TIC). 
According to more recent studies the original model has been refined and in some cases 
modified, as will be outlined below. 
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Cellular concentrations of steroid hormone receptors are very low, and therefore they are 
not easy to study. The molecular cloning of cDNAs encoding the steroid hormone receptors 
was an essential contribution to the current knowledge on transcriptional regulation by steroid 
hormones. 
1.1.1. NUCLEAR RECEPTORS 
The steroid receptors are members of the family of nuclear receptors, that comprises over 
60 different proteins in vertebrates and insects. Elucidation of the primary structure of the 
nuclear receptors provides understanding of their modular structure and functional domains. 
All receptors are characterized by a central DNA binding domain (DBD), that targets the 
receptor to specific DNA sequences (HREs). The DBD is composed of two highly conserved 
zinc coordinating domains. The N-terminal modulating domain is highly variable in size and 
in amino acid composition by comparing the various receptors, and contains transactivation 
functions. The C-terminal part of the receptor encompasses the ligand-binding domain 
(LBD), that is partially conserved between the various family members. 
Phylogenetic studies indicate a common ancestor of nuclear receptors (Amero et al. 1992, 
Laudet et al. 1992, Detera-Wadleigh & Flemming 1994, Mangelsdorf et al. 1995). In this 
view, the individual receptors originate from a single precursor gene by processes of gene 
duplication, rearrangement, mutation, exon shuffling and transposition (O'Malley 1989, Dorit 
et al. 1990, Amero et al. 1992, Keese & Gibbs 1992, Laudet et al. 1992). Based upon 
phylogenetic analysis, the nuclear receptor family can be divided into three major subfamilies 
(Gronemeyer & Laudet, 1995). Subfamily I contains as best defined members the receptors 
for thyroid hormone (TRCI and (3), vitamin D (VDR), retinoic acid (RARCI, (3 and 'Y), the 
retinoic X receptors (RXRCI and (3), the peroxisome proliferator activated receptors (PPARCI, 
(3 and 'Y), and the Drosophila ecdysone receptor (EcR). Subfamily II contains the majority 
of the so called orphan receptors. For orphan receptors, the ligands have not been identified 
as yet, or they are active without specific ligand binding. Subfamily III encompasses the 
steroid hormone receptors except for EcR. 
Starting with the human glucocorticoid receptor (GR) (Hollenberg et al. 1985, Miesfeld 
et al. 1986) and estrogen receptor (ER) (Green et al. 1986, Greene et al. 1986) the cDNAs 
of all human steroid hormone receptors were cloned [progesterone receptor (PR) (Mishari 
et al. 1987); mineralocorticoid receptor (MR) (Arriza et al. 1987) and the androgen receptor 
(AR) (Chang et\~l. 1988, Lubahn et al. 1988a, Trapman et al. 1988)]. Surprisingly, ten years 
after the cloning of the ER (now renamed ERCI), the isolation of a second ER cDNA, ER{3 
was reported (Kuipe\ et al. 1996, Mosselman et al. 1996). The schematical organization and 
the structural homology between the various domains of the different steroid receptors are 
depicted in Figure 1.2. With the exception of ER, the DBDs of the steroid receptors show 
more than 75 percent homology, whereas the homology between the LBDs is approximately 
50 percent. At the C-terminal end the ERs are slightly longer. 
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N - TERMINAL DOMAIN DBD LBO 
AR • ~ 548 612 662 910 
GR <15 1771 50 
419 483 530 777 
MR <15 1771 51 
601 665 738 984 
PR <15 lao I 55 
565 629 685 933 
ER-C\ <15 1571 20 
183 247 313 553 597 
ER-B 1<15 159 1 19 
103 168 259 457 484 
Figure 1.2. Stnlctllrai homology of steroid hOntlOlle receptors. T71e structural homology ill the N-
termillal domaill, DNA-billdillg domain (DBD; black bOA) alld ligand bindillg domain (LBD; hatched 
box) of the humall androgen receptor. glucocorticoid receptor, mineralocorticoid receptor, 
progesterone receptor, estrogell receptor a alld estrogen receptor {3. Numbers ill the open bars 
represellt the percellfage of homology. 
1.1.2. STRUCTURAL ANALYSIS OF STEROID RECEPTORS 
The separate domains of steroid hormone receptors contain one or more functional units 
involved in their specific function (see Figure 1.3 for a schematical representation)_ As 
pointed out above, they include domains for DNA binding and ligand binding. Additionally, 
they include regions essential for transcription regulation, dimerization and for effective 
transport to the nucleus. 
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Figure 1.3. Schematic illustration of 'he struclllral/jllllctiOllal orgallization of steroid lI017I101le 
receptors. 171e N-termillal domaill is shoWIl as all open box, the DBD alld LBD as black and hatched 
boxes, respectively. Domaillfimcfiolls are depicted under the schematic receptor represelltalioll. NLS: 
/luclear localization signal, AF: trallsuctivatioll/Ullctioll. 
The N-terminal domain 
The N-terminal domain of most steroid receptors is very long (601, 565, 419 and 548 
amino acid residues for MR, PR, GR and AR respectively). In contrast, both ERa and ERJ1 
contain much shorter N-terminal domains (183 and 103 amino acids, respectively). The N-
terminal domains of all steroid hormone receptors including the ERs, contain at least one 
region with a hormone dependent transactivation function (AF-l), which is essential for the 
maximal transcriptional response of hormone-inducible promoters. AF-l is constitutively 
active in truncated receptors, that lack the LBD. Furthermore, AF-l activity is cell and 
promoter dependent (Bocquel et al. 1989, Tasset et al. 1990, Muller et al. 1991, Dieken & 
Miesfeld 1992, McEwan et al. 1993, 1994, Tzuckerman et al. 1994, reviewed in Evans 
1988, Green & Chambon 1988, Carson-Jurica et al. 1990, Gronemeyer & Laudet 1995). 
Deletion mapping of the N-terminal domain established that the AF-l regions of the different 
steroid receptors are structurally distinct, and are located at different positions (see Figure 
104) (Hollenberg et al. 1987, Hollenberg & Evans 1988, Tora et al. 1989, Simental et al. 
1991, Meyer et al. 1992, Pakdel et al. 1993, Metzger et al. 1995a, Dahlman-Wright et al. 
1994 and 1995, Jenster et al. 1995, Chamberlain et al. 1996). The AF-l region in the N-
terminal domain of the GR was mapped to an acidic 185 amino acid segment close to the N-
terminus of the receptor (Hollenberg et al. 1987). Internal deletions in this region revealed 
the presence of a 41 amino acid core region, crucial for activity (Dahlman-Wright et al. 1994 
and 1995). The AF-l region of the PR is located in a proline-rich 91 amino acid sequence, 
adjacent to the DBD (Meyer et al. 1992). Two PR isoforms are known, designated PR-A and 
PR-B, respectively (see Figure 1.4). 
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N - TERMINAL DOMAIN DBD 
I AR 
101 370 465 546 
I GR 
77 167 227 262 419 
[+'B [+'A 
11111111111 ~ I PRNB 
165 456 546 565 
AF-3 
I II ... fj B I ER-OI. 
51 93 102142 149 163 
Figure 104. Locatiou of N-Ienllillallrallsactivatioll flllitS ill Ihe illdividual sleroid llOnllOlle 
receplors. The N-termillal domain is shown as all opell box, the DBD as black box. 77le AF-J 
regiolls are depicted by hatched boxes; core regiolls are represented by grey boxes. 
In PR-B, besides the AF-l region, an additional activation function (AF-3) has been 
defined (Sartorius et al. 1994). This AF-3 region is located in the most N-terminal164 amino 
acids specific for PR-B, and enhances the activity of AF-l. The AF-l function ofER-a was 
assigned to a 99 amino acid hydrophobic, proline-rich region, which differs from the proline-
rich AF-l region in the PR (Metzger et al. 1995). Two AF-l subfragments were found to 
synergize independently with the AF-2 function in the receptor LBD (see below). Ahnost the 
entire N-terminal domain was necessary for maximal AR activity (Simental et al. 1991, 
Jenster et aI. 1995). A 260 amino acid core region starting at position 101 contains 
approximately 50 percent of the maximal activity (Jenster et al. 1995). This core region 
contains a relatively high number of acidic amino acids. Chamberlain et al. (1996) recently 
identified two small subfragments within the core region involved in the transactivation 
function of AF-l. 
The DNA binding domain 
The DBD mediates the sequence specific interaction of the receptor with DNA (Schwabe 
et al. 1990, Freedman 1992), and contains sequences involved in dimerization of receptor 
molecules (Vmesono & Evans 1989, Luisi et al. 1991). The DBD contains nine conserved 
cysteine residues (see for a review Laudet et al. 1992). Originally, the DBDs of steroid 
hormone receptors were proposed to form two zinc fmger motifs, identical to those observed 
in the Xenopus laevis transcription factor IlIA (TFIIIA) (Miller et al. 1985, Evans & 
Hollenberg 1988). 
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ex-HELlX-N ex-HELlX-C 
Figure 1.5. FlIIlCliollal11lotijs ill the androgen receptor DNA binding domaill. 1he sequellce shows 
tlte two Cysteine-Zillc coordillatiolls alld tlte N- and C-termillal a-helices (boxed ill dashed Iilles). 17le 
P-box and D-box, involved in DNA recognition and dimerizalion, respectively, are shown as open 
boxes. 171e amino acids ill the P-box essellf;al ill AREIGREIPRE versus ERE recogllition are ill open 
characters. 
However, mutational and NMRlcrystallographic analysis of GR and ER DBD demonstrated 
that the steroid hormone receptor DBD is folded differently, into so-called zinc-domain-helix-
extended regions. The two zinc domains contain the zinc-ions, that are each coordinated by 
four cysteine residues (Figure 1.5)_ The two a-helices that follow the zinc domains (indicated 
by a dashed box in Figure 1.5) are packed perpendicularly to each other, and hydrophobic 
side-chains form an extensive hydrophobic core between the two helices (Freedman et al 
1988, Hard et al. 1990, Schwabe et al. 1990, 1993a and 1993b, Luisi et al. 1991, Freedman 
1992), 
Figure 1.6. Model of a steroid hormoJle receptor DBD dimerJ bound fa DNA. Black dots are zinc 
iOllS, the N- alld C-termillal a-helices are represented by cylinders. 
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Figure 1.6 shows a schematical presentation of two steroid receptor DBDs bound to DNA. 
They bind to adjacent major grooves from one side of the DNA double helix. The molecules 
make extensive contacts to the phosphate backbone at one side, orienting the DBDs such that 
the recognition helices enter the major groove. This allows surface side-chains to make 
sequence-specific contacts to the DNA (Luisi et al. 1991, Schwabe et al. 1990, Suzuki & 
Yagi 1994). 
Steroid hormone receptor homodimers predominantly recognize imperfect palindromic 
sequences, with a 3 bp spacer between the 6 bp half-sites. The consensus high affinity 
binding site for steroid receptor homodimers except for ERs is GGTIAACAllllllTGTTCT 
(GRE/PRE/ARE) (Nordeen et al. 1990, Roche et al. 1992, Lieberman et al. 1993, Lombes 
et al. 1993); the consensus sequence for ER binding is AGGTCAllllllTGACCT (ERE) 
(Martinez et al. 1987, Beato et al. 1989). Recent studies on synthetic promoters have 
indicated that steroid receptors might also interact with direct repeats with different spacings 
between half-sites (Kato et al. 1995a; Aumais et al. 1996). However, the transactivation 
efficiency mediated by these direct repeats was considerably less than the activity directed 
by classical palindromic sequences. In natural promoters, functional activity of a region 
containing several HRE half-sites has been postulated (Kato et al. 1992, Ho et al. 1993). In 
these promoters, additional regulatory elements contribute to maximal hormone stimulated 
activity. 
The determinants for HRE specificity have been studied in detail for GR and ER. 
Mutational analyses and domain swapping of GR and ER have resulted in the identification 
of the P-box, at the base of the N-terminal zinc coordinating domain, involved in the 
recognition of the HRE sequence (Green et al. 1988). Three amino acids essential for 
receptor interaction with its cognate response element were identified (open characters in 
Figure 1.5) (Umesono et al. 1989). Exchange of these three amino acids of the ER P-box 
(EGxxA) to the corresponding amino acid residues in the GR (GSxxV), changed the 
specificity, and resulted in high transcriptional activity of a GRE directed reporter gene 
(Mader et al. 1989). Mutations of three P-box amino acid residues in the GR DBD (GSxxV) 
to those in the ER (EGxxA), resulted in a mutated protein that bound with high affinity to 
the ERE, but retained some affinity to a GRE (Zilliacus et al. 1991). The second zinc 
containing domain encompasses a sequence, named D-box (indicated in Figure 1.5), that 
facilitates cooperative DNA binding of two receptors by protein-protein interactions, and 
thereby determines half-site spacing (see also Figure 1.6) (Umesono et al. 1991, Luisi et al. 
1991, Dahlman-Wright et al. 1991). 
In contrast to steroid receptors, most other nuclear receptors form predominantly 
heterodimers, and recognize direct repeats with various spacings between the two half-sites 
(Green 1993, Mangelsdorf & Evans 1995). RXR is a key factor in this respect, because it 
is the heterodimerization partner of RAR, TR, VDR, PPAR and some orphan receptors 
(Gronemeyer & Laudet 1995, Mangelsdorf & Evans 1995). The direct repeat half-sites 
closely resemble the consensus half site for ER binding (TGACCT), and are in general 
separated by a 1 bp spacer in case of RXR-PPAR dimers, 3 bp for RXR-VDR, 4 bp for 
RXR-TR, and I, 2 or 5 bp in case of RXR-RAR heterodimers. Crystallographic and 
extensive mutational analyses revealed the formation of distinct, asymmetric DBD interfaces 
in the individual heterodimers, discriminating between direct repeats with different half-site 
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spaciog (Zechel et al. 1994, Rastinejad et al. 1995). So, sterie hiodrance between receptor 
pairs is involved io spacer recognition, it also determioes the polarity of the receptor pair on 
the response element. 
In steroid receptors the DBD is linked to the LBD by the so-called hinge region, which 
contaios the bipartite nuclear localization signal (NLS) necessary for translocation to the 
nucleus. 
The ligand binding domain 
The C-terminal region of steroid receptors of approximately 250 amioo acids contains the 
ligand bindiog function (Kumar et al. 1986, Giguere et al. 1986, Rusconi & Yamamoto 1987, 
Gronemeyer et al. 1987, Jenster et al. 1991). The integrity of the complete domaio is 
important for steroid binding, because all deletions and the majority of point mutations in this 
region abolish ligand binding. LBD sequences also play a role io receptor dimerization 
(Fawell et al. 1990, Nemoto et al. 1994). Furthermore, most steroid receptors (ER, PR and 
GR) have been shown to contain transactivating activity in this region (Hollenberg & Evans 
1988, Bocquel et al. 1989, Gronemeyer 1991, Danielian et al. 1992, Tzuckerman et al. 
1994). This transactivatiog function (AF-2) depends on hormone bioding for activity. The 
AF-2 domains of the various receptors contain at their C-terminus an autonomous, 
constitutively active, but weak activation function, the AF-2 core region (see Figure 1. 3) 
(Danielian et al. 1992, Meyer et al. 1992, Tzuckerman et al. 1994). The integrity of the core 
domain is crucial for AF-2 function. To date, no apparent AF-2 activity has been identified 
in the AR LBD, despite the high degree of homology between AR and the other steroid 
hormone receptors io the AF-2 core region (Pierrat et al. 1994). 
In contrast to other nuclear receptors, unliganded steroid receptor LBDs are associated 
with a large multiprotein complex composed of heat shock proteios (hsp90, hsp70 and 
hsp56), that maiotains the receptor in a transcriptionally ioactive form (Smith & Toft 1993, 
Pratt 1993, Bohen et al. 1995). Heat shock proteins are thought to be involved in proper 
folding of the LBD (Pratt 1993, Bohen et al. 1995, Fang et al. 1996). It has also been 
suggested that hsp-receptor association is implicated in intracellular trafficking and nuclear 
import (Smith & Toft 1993, Prat 1993, Pratt et al. 1993). 
The subcellular localization of the individual steroid hormone receptors is still a matter of 
dispute. Experimental evidence supports a model of constant bi-directional shuttling of the 
receptor/chaperone complex between the nucleus and the cytoplasm (Guiochon-Mantel et al. 
1991, Chandran & DeFranco 1992, Dauvouis et al. 1993, Madan & DeFranco 1993). 
Probably, the unliganded ER and PR are predominantly nuclear (Yilkomi et al. 1992), and 
the unliganded GR and MR cytoplasmic (Guiochon-Mantel et al. 1991, Madan & DeFranco 
1993). Immunohistochemical studies of major androgen target tissues demonstrated that the 
AR was predominantly present in the nucleus in either the absence or presence of hormone 
(Husman et al. 1990, Sar et al. 1990, van der Kwast et al. 1991). In transiently transfected 
cell lines, unliganded AR has been detected both io the nucleus and in the cytoplasm, 
depending on the cell line tested (Jenster et al. 1993, Zhou et al. 1993). 
Hormone binding results in the dissociation of receptor associated chaperone proteins 
(Smith & Toft 1993), and initiates conformational changes necessary for dimerization, DNA 
binding and interaction with transcriptional mediators (Carson-Jurica et al 1990, Gronemeyer 
1992, Truss & Beato 1993, Beekman et al. 1993). 
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Figure I. 7. Predictetlmodel of lite audrogen receptor ligand billding domaill. The model is adapted 
from Rellaud et al. 1995, alld represents all alltiparallel ex-helical saudwich, containing 12 a-helkes 
(H1 to H12) alld 2 sllOrt {3-strallds (S1 alld S2). The a-helices H1 to H11 are orgallized ill a three 
layer structure. ill which H4, H5, H6, H8 alld H9 are sandwiched between HI to H3 alld H7, H10 
and H11. III the ullligallded state, Hl2 protrudes/rom the LBD, whereas Hl2folds towards the LBD 
ill the ligallded state (showlI by the dashed box) (Rellaud et 01. 1995, lVllrtz et 01. 1996). 111 the 
model, the postulated positiolls of a-helices 1 alld 3 to 12, and {3-strallds 1 and 2 of the AR LBD are 
illdicated,' hellt 2 might be absellf ill AR. 
Recently, the three dimensional structures ofRXRa (Bourguet et al. 1995), RARr (Renaud 
et al. 1995) and TRa (Wagner et al. 1995) LBDs have been elucidated. They were shown 
to fold in an anti-parallel a-helical sandwich, containing 11 to 12 a-helices and 2 short {3-
strands. The overall homology of the various LBDs might be sufficient to predict the folding 
of the steroid receptor LBDs (see Figure 1.7 for AR; Wurtz et al. 1996). Homology modeling 
of the unliganded RXRa and GR LBDs according to the structure of the ligand bound RARr 
LBD predicted a common ligand-binding pocket, involving mainly hydrophobic residues. 
Mutant studies support this common three dinlensional structure. Alignment of all nuclear 
receptors to this model has resulted in the proposal of a common, so-called 'mouse trap-like' 
mechanism of ligand binding (Wurtz et al. 1996). By folding back to the LBD core, a-helix 
12, containing the AF-2 core sequence, comes in close contact with the ligand and a-helix 
4, and seals the ligand binding pocket like a lid (see Figure 1.7). The conformational change 
induced by hormone binding creates an interaction surface which presumably allows binding 
of transcriptional co-activators, or interaction (direct or indirect) with the N-terminal domain, 
exposure of the nuclear localization signal, and allows receptor dimerization (Picard & 
Yamamoto 1987, Picard et al. 1988, Ylikomi et aI. 1992, Wong et al. 1993, Langley et al. 
1995, Kraus et al. 1995, Beato et al. 1995,1996b, Wurtz et al. 1996, Doesburg et al. 1997). 
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Previously, so-called heptad repeat residues were proposed to trigger dimerization of 
ligand bound LBD (Lees et al. 1990, Forman & Samuels 1990). However, the crystal 
structure of the ligand bound RARy LBD dimer showed that these heptad repeat residues 
contribute to the overall stability of the LBD fold and their mutation can only indirectly 
affect the dimer interface (Bourguet et al. 1995). In RXRa, the dimerization interface is 
supposed to be formed by helix 10 (Bourguet et al. 1995, Wurtz et al. 1996). 
Antagonists inhibit the biological effects of steroid hormones by competing for binding to 
the receptor (Wakeling 1992). They are frequently applied in the treatment of hormone 
dependent disorders, including hormone dependent malignancies. Most studied in this respect 
are the anti-estrogen Tamoxifen, the anti-progestin RU486, and the anti-androgen cyproterone 
acetate. In general, steroidal antagonists are thought to induce a different conformational 
change upon binding to the LBD. Several studies have indeed shown that this indeed the case 
(Moudgil et al. 1989, Weigel et al. 1992, Allan et al. 1992a and 1992b, Beekman et al. 
1993, Kallio et al. 1994, Kuil & Mulder 1994, Kuil et al. 1995). The conformational state 
induced by antagonists results in a receptor without, or with reduced transcriptional activity. 
Different antagonists may affect different aspects of receptor function, such as hsp 
dissociation, dimerization, binding to DNA, and interaction with general or specific 
transcription factors and co-activators, and with the N-terminal domain of the receptor 
(Meyer et al. 1990, Baulieu et al. 1990, Gronemeyer et al. 1992, Agarwal 1994, Metzger 
et al. 1995b, Langley et al. 1995, Kraus et al. 1995, Doesburg et al. 1997). 
Steroid receptor specificity 
Despite the shared consensus DNA-binding site, AR, GR, MR and PR mediate diverse 
cellular responses. Several, mutually not exclusive mechanisms to achieve specificity have 
been proposed (Katzenellenbogen et al. 1996, Beato et al. 1996b). One of the molecular 
mechanisms, that can account for specificity includes sequence differences in natural HRE 
sequences, }yIJich can deviate considerably from the consensus, high affinity binding sequence 
(Claessens et al. 1996). Other mechanisms can include differences in the DNA context of the 
HRE (Bear & Yamamoto 1994, Scheller et al. 1996), differential affinities to general or 
sequence specific transcription factors (Adler et al. 1992 and 1993, Ho et al. 1993, Pearse 
& Yamamoto 1993), different capacities to modulate chromatin structures (Archer et al. 
1994a,b and 1995, Mynnik et al. 1995, Truss et al. 1995, Beato et al. 1996a), and ligand 
availability (Funder et al. 1993, Russell & Wilson 1994, Kralli et al. 1995). 
1.1.3. INTERACTION WITH GENERAL AND SEQUENCE SPECIFIC 
TRANSCRIPTION FACTORS, AND CO-ACTIVATORS 
Hormonal activation and nuclear import are prerequisites for DNA bound steroid receptors 
before performing their transcription regulation function. By binding to the HRE in promoter 
or enhancer regions of target genes, steroid hormone receptors initiate the assembly, or 
increase the stability of the transcription initiation complex, resulting in modulation of target 
gene expression. The transcription initiation complex is composed of RNA polymerase II and 
basal or general transcription factors (GTFs). GTFs interact with the core promoter elements, 
and are sufficient to direct RNA polymerase specificity and low levels of transcription. 
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Figure I.S. Schematic representation o/illteractious between steroid hormone receptors alld other 
Iluclear pro/eills involved ill transcriptional actimnoll. nJese illferactioJls call be elt/ler direct (A) 
or indirect via bridging factors (8) or chromatill remodeling factors (C). HR: Steroid hormone 
receptor, TF: transcription/actor, HRE: hormone response elemellf, TFE: TF bindillg element, TIC: 
transcription initiation complex, TSS: trat/scription start site. 
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Figure I.8A schematically represents the simplified building of the activated transcription 
initiation complex. In this model, direct interactions are proposed between a steroid receptor 
homodimer and the transcription initiation complex. Additionally, direct interactions are 
proposed between the steroid receptor dimer and a second specific transcription factor bound 
to its cognate DNA element, resulting in synergistic cooperativity. However, accumulating 
evidence indicates that interactions carolOt only be direct. but also indirect, via transcription 
intermediary factors (TIFs) or co-activators. These co-activators can function as bridging 
factors between the various components of the transcription machinery (see Figure I. 8B as 
an example). Furthermore, specific transcription factors and co-activators can playa role in 
chromatin remodeling, thereby enhancing the activity of the transcription initiation complex 
(Figure I.8C). The study of protein-protein interactions in the formation of specific, stable 
transcription initiation complexes is a rapidly developing research field, and currently 
investigated in many different laboratories. 
Interaction with general transcription factors 
RNA polymerase II is the central player in transcription initiation. It interacts with several 
GTFs, in particular through the C-terminal repeat domain (CTD) of its largest subunit. Two 
different mechanisms for the assembly of the transcription initiation complex have been 
proposed. For many years it was believed, that the initiation complex is assembled in an 
ordered step-wise fashion (reviewed by Buratowski 1994, Zawel & Reinberg 1995, 
Orphanides et al. 1996). Starting with recognition of the TATA-box by TFIID, followed by 
recognition of this complex by TFIIB, recruitment of the TFIIF/RNA polymerase II complex, 
and finally binding of TFIIE and TFIIH. TFIIA can bind to the initiation complex at any 
stage after TFIID binding, and stabilizes the complex. More recently, the concept of a 
preformed complex, containing RNA polymerase II and many GTFs has been postulated 
(Koleske & Young 1994 and 1995, Halle & Meisterernst 1996, Orphan ides et al. 1996). Such 
a holoenzyme could be directly recruited to the promoter by sequence specific transcription 
factors. 
All GTFs are composed of two or more subunits, and cDNAs encoding most subunits have 
been molecularly cloned (reviewed by Burley & Roeder 1996, Orphanides et al. 1996). The 
TFIID complex is composed of the TATA-box binding component TBP and a variety of 
other subunits, named TBP-associated factors (TAFs). The TFIID complex seems to be the 
central part in the communication between RNA polymerase II and the sequence specific 
transcription factors, such as steroid receptors, either direct or via co-activators (see Figure 
I.8). 
Steroid receptors are found to interact with several GTFs. Transactivation by ER is 
enhanced by overexpression of TBP, and direct ;Jl vitro interaction between the two proteins 
has been demonstrated (Sadovsl,:y et al. 1995). Also, a direct interaction between steroid 
hormone receptors and several TAFils has been detected. Transactivation by ER requires 
TAFII30 (Jacq et al. 1994), and Drosophila TAFillIO interacts with the DBD of the PR 
(Schwerk et al. 1995). Furthermore, interactions of ER and PR and TFIIB have been 
reported (Ing et al. 1992). The ill vivo significance of these ill vitro observed interactions, 
and effects on transcriptional activation remain to be established. 
21 
Chapter I 
Interaction with sequence-specific transcription factors 
Steroid hormone receptors not only interact, directly or indirectly, with GTFs but also with 
sequence-specific transcription factors. On artificial promoters, containing properly spaced 
binding sites, many sequence-specific transcription factors cooperate synergistically with 
steroid hormone receptors (Schiile et a!. 1988, Strahle et a!. 1988). In several natural steroid 
responsive genes, synergism between two or more HREs has also been described. One of the 
first examples of synergistic activity of HREs was found in the promoter of the chicken 
vitellogenin II gene. Synergistical activity of both ER and GR, and ER and PR has been 
demonstrated (Ankebauer et a!. 1988, Cato et a!. 1988a). Also, cooperativity between two 
EREs has been described (Burch et a!. 1988). Although the mechanism of this synergistical 
activation is not clear, it has been suggested that it is based upon cooperative binding of 
receptors to multiple HRE sequences (Ankebauer et a!. 1988, Tsai et a!. 1989). 
The best studied natural promoters showing synergistical effects of steroid hormone 
receptors and other sequence specific transcription factors are the MMTV-LTR (mouse 
mammary tumor virus long terminal repeat) promoter, the TAT (tyrosine aminotransferase) 
promoter and the ovalbumin promoter. The MMTV promoter contains two separated regions 
interacting with GR, PR and AR (Scheidereit et a!. 1983, von del' Ahe et a!. 1985, Cato et 
a!. 1988b), a distal region, with high homology to the HRE consensus sequence, and a 
proximal region that consists of a cluster of three perfect HRE half-sites. The individual half-
sites do not show receptor binding. The notion that different receptor binding sequences act 
synergistically, is based upon the observation that mutation of any of the HRE motifs 
strongly reduced hormone inducibility (Cato et a!. 1988b). The MMTV promoter contains 
also NF-I and Oct binding sites, and both are required for optimal induction by steroid 
hormone receptors. However, in ill vitro transcription assays, on naked DNA templates, the 
steroid receptors do not synergize, but rather compete with NF-l for binding to the promoter 
(Kalff et a!. 1990, Brilggemeier et a!. 1990, 1991). Functional studies indicated that the 
observed synergism between steroid receptors and NF-l might be mediated by the 
organization of the DNA in chromatin (Brilggemeier et al 1991, Beato et a!. 1996a). 
Hormone induction is believed to cause a displacement or disruption of the nucleosome 
positioned over the hormone responsive region, which enables free access of NF-l to its 
binding site, resulting in optimal transcriptional activity (reviewed by Beato & Sanchez-
Pacheco 1996). 
Evidence about the role of the chromatin structure in the liver-specific and glucocorticoid 
regulated activity of the rat TAT gene has also been collected. In the TAT enhancer region, 
2.5 Kb upstream of the transcription start-site, three candidate GRE sequences have been 
identified (Jantzen et a!. 1987, Grange et a!. 1989). Functional synergism between the GR 
and the liver enriched transcription factors HNF-3 (previously named HNF-5) and HNF-4 
has been described (Rigaud et a!. 1991, Nitsch et a!. 1993, Roux et a!. 1995). Results 
obtained by ill vivo footprinting suggest that the GR may function, at least in part, by 
allowing access of HNF-3 to its DNA binding site through an alteration of the chromatin 
structure. In addition to the synergistic action of proteins binding to the -2.5 Kb enhancer 
region itself, this enhancer region also acts synergistically with a region 5.4 Kb upstream of 
the transcription start site. The latter region is almost inactive in itself. but it cooperatively 
enhances the glucocorticoid induced activity of the -2.5 Kb enhancer region (Grange et a!. 
1989). 
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Synergistical cooperativity between steroid hormone receptors and another sequence 
specific transcription factor was also observed in the ovalbumin gene. Synthesis of ovalbumin 
mRNA in chicken oviducts is controlled by estrogens and progestins, primarily at the level 
of transcription (O'Malley et al. 1979). Both a functional ER and PR binding site are found 
in the proximal promoter region, and in a far upstream enhancer several synergistically 
acting ERE half-sites have been identified (Compton et al. 1986, Tora et al. 1988, Kato et 
al. 1992). Besides the steroid hormone receptors, a chicken ovalbumin upstream promoter 
(COUP) element was found to be essential for efficient transcription of the gene (Sagami et 
al. 1986). The transcription factor binding to this element, COUP-TF is a well known orphan 
receptor (Wang et al. 1989). 
Besides for the extensively studied promoters discussed above, synergistical effects of 
sequence specific transcription factors and steroid hormone receptors were also suggested for 
several other natural occurring promoters. A subset of these will be discussed in section 
1.2.4. 
Interaction with co-activators 
Transcriptional interference or squelching between steroid hormone receptors has suggested 
the existence of common co-activators or TIFs (Meyer et al. 1989, Bastian & Nordeen 1991). 
By protein-protein interaction-screening assays [the yeast two hybrid system (Chien et al. 
1991), or others] several proteins interacting with steroid hormone receptors have been 
identified (see Table 1.1 for an overview of candidate co-activators). At the moment the 
description co-activator is loosely defined by the various authors (Horwitz et al. 1996, and 
references therein), In this section steroid hormone receptor co~activators are defined as 
proteins that interact with DNA bound steroid hormone receptors, and positively influence 
receptor mediated transcriptional activity either by bridging between the steroid receptor and 
the basal transcription machinery, by chromatin remodeling, or by both. For most candidate 
co-activators, an interacting partner of the basal transcription machinery is yet unknown. The 
ill vivo relevance of many of the co-activators discovered in mammalian and yeast protein-
protein interaction systems needs to be further determined. Most candidate co-activators are 
identified by their ability to interact with the ligand bound receptor LBD. Some of the best 
studied examples wiII be briefly discussed below. 
SUGlITRIPI, a component of the RNA polymerase II holoenzyme, was shown to interact 
with the AF-2 domain of the ER LBD (vomBaur et al. 1996). Furthermore, SUGI was 
demonstrated to interact with TBP (Swaffield et al. 1995) and TAFn30 (vomBaur et al. 
1996). It was postulated that steroid hormone receptors can use SUG1ITRIPI to recruit the 
complete basal transcription machinery in one single step (Beato et al. 1996b). Recent data 
indicate that SUG 1 is a subunit of the 26S proteosome complex. It therefore may affect 
transcriptional activation by steroid receptors indirectly, by controlling the turnover rates of 
other regulatory factors (Rubin et al. 1996). 
TIF2/GRIPI functionally interacts with the LBD of ER, GR, PR and AR in a Jigand-
dependent manner (Voegel et al. 1996, Hong et al. 1996). TIF2/GRIPI is thought to bridge 
the AF-2 core region and one of the GTFs. TIF2/GRIP! is expressed in many tissues, and 
enhances transcriptional activity of AF-2 of the various receptors in mammalian cells and in 
yeast. 
SRC-I was isolated as a protein interacting with ligand bound PR LBD (Oftate et al. 
1995). SRC-! is ubiquitously expressed and enhances transcription activation by PR, GR and 
ER. Recently, SRC-l and ERAP160/p160 (Halachmi et al. 1994) were shown to be 
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structurally closely related (Kamei et a1. 1996). McInerney et a1. (1996) suggested that SRC-
1 might act as an adaptor protein that facilitates the productive association of N-terminal 
domain and the LBD of the ER. 
ARA10 was isolated as a protein binding to AR LBD (Yeh & Chang 1996). The protein 
exclusively interacts with the agonist bound and not with the antagonist bound AR. In 
cotransfection experiments in ARA70 negative DUI45 prostate cells, ARA,o enhanced AR-
dependent transcription IO-fold, but had only a mininlal effect on ER, GR and PR. 
TABLE 1.1. Calldidate transcriptiollal illtermediwy factors or co-activators for steroid hormone 
receptors 
STEROID RECEPTOR 
CO-ACTIVATOR TARGET REFERENCES 
partner domain 
SUGl/TRIP! ER AF-2 TBP/TAFu3 Swaffield et al. 1995 
0 vomBauer et al. 1996 
ARA 70 AR LBD ? Yeh et al. 1996 
GRIPl/TIF2 ER/GR/ AF-2 ? Voegel et al. 1996 
PR/AR /LBD Hong et al. 1996 
SRC-l/pI60/ ER/GR/ LBD CBPjp300 Onate et al. 1995 
ERAP 160 PR Halachmi et al. 1994 
Kamei et al. 1996 
RIP 140 ER/GR AF-2 ? CavailH~s et al. 1994,1995 
RAP 46 ER/GR/ LBD ? Zeiner et al. 1995 
PR 
GRIP 170 GR DBD ? Eggert et al. 1995 
hRPF 1 GR/PR LBD TAFLJ18 ? Huibregtse et al. 1995 
Imhof et al. 1996 
PML PR AF-l/2 ? Guiochon-Mantel et al. 
1995 
TIFI (TIFla) ER/GR AF-2 chromatin Le Douarin et al. 
1995,1996 
vomBauer et al. 1996 
BRG1/hBRM ER/GR ? chromatin Muchardt et al. 1993 
Chiba et al. 1994 
HMG-1 PR/ER ? Onate et al. 1994 
chl.·omatin Verrier et al. 1995 
? 
CBP/p300 GR LBD nucleosom Kamei et al. 1996 
al Yao et al. 1996 
core 
his tones 
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Candidate co-activators described so far were shown or presumed to interact with the basal 
transcription machinery. Co-activators can also interact with components of the chromatin, 
resulting in nucleosome remodeling. TIFI interacts with the AF-2 domain of ligand bound 
ER and GR ill vitro and in yeast (Le Douarin et aI., 1995, vomBauer et al. 1996). Recently, 
it was shown that TIFI also interacts with two mouse heterochromatin proteins, mHPla and 
mMOD1, likely involved in chromatin structure and function (LeDouarin et al. 1996). A 
yeast two hybrid screen to identify proteins interacting with HPla, identified a protein 
closely related to TIFI. This newly identified protein was named TIFl{3 (TIF is now TIFla). 
So far it is not known whether TIFI{3 interacts with steroid hormone receptors. 
Hbrm and BRG I, two human homo logs of the yeast proteins SWI2/SNF2, are believed to 
play a role in the remodeling of nucleosomes by the displacement of histone H2AIH2B 
dimers. This function might involve the proposed helicase activity of hbrmlBRGI (Winston 
et al. 1992, Cote et al. 1994, Beato & Sanchez-Pacheco 1996). It has been shown that hbrm 
and BRGI can cooperate with the ER and GR (Muchardt et al. 1993, Chiba et al. 1994). 
CBP and the related p300 protein were shown to interact with the LBD of the GR, and 
with SRC-I/ERAPI60/pI60 co-activators (Ogryzko et al. 1996). CBP and p300 were found 
to be histone acetyltransferases of all four core histones in nucleosomes. Acetylation of 
histone tails presumably destabilizes the nucleosome and thereby facilitates access by 
regulatory proteins. A direct link between histone acetylation and transcriptional activation 
was recently shown for yeast GCN5 and its human homolog (Wang et al. 1997). Because 
CBP and p300 can interact with a wide array of different transcription factors, they were 
postulated to be involved in the cross-talk between multiple signal transduction pathways 
(Kamei et al. 1996, Yao et al. 1996). 
The DNA bending protein HMG-l has been reported to stimulate the PR and ER DNA 
binding (Oilate et al. 1994, Verrier et al. 1995). Co-immunoprecipitation experiments showed 
that both HMG-l and PR can be found in a complex with the PRE although it appeared that 
HMG-l enhanced PR binding without stably participating as a component of the final 
PRE/PR complex (Prendergast et al. 1994). The physiological relevance of enhanced steroid 
receptor/HRE binding by HMG-l needs to be determined. 
Besides co-activators, also co-repressors have been described. For the non-steroid nuclear 
receptors TR, RAR and RXR, two candidate co-repressor proteins have been identified, a 
270 kDa protein N-CoR (Horlein et al. 1995, Kurokawa et al. 1995) and the related 168 kDa 
protein SMRT (Chen & Evans 1995). Members of the TRJRARJRXR family of nuclear 
receptors can bind to DNA in the absence of ligand and actively repress transcription. N-CoR 
and SMRT are thought to exert their function by their interaction with DNA bound, 
unliganded TRJRXR and RARJRXR heterodimers. Upon ligand binding, the co-repressor 
dissociates and thereby allows interaction with co-activators, and subsequent transcriptional 
activation by the ligand bound receptor dimer. So far nuclear co-repressors for steroid 
hormone receptors have not been reported. It might be argued that co-repressors for steroid 
receptors do not exist, because the unliganded steroid receptor is unable to bind to DNA. 
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1.1.4, CROSS-TALK OF STEROID HORMONE RECEPTORS 
Alternative pathways of receptor activation 
For many years, ligand binding was assumed to be a prerequisite for activation of steroid 
hormone receptors. With the observation that modulation of kinase activity can cause 
activation of steroid hormone receptors in the absence of hormone (reviewed by Weigel 
1996), it becarue apparent that there are alternative, steroid-independent, pathways. 
In addition to the nuclear receptor signal transduction pathway, there are three general 
mechanisms of signal transduction by extracellular components that involve protein 
phosphorylation (reviewed by Hill & Treisman 1995, Karin & Hunter 1995). Figure I.9 
represents a schematical and simplified overview of these general mechanisms. 
STEROIDS 
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HR 
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GROWTH FACTOR 
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Figure 1.9. General mechanisms of signa/transduction. HR: steroid hormone receptors. 
Y indicates tyrosine residues. 
One pathway involves the mitogen-activated protein (MAP) kinase cascade. Growth factor 
or peptide hormone binding results in transmembrane receptor dimerization, that triggers 
auto-phosphorylation of tyrosine residues, followed by activation of intrinsic protein tyrosine 
kinase activity. This in turn leads to the activation of the MAP kinase family of 
serine/threonine protein kinases. This signal transduction pathway also involves the PKC 
family of protein kinases. Ultimately the MAP kinase pathway leads to activation of API 
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family of transcription factors in the nucleus. A second signal transduction pathway involves 
the intracellular Janus protein tyrosine kinases (JAKs). Upon polypeptide (for example 
cytokines and interferon) binding to a specific transmembrane receptor, JAKs phosphorylate 
members of the Stat family of transcription factors. Following dimerization, phosphorylated 
Stat protein is able to bind DNA at the Stat-response element and regulate expression of 
target genes. The third mechanism is formed by the G protein coupled "seven 
transmembrane" receptors. In this pathway, binding of the ligand, for example dopamine, 
ultin18tely results in rise of the cAMP concentration in the cell. cAMP then activates the 
cAMP dependent protein kinase (PKA), which translocates to the nucleus, where it can 
phosphorylate its specific target proteins, including the CREB transcription factor. 
Ligand independent activation of steroid hormone receptors was initially discovered for the 
chicken PR, that can be transcriptionally activated by both a protein kinase A activator and 
a phosphatase 1 and 2A inhibitor (Denner et al. 1990). Subsequent studies showed membrane 
receptor mediated signal transduction pathway coupled activation of PR by dopamine (Power 
et al. 1991). At present, a considerable amount of evidence for ligand-independent activation 
of mammalian PR in transiently transfected mammalian cells and in animal models is 
available (reviewed by Power et al. 1992, and O'Malley et al. 1995). 
Steroid-independent receptor activation in many cases involves growth factorlreceptor 
tyrosine kinase pathways. Recently, it has been shown that a serine residue (Ser ll8), 
essential for full transcriptional activation of the ER, can be phosphorylated by mitogen-
activated protein (MAP) kinase ill vitro (Kato et al. 1995b) and by EGF and IGF-I 
activation, and activated K-ras ill vivo (Kato et al. 1995b, Bunone et al. 1996). Curtis et al. 
(1996) demonstrated that ER-CI knockout mice lack the estrogen-like response mediated by 
EGF in ER positive mice, clearly indicating the coupling of EGF and ER signaling pathways 
ill vivo. At present, a wide array of growth factors, mitogens and other compounds affecting 
phosphorylation by PKA or PKC activation have been shown to be able to activate the 
unliganded steroid hormone receptors or enhance steroid-dependent transcriptional activity 
(reviewed by Weigel 1996). 
The outcome of the effect of growth factors and mitogens on steroid-independent receptor 
activation can be influenced remarkably by the cell type, and culture condition used (Nordeen 
et al. 1995, Reinikainen et al. 1996, Nazareth & Weigel 1996). Similarly, the effect of ligand 
independent activation of steroid receptors is promoter dependent. Therefore, it is important 
to study the mechanism of ligand independent activation in more detail, and establish its ill 
vivo relevance. Steroid-independent receptor activation might contribute to the failure of 
endocrine therapy in several human tumors. 
Cross-talk of steroid hormone receptors with other specific transcription factors 
The cross-talk between steroid hormone receptors and other signal transduction pathways 
not only leads to alternative activation of the steroid hormone receptor, but the cross-talk can 
also work in the opposite direction. Ligand bound GR can act as a transcriptional activator 
of Stat5 and enhances Stat5-dependent transcription (St6cklin et al. 1996). Phosphorylated 
Stat5 and the liganded GR are able to form a complex, and cooperate in transcriptional 
activity of a Stat5 inducible promoter. DNA binding by the GR is not necessary for the 
transcriptional activity of the Stat5/GR complex since a GR mutant, lacking DNA binding, 
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is still functional. It is suggested that the strong transactivation domain of the GR enhances 
Stat5 action. As a result of Stat5/GR dimerization, glucocorticoid induction of a GR target 
gene is strongly repressed. 
Several groups have reported interaction between steroid hormone receptors and AP-I 
components (fos andjun) (reviewed by Herrlich & Ponta 1994). Depending on the promoter, 
the cell line and the specific receptor, both negative and positive regulatory interactions have 
been described (Shemshedini et al. 1991). The mechanism by which this cross-talk acts is 
still elusive. Evidence leading early on to the idea that AP-l and steroid hormone receptors 
form complexes which abort DNA binding, might represent an ill vitro artefact. A recently 
postulated alternative hypothesis is that AP-I and steroid hormone receptors do not interact 
directly, but via transcriptional mediators (Pfahl 1993, Beato et al. 1995, Gronemeyer & 
Laudet 1995, Kallio et al. 1995). This hypothesis is supported by the recent discovery that 
activation of nuclear receptors requirs CBP or p300 (Kamei et al. 1996, Yao et al. 1996). 
As discussed above, CBP (Kwok et al. 1994) and p300 (Eckner et al. 1994) directly interact 
with the LBD of several steroid hormone receptors. Previous studies already revealed that 
CBP/p300 is required for AP-I activation (Arias et al. 1994, Arany et al. 1995, Lundblad 
et al. 1995). Combination of these results led to the proposition that inhibition of AP-I by 
nuclear receptors and vice versa might be the result of competition for limiting amounts of 
CBP/p300 present in target cells (Kamei et al. 1996). 
Negative cross-talk has also been observed between NF-KB and members of the steroid 
hormone receptor family (Stein & Yang 1995, Marx 1995). Best studied in this respect, is 
the mediation of immunosuppression by glucocorticoids. ReIA, the p65 subunit of the 
composite transcription factor NF-KB, is not only inhibited by GR in stimulating NF,B-
responsive genes but also antagonizes GR action on GRE-containing promoters (Ray & 
Prefontaine 1994, Caldenhoven et al. 1995, Scheinman et ai, 1995a). Additional research 
showed that direct binding of the GR to NF-KB perhaps comprises only part of the molecular 
mechanism of glucocorticoid suppressed immunity. Expression ofIKBa, the NF-KB inhibitory 
protein that keeps NF-KB trapped in the cytoplasm, is increased by glucocorticoids. As a 
result, NF-KB might be retained in its inactive form in the cytoplasm, even under conditions 
where it would normally be released to migrate to the nucleus, and act as transcriptional 
regulator (Auphan et al. 1995, Scheinman et al. 1995b). 
Cross-talk has also been observed between AR and GR, and calreticulin. Cal reticulin, a 
ubiquitously expressed intracellular Ca'+ -binding protein has been shown to bind to integrins 
as well as to nuclear receptors. Calreticulin binds to a six amino acid motif, KxFFKlRR, 
found in the DBD of all nuclear receptors (Burns et al. 1994, Dedhar et al. 1994). These 
amino acids are crucial for DNA binding, and cal reticulin is believed to block the ability of 
steroid receptors to bind to their response elements, and thereby inhibit transcriptional 
activity. Cal reticulin may represent a link between cellular phenotype, via the extracellular 
matrix, and specific gene expression (Dedhar 1994). 
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1.2. ANDROGEN REGULATED AND PROSTATE SPECIFIC GENE 
EXPRESSION 
The male sex hormones or androgens [testosterone (T) and its metabolite 5a-
dihydrotestosterone (DHT)] playa central role in development of the male phenotype during 
fetal life and puberty, and control male fertility and sexual behavior in adults. T is produced 
by the Leydig cells in the testis. In target tissues, T can be converted into the more active 
DHT by the enzymes Sa-reductase 1 and 2 (Andersson et al. 1989, 1991). Sa-Reductase 1 
is predominant in nongenital skin, whereas 50:'-reductase 2 is mainly expressed in the male 
urogenital tract (Thigpen et al. 1993). Both T and DHT exert their biological functions by 
activation of the AR. High AR expression is mainly restricted to the male urogenital system, 
including the prostate. 
1.2.1. ANDROGEN REGULATED PROSTATE DEVELOPMENT 
The presence of a functional AR and the appropriate androgenic hormone are essential for 
the development and maintenance of the prostate (Cunha et al. 1987, Cunha 1994). The 
prostate is an exocrine male reproductive organ, that is only present in mammals. The 
prostate gland is composed of ductal-acinar structures with a complex architecture. The acini 
and ducts are lined by a double layer of epithelial cells, the basal and luminal cells. Along 
the secretory epithelial cells, a third epithelial cell type, the neuroendocrine cells, which form 
a small proportion of the epithelial compartment, can be found. A role in prostate growth and 
differentiation, and in homeostasis has been proposed (reviewed by Noordzij et al. 1995). 
The acini and ducts are surrounded by stromal tissue, that is mainly composed of smooth 
muscle cells, connective tissue and lymphatic cells. The function of the basal ductal cells is 
essentially unknown, although it has been suggested that prostate stem cells are located within 
this cell layer (Bonkhoff & Remberger, 1996). The luminal epithelial cells are regarded as 
highly differentiated, and produce many components of the seminal fluid. The best known 
of these is prostate specific antigen (PSA), but large amounts of prostate acid phosphatase 
(PAP) and Prostate-Specific Protein (PSP,,) are also secreted. 
The prostate is situated immediately below the bladder and surrounds the urethra. Prostate 
morphology is different in various species. In the human prostate, regions with different 
anatomy are fused together to form a compact organ with a chestnut-like shape. In contrast, 
the prostate of rodents is organized in dorsal, lateral, ventral and anterior lobes, each of 
which has a distinct function, in keeping with its unique branching pattern and the production 
of specific proteins (Cunha et al. 1987). 
In humans, prostate development initiates around the 10th week of gestation from solid 
epithelial outgrowths (prostatic buds) of the urogenital sinus. Embryonic prostate 
organogenesis is strictly androgen dependent. During the initial steps of prostate development 
the AR is expressed in the mesenchymal compartment, but undetectable in the epithelial cells. 
However, it has been well established that epithelial cell differentiation is regulated by 
androgens (Cunha et al. 1987, Cunha 1994). It is assumed that androgen regulated growth 
factors and extracellular matrix components produced by the mesenchyme drive the initial 
androgen regulated differentiation of the prostate epithelium (see Figure I. 10). Keratinocyte 
growth factor (KGF), an androgen regulated member of the fibroblast growth factor family 
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that is expressed in stromal cells, is suggested to be involved in androgen regulated prostate 
development (Yan et al. 1992, Sugimura et al. 1993, Rubin et al. 1995, Cunha et al. 1996). 
DEVELOPING 
PROSTATE 
o 
EPITHELIAL CELL 
STROMAL CELL 
ADULT 
PROSTATE 
Figure 1.10. Schematic representation of (lm/rogell dn'ven illferactiolls betweell epithelial alld 
mesenchymal cells during prostate development Ulld between epithelial cells alld stromal cells ill the 
muhlre prostate. AR+ indicates the presence offimctiol1al androgen receptors. 
During puberty a second, androgen-dependent, step in prostate growth and development 
takes place, ultimately resulting in the formation of the adult prostate and the production of 
prostate specific proteins (Cooke et al. 1991, Donjacour & Cunha 1993). In these later stages 
of development, AR expressed in the epithelial cells is also an essential factor. Androgens 
are indispensable for the maintenance of prostate structure and function, because orchiectomy 
or inhibition of AR activity by anti-androgens leads to prostate involution, concomitant with 
a rapid loss of luminal epithelial cells. DHT is the androgenic hormone responsible for 
prostate development, since patients with 5a-reductase deficiency show rudimentary or absent 
prostate glands, despite the presence of functional AR and T (Wilson et al. 1993). 
Besides their role in normal prostate development and differentiation, androgens are 
implicated in prostate carcinogenesis (see for reviews Henderson et al. 1991, Karp et al. 
1996) and benign prostatic hyperplasia (BPH). For example, prostate cancer develops only 
rarely in men, who have been castrated before puberty or in early adulthood (Pienta & Esper 
1993). The role of the AR in prostate cancer will be discussed in section 1.2.7. 
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1.2.2. THE ANDROGEN RECEPTOR 
cDNAs encoding Ihe full lenglh human AR have been cloned by several groups (Chang 
el al. 1988a,b, Lubahn el al. 1988a,b, Trapman et al. 1988, Paber el al. 1989, Tilley et al. 
1989). The open reading frame of Ihe AR cDNA (approximalely 2.7 Kb) is flanked by very 
long 5' and 3' unlranslaled regions (UTRs) (1.1 Kb and 6.8 Kb, respeclively). The AR gene 
is localed on Ihe X chromosome al ql1.2-qI2, and spans al leasl 90 Kb (Paber el al. 1989, 
Kuiper el al. 1989, Lubahn el al. 1989). The gene is composed of 8 exons, Ihe N-Ierminal 
domain is encoded by parI of exon 1, Ihe DBD is encoded by exons 2 and 3, and exoDS 4 
107 and parI of exon 8 encode Ihe LBD. 
The N-Ierminal domain of Ihe AR conlains several homopolymeric amino acid slrelches, 
including long, glulamine (encoded by CAG) and glycine (encoded by GGN) slrelches 
(Chang et al. 1988b, Paber et al. 1989). Especially Ihe glulamine slrelch is highly 
polymorphic (Caskey el al. 1992, Edwards el al. 1992, Sleddens el al. 1992). Cloned AR 
cDNAs encode proleins of 910 and 919 amino acid residues with an apparenl molecular mass 
of 110-114 kDa (Paber el al. 1989, Quarmby et al. 1990, Wilson el al. 1992, Jensler el al. 
1991, 1994). The variabilily in Ihe lenghl of Ihe CAG and GGN repeals has resulled in 
confusion concerning Ihe exacl size of Ihe AR, and Ihe numbering of Ihe individual amino 
acids. In Ihis chapler, Ihe numbering of Ihe amino acid numbers correspond 10 an AR 
composed of 910 amino acid residues (20 Gin and 16 Gly). A varianl (87 kDa) form of Ihe 
AR has also been described (Wilson & McPhaul 1994, 1996). This lruncaled receplor is 
believed to originate from translation initiation at the first internal translation start codon 
(melhionine, position 188). II represenls about 10% of Ihe tOlal AR level in felal tissues and 
adull genital skin fibroblasls. lis ill vivo relevance is unknown. 
Norlhern blot analysis revealed Ihe presence of lwo hAR mRNA species of approximalely 
11 and 8.5 Kb, Ihe latter as a resull of allernalive splicing in Ihe 3' UTR (Trapman et al. 
1988, Paber et al. 1991, Wolf el al. 1993). In many cell lines and tissues, androgens 
decrease Ihe level of AR mRNA, however, in some tissues and possibly also al cerlain 
developmenlal slages, AR mRNA is upregulated by androgens (Quarmby et al. 1990, 
Burnslein et al 1995, Dai et al. 1996, Dai & Burnslein 1996). The physiological role of Ihis 
differenlial aulo-regulation is unknown as ye!. In LNCaP proslale cells, androgen induced 
decrease of Ihe AR mRNA level is found 10 be Ihe resull of a decrease in Iranscription rale 
(Blok el al. 1992, Wolf et al. 1993). The observed upregulalion of AR prolein in LNCaP 
cells by androgens (Kongrad el al. 1991, Wolf el al. 1993) might be Ihe resull of slabilization 
of Ihe ligand (and DNA) bound AR during Ihe prolein exlraclion procedures (Kemppainen 
el al. 1992, Wolf et al. 1993, Zhou et al. 1995a). 
Immunohistochemical staining of human tissues with specific AR directed antibodies 
revealed a high level of AR expression in tissues of Ihe male urogenital syslem. Low levels 
of expression were found in several olher lissues including female mammary gland, kidney, 
liver, brain, genilal skin fibroblasls and keratinocyles, hair follicles and cardiac muscle 
(Ruizeveld de Winler el al. 1991, Kimura el al. 1993). At variance wilh AR expression in 
humans, rodenls show high AR expression in salivary glands. 
Slarting from Ihe inlacl AR, delelion mapping of Ihe N-Ierminal domain has been 
performed 10 identify Ihe regions essenlial for AP-l Iransactivating activily. A large parI 
(amino acid residues 1 to 485) was found to be necessary for maximal transcriptional activity 
of Ihe AR (Simenlal el al. 1991, Jensler el al. 1991, 1995). A core segmenl, covering more 
Ihan 50 percenl activily has been defined belween amino acids 101 and 370 (Jensler el al. 
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1995). Recently, Chamberlain et aJ. (1996) postulated the presence of two noncontiguous 
transactivation units in the AF- I core region of the rat AR. The first region (AF-la) consists 
of a 16 amino acid segment, of which the inner 14 amino acids (position 154 to 167) are 
predicted to form a {J-turn followed by an amphipatic a-helix. An identical region is present 
in the human AR (positions 172 to IS5). An acidic activator (AF-lb) has been postulated 
between amino acids 295 to 359. The comparable region (amino acids 296 to 360) in the 
human AR is also acidic, which is not unexpected because the N-terminal domain is highly 
conserved between species. Deletion of the individual AF-l subfragments resulted in a small 
reduction of transcriptional activity of the mutant receptors. However, an AF-la and AF-lb 
double mutant receptor showed less than 10 percent transcriptional activity compared to wild 
type AR. Interestingly, in addition to the AF-l core region active in the full length receptor, 
amino acids 360 to 4S5 of the human AR N-terminal domain function as a strong 
transactivation domain (tau-5) in a constitutively active AR mutant lacking the entire LBD 
(Jenster at aJ. 1995). This observation suggests interactions between the N-terminal domain 
and LBD. Recent in vivo protein-protein interaction studies with separate AR LBD and N-
terminal domains demonstrated that such a functional interaction is possible (Langley et aJ. 
1995, Doesburg et aJ. 1997). This interaction is ligand dependent, and might be direct or 
indirect. However, it is unknown whether interaction between the LBD and N-terminal 
domain really occurs in the full length AR. 
For all steroid hormone receptors except for AR a transactivation function in the LBD 
(AF-2) has been demonstrated. Although the AF-2 core sequence is present in the AR LBD, 
AR mutants composed of DBD and LBD do not display a clear transactivation function 
(Simental et aJ. 1991, Jenster et aJ. 1991, Wurtz et aJ. 1996). 
Recently, it was shown that the co-activator TIF2(GRlPl) can functionally interact with 
GAL4(DBD)AR(LBD) fusion proteins (Voegel et aJ. 1996,Hong et aJ. 1996). As already 
discussed, this interaction is not AR specific. A more specfic interaction can be found 
between AR LBD and ARA70 (Yeh & Chang 1996). Co-transfection of ARA70 and AR 
expression plasmids to ARA 70 minus prostate cells leads to upregulation of reporter gene 
expression. These effects were much less pronounced for GR and PRo 
AR, like the other steroid hormone receptors, shows a basal phosphorylation level, and 
hormone binding initiates additional phosphorylation events. Most of the hormone induced 
phosphorylation sites are located in the N-terminal domain (Kempainen et aJ. 1992, Kuiper 
et aJ. 1993), with phosphorylation occurring predominantly at serine and threonine residues. 
Recently, three phosphorylation sites in the human AR have been identified, two sites, SerSO 
and Ser93, in the N-terminal domain, and Ser641 in the hinge region (Zhou et aJ. 1995b). 
The effect of loss of each individual phosphorylation site on transcriptional activity was 
studied by mutation of the individual serine residues to alanine. Mutation of SerS 1 and Ser94 
had little effect, whereas mutation of Ser641 resulted in a small reduction of transcriptional 
activity. 
1.2.3. ANDROGEN RECEPTOR MUTATIONS IN HUMAN DISEASE 
Mutations in the AR gene have been demonstrated in the androgen insensitivity syndrome 
(AIS), Kennedy's disease, and in prostate cancer (Gottlieb et aJ. 1997). Best documented are 
the mutations in AIS. The initial recognition of AIS dates 60 years back, when individuals 
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with a female phenotype, but with undescended testes instead of ovaria were reported 
(Petterson & Bonnier, 1937). AIS constitutes a wide clinical spectrum of phenotypes. The 
complete form of AIS is characterized by an external female phenotype in combination with 
a 46, XY karyotype (reviewed by Quigley et al. 1995). Patients with complete AIS show 
intra-abdominal testes, a blind ending vagina, absence of the uterus and ovaries, and 
gynaecomastia. Besides the complete form, mutations in the AR gene can result in partial 
impairment of AR function leading to partial AIS (pAIS). Clinical indications for pAIS can 
be abnormal sexual development with a predominant male phenotype (micropenis, 
hypospadias), or clitoromegaly in individuals with a predominantly female phenotype. A 
variety of different mutations in the AR causing AIS have been reported (reviewed by Pins!")' 
et al. 1992, Brinkmann & Trapman 1992, McPhaul et al. 1993, Quigley et al. 1995, Brown 
1995, Gottlieb et al. 1997). They include large deletions, frameshifts and point mutations. 
Especially the mutated receptors showing a single amino acid substitution have revealed 
important information concerning the structure and function of the AR. Most point mutations 
resulted in inhibition of ligand or DNA binding. Only a few mutations have been detected 
in the N-terminal domain, all leading to the synthesis of a truncated protein. 
A disease related to AIS is 5a-reductase deficiency, an androgen (DHT) biosynthesis 
defect. 5a-Reductase deficiency caused by mutations in the 5a-reductase type 2 gene leads 
to male pseudohermaphroditism with rudimentary or absent prostate glands (Wilson et al. 
1993). The occurrence of this disorder indicates the physiological importance of DHT, and 
proposes a different role for T and DHT in AR mediated activity. 
Kennedy's disease (a slowly progressing spinal and bulbar muscular atrophy) is linked to 
an expansion of the glutamine (CAG) stretch in the N-terminal domain of the AR to over 40 
residues (La Spada et al. 1991). In the normal population, this stretch ranges from 11-35 
elements with an average of 21 (Caskey et al. 1992, Edwards et al. 1992, Sleddens et al. 
1992). Depending on the cell and promoter tested, the expanded glutamine stretch has been 
shown to cause a minor decrease, or no effect at all on transactivational activity (Jenster et 
al. 1994, Kazemi-Esfarjani et al. 1995). Choong et al. (1996) recently reported that the 
expanded CAG repeat reduces mRNA and protein expression, and does not alter AR 
functional activity. The possible role of AR mutations in prostate cancer will be discussed 
in section 1.2.6. 
1.2.4. FUNCTIONAL AREs IN ANDROGEN RECEPTOR TARGET GENES 
Androgen responsive gene expression can be regulated at the level of transcription, RNA 
processing, RNA stability and translation. Regulation of transcription can be direct or 
indirect. Direct regulation is the result of direct interaction of the activated AR with one or 
more androgen response elements (AREs) in the regulatory regions of the gene. In 
secondary response genes, androgen regulation of transcription is indirect and needs protein 
synthesis. In this case, androgen regulation of one gene can trigger regulation of the 
secondary response gene. 
Although many androgen-regulated genes have been identified, for most of them only 
limited information on the mechanism of androgen regulation is available. A serious 
drawback in the study of directly androgen regulated genes is the lack of cell lines expressing 
both the gene of interest and the AR. Therefore, functional analysis of potential androgen 
response sequences is mostly studied in heterologous cells, and in cells cotransfected with 
33 
Chapter I 
an AR expression vector. An exception forms the analysis of the androgen regulation of the 
PSA promoter in LNCaP human prostate cancer cells (Horoszewicz et al. 1983), which 
showed endogenous expression of both AR and PSA. Many genes known to be regulated by 
androgens also display a cell or tissue specific expression pattern. Especially in this situation, 
structural analysis of complex regulatory elements involved in tissue-specific and androgen 
regulated gene expression will depend on the availability of cell lines expressing the target 
gene, which implicates the expression of all necessary transcription factors, (including AR) 
and co-activators. 
Table 1.2. Functio1lal AREs ill hU1IIall allli rodellt androgell-regulaled gelles. 
GENE 
ARE-SEQUENCE POSITION REFERENCES 
PSA (ARE-I) (h) AGAACA gca AGTGCT - 170 Riegman et al. 1991b 
PSA (ARE-II) (h) GGATCA 999 AGTCTC - 394 Cleutjens et al. 1996 
PSA (ARE-III) (h) GGAACA tat TGTATe 
--
4200 Cleutjens et al. 1997 
Factor IX (h) AGCTCA get TGTACT - 36 Crossley et al. 1992 
hGK-l (= hKLK2) (h) GGAACA gca AGTGCT - 170 Murtha et al. 1993 
C3(1) core II (r) AGTACG tga TGTTeT + 1359 Claessens et al. 1989 
Prohasin (ARE-I) (r) ATAGCA tet TGTTCT - 241 Rennie et al. 1993 
Probasin (ARE-II) AGTACT eea AGAACC - 140 Rennie et al. 1993 
(r) Claessens et al. 1996 
SIp (HRE 3) (m) AGAACA gee TGTTTC - 1922 Adler et al. 1991 
Gus (m) AGTACT tgt TGTTCT + 7833 Lund et al. 1991 
ODC (m) AGAACA agt GGGACT - 924 Crozat et al. 1992 
arMEP24 (m) TGTTGA gag AGAACA - 896 Ghyselinek et al.1993 
MVDP (m) TGAAGT tee TGTTCT - 111 Fabre et al. 1994 
ARE CONSENSUS GdiACA nnn TGTTCT Roche et al. 1992 
--
(h): human, (r): rat, (m): mouse. 
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At present, only a limited number of functional AREs have been characterized and studied 
in detail. Table 1.2 summarizes the functional AREs identified in human and rodent 
androgen-regulated genes. None of the functional AREs in natural genes is completely 
identical to the ARE consensus sequence GGT/AACAnnnTGTTCT. However, in most AREs 
one half site is almost or completely identical to the consensus sequence. Exceptions are the 
rat probasin ARE-2 and the ARE in the mouse arMEP24 promoter. In most functional AREs 
at least 5 of the 6 nucleotides (positions 2,3 and 5 in each half-site, underlined in Table 1.2) 
most critical for high affInity AR binding and functional activity (Nordeen et al. 1990, Roche 
et al. 1992) are present. 
C3 (1) 
OCT NF 1 PROSTATE 
SLP 
SPECIFIC 
FACTOR 
ee f1a w,: 
.j I· !~
NF kB • OCT 
120 bp ANDROGEN 
RESPONSIVE ENHANCER REGION 
160 bp ANDROGEN AND GLUCOCORTICOID 
RESPONSIVE ENHANCER REGION 
CRP 1 120 kDa PROTEIN 
01 
Figllre 1.11. Schematic representation of (plltative) reglllatO/y elements involved in 
alldl'Ogell-reglllated expression of the C3(1), Sip, and clpl/20 kDa protein. Tss represellls 
the transcription stmt site. Core 1 alldll in the C3(l) gene are AR binding sites. N39, DI 
and D2 in the CRP1I20 kDa protein represent candidate complex ellhallcer regions. 
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Best documented examples of androgen regulated genes are the C3(l) (prostatic binding 
protein) gene (expressed in rat ventral prostate), the probasin gene (expressed in rat 
dorsolateral prostate), the mouse Sip genes (sex linliting protein) and GUS «(3-glucuronidase) 
both expressed in kidney, and the human PSA gene. 
The C3(1) gene 
The androgen regulated C3(1) gene encodes the C3 glycoprotein component of rat prostatic 
binding protein (Heyns et al. 1978). Androgen regulation occurs at least in part at the 
transcriptional level (Page & Parker 1982). For many years C3(l) expression was thought 
to be confined to the ventral prostate, but recently C3(l) expression was also detected in the 
lacrimal gland (Allison et al. 1989, Buttyan & Slawin 1993, Vanaken et al. 1996). A 
schematical representation of the (putative) regulatory regions of the C3(l) gene is shown in 
Figure 1.11. Three candidate AREs have been found in the C3(1) gene, one in the proximal 
promoter (-150/-136, AGAACActgGTTTCA), and two in the first intron: 
AGAACAactTGGCTA [Core I (+1307/+1321)] and AGTACGtgaTGTTCT [Core II 
(+ 1359/+ 1375)] (Claessens et al. 1989, 1993, De Vas et al. 1991, Tan et al. 1992). 
Although ill vitro binding of AR to the promoter ARE and both Core I and II has been 
observed, only Core II is active in transfection experiments. Activity of Core II is strongly 
enhanced by surrounding sequences including Core I, candidate OCT and NF-I binding sites, 
and a binding site for an unidentified prostate-specific factor (Celis et al. 1993). Zhang et al. 
(1990) showed tissue-specific differences in proteins binding to the CCAAT box at position-
63 to -55, and postulated the involvement of the C/EBP transcription factor family in C3 
promoter activity. Additionally, they observed binding of an androgen regulated protein to 
the proximal promoter (position -149 to -119) region (Zhang et al. 1993). It is at present 
unknown whether these two proximal promoter regions contribute to maximal androgen 
regulated gene expression in the ventral prostate. The functional analysis of putative 
regulatory sequences was hindered by lack of appropriate cell cultures expressing C3(1). This 
problem might have been overcome recently by the discovery of C3(l) expression in primary 
cultures from lacrinral gland (Vanaken et al. 1996). 
The mouse sex-limited protein (SIp) gene 
SIp is a duplicated complement C4 gene, whose expression is androgen-dependent in several 
tissues including liver and kidney due to an inserted provirus, that functions as a hormone-
dependent enhancer. A schematical drawing of the candidate regulatory elements in the 
enhancer fragment is presented in Figure 1.11. A 160 bp fragment directs both androgen and 
glucocorticoid response, whereas a 120 bp subfragment is activated by AR in CV -1 cells, and 
by both AR and GR in T47D cells. In the 120 bp androgen responsive enhancer, three 
tandemiy repeated HRE-like sequences are present (Adler et al. 1992). The most proximal 
HRE3 [AGAACAggcTGTTTC (-19221 -1908)] is sufficient to confer both androgen and 
glucocorticoid induction if linked to a TK promoter. Mutational analysis and protein binding 
assays demonstrated that in addition to the AR binding HRE3, other sequences including two 
HRE-like structures GTAATTatcTGTTCT (-1954/-1940) and TGGTCAggcAGTTCT 
(-1938/-1924), and several non-receptor binding elements, including an OCT binding site, 
contribute to the characteristic androgen response of this complex enhancer (Adler et al. 
1993). The observation that the OCT binding site was occupied in males, but not in females, 
and only in tissues expressing sip, in in vivo foatprinting experiments, provided evidence that 
it is involved in tissue-specific androgen regulation (Scarlett & Robins 1995). Scheller et al. 
recently reported that a NF-KB binding site present in the 160 bp, but not in the 120 bp 
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enhancer fragment might be important for GR induced activity as observed in CV -I cells 
(Scheller et al. 1996). In CV-I cells, one or more proteins binding to the NF-KB binding site, 
allow GR mediated activity of the enhancer. In T47D cells these sequences seem not essential 
for glucocorticoid induced activity. 
The cystatin related protein (em) 1 1 20 kDa protein gene 
Expression of the CIP I gene, also referred to as 20 kDa protein gene in the ventral prostate 
and lacrimal gland of the male rat strongly depends on androgens (Ho et al. 1989, 
Winderickx et al. 1990, 1994). DNase! footprinting revealed the presence of a region in the 
proximal promoter interacting with the AR DBD. This putative ARE 
(GGGAACaagTGTACT, -139 to -125) differed strongly from the ARE consensus sequence 
and binds AR with low affinity in band shift experiments. Mutation of the ARE strongly 
affected the androgen response of a proximal promoter fragment (-271 to + 11) (Devos 
1995). A second candidate region for androgen regulation was found in the first intron (see 
Figure I. 11). It contains a cluster of three ARE-like half sites (underlined) spauning the 39 
bp fragment N39 (CAGAGCAGATCATGTACTGGCAATGGTTCTTACCTGTCCT: 
+2684/+2722), which shows AR binding and confers weak androgen response to a 
heterologous promoter. Additional sequences surrounding this cluster of ARE-like sequences 
are needed for full activity (Ho et a1. 1993). These include a flanking upstream region [D2], 
that showed high AR binding affInity and androgen, but not glucocorticoid induced enhancer 
activity (see Figure I. 11). In D2, initially no candidate ARE sequences were identified. 
However, as a result of the establishment of the functional activity of AREs that deviate 
considerably from the consensus sequence (Table 1.2), two candidate AREs can be predicted, 
TGATCAtttGGTGAT (+2559 to +2573) and GGATCAtlcAATTCA (+2637 to +2651). 
Like in the Sip and C3 promoters, other transcription factors, including OCT and C/EBP (see 
Dl in Figure 1.11), are supposed to be involved in the full AR specific response of the 20 
kDa Proteinlerpl gene (Ho et a1. 1993). 
The pl'obasill gene 
The rat probasin gene codes for a nuclear and secreted protein of the dorsolateral prostate. 
Its expression is ill vivo regulated by androgens (Dodd et al. 1983), and to a lesser extent by 
glucocorticoids (Matusik et al. 1991). In the probasin promoter, two fragments [ARBS-I: 
ATAGCATCTTGTTCTTTAGT (-24 I 1-223) and ARBS-2: 
GT AAA GT A CTCCAA GA A CCT A TIT (- 1401-117), putative AREs are underlined], that are 
important for androgen-regulation of the promoter and that bind AR, can be found (Rennie 
et al. 1993, Kasper et al. 1994). Although both sequences were able to interact with AR 
outside the probasin promoter context, initially both AR binding sites were found to be 
individually functional inactive (Kasper et al. 1994). Even three copies of the two separate 
AR binding sites failed to give rise to androgen-induced reporter gene activity. The putative 
ARE in the ARBS-2 region (PB-ARE2: AGTACTccaAGAACC, -136 to -123) represents the 
first AR binding site which selectively interacts with the AR-DBD and not with the GR-DBD 
(Claessens et al. 1996). From studies with swapped half-sites, it was deduced that the right 
hand half-site, 5'-AGAACC-3' excludes GR binding. Reporter constructs, containing three 
copies of PB-ARE-2 linked to a mininml TK promoter, showed in transfections induction 
upon androgen treatment but not after glucocorticoid treatment, indicating that PB-ARE-2 
represents a functionally active, AR specific ARE. The functional activity of PB-ARE-2 was 
unexpected, because of the previous negative results of Kasper et al. (1994). The observed 
discrepancy might be due to differences in cell lines and culture conditions used. 
37 
Chapter I 
The B-glucuronidase (gIlS) gene 
The mouse glls gene is constitutively expressed in almost all tissues, but its expression is 
androgen regulated in kidney cells (Lund et al. 1988). The identification of the regulatory 
elements involved in this androgen regulated expression benefitted from the occurrence of 
three natural genetic variants displaying different phenotypes of androgen regulated glls 
expression (Lund et al. 1991). The presence of an androgen-inducible DNAseI hypersensitive 
site in intron 9 coincided with the androgen responsive phenotype. Careful analysis of this 
region revealed the presence of a functional ARE (AGTACTtgtTGTTCT, +7833 to +7847) 
which cooperates with a 57 bp segment at position +7990 to +8046 to generate maximal 
androgen response. Mice showing a complete absence of the androgen response were found 
to have a mutation in the ARE sequence, whereas mice with a reduced androgen response 
showed a deletion of the +8005 to +8026 segment. This region is recognized by an 
androgen inducible and kidney specific transcription factor (Lund et al. 1991). 
The human coagulation factor IX gene 
The presence of a functionally active ARE in the factor IX gene has been suggested by 
natural occurring mutations. A mutation at position -26, within the putative ARE sequence 
(AGCTCAgctTGTACT; -36 to -22) in the promoter of this gene caused a variant form of 
Hemophilia B Leyden, a bleeding disorder due to a very low level of factor IX (Crossley et 
al. 1992). Unlike the classical cases, the patient carrying this -26 mutation did not recover 
during puberty, when circulating T levels start to rise. Despite the mutation in the ARE 
sequence, the mechanism of failure of androgen response is not clear. Although AR can bind 
to this ARE, AR is only a weak activator of factor IX promoter activity in transient 
transfection experiments. The putative ARE sequence overlaps with a HNF-4 binding site 
(TTGTACTTTGGT; positions -28 to -17). The -26 mutation has been shown to completely 
block HNF-4 binding, and it has been suggested that Hemophilia throughout life is a result 
of the complete loss of HNF-4 binding (Reijnen et al. 1990). CCAAT-box binding proteins, 
binding to a region (positions + I to + 18) just downstream of the first major transcription 
start site (Reijnen et al. 1992), have been suggested to be involved in the phenotypical 
recovery of Hemophilia B Leyden around puberty in most patients (Pickets et al. 1993). 
The human glandular kallikrein-l (hGK-ll gene 
hGK-I (also known as KLK2 and hK2) is a member of the human kallikrein-like serine 
protease family. This family consists of three members, hGK-I, tissue kallikrein KLK1, and 
the extensively studied PSA gene (see sections 1.2.5., 1.2.6 and Chapters III, V and VI). 
Both PSA and hGK-I expression are regulated by androgens at the level of transcription 
(Riegman et al. 1991b, Wolf et al. 1992). The proximal promoter regions of both genes show 
80 percent homology. Expression of the hGK-I gene is restricted to the prostate. 
Transcriptional activity of hGK-I promoter fragments is induced upon androgen treatment 
(Murtha et al. 1993). In the proximal promoter a putative ARE (GGAACAgcaAGTGCT; 
-170 to -156) lVas identified, this sequence differs at only one position from the functionally 
active ARE at the same position in the PSA gene (Riegman et al. 1991b, Chapter III). 
Deletion of one half-site of this putative ARE completely abolished androgen response of 
hGK-I promoter fragments, and two copies of the ARE sequence conferred hormone 
response to a minin131 TK promoter (Murtha et al. 1993). These results clearly indicate that 
the sequence at position -170 to -156 in the hGK-l gene represents a functionally active 
ARE. 
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Other androgen regulated genes 
Transcription of the prostate arginine esterase gene, a dog kallikrein-like gene related to 
the human PSA and hGK-1 genes, is regulated by androgens (Gauthier et al. 1993). Two 
putative ARE sequences could be identified (Arg-est-ARE2: AGGGCTataGGTCCT at 
positions -230 to -216, and Arg-est-ARE1: AGGACAacaGGTGTT at positions -165 to -151) 
(Dub" et al. 1995). Although Arg-est-ARE1 was shown to interact with the AR, no 
significant effect on androgen regulation of a heterologous promoter was observed in 
transfection experiments. Arg-est-ARE2 was not tested in this respect. It might be postulated 
that cooperative action of both AREs is needed to obtain measurable androgen-induced 
activity. 
Mouse vas deferens protein (MVDP) is exclusively expressed in the epithelial cells of the 
vas deferens. In the MVDP gene promoter two ARE sequences, one in the proximal 
promoter: TGAAGTtccTGTTCT (-I I 1/-97) and one more upstream: AGAACAtgcTGCTCT 
(-1186 1-1172), are present (Fabre et al. 1994). Only the proximal ARE is functionally 
active when fused to a heterologous promoter. Although a minimal MVDP promoter 
fragment (-121 to +41) is sufficient for androgen regulation, the region -510 to + 41 gave 
maximal androgen induction. Putative binding sequences for several sequence specific 
transcription factors, including Sp1, NF-I, OCT and CCAAT box binding factors were found 
to be located in this region. 
Ornithine decarboxylase (ODC) is an ubiquitously expressed enzyme involved in polyamine 
biosynthesis. Androgen regulated expression is found in ventral prostate, seminal vesicle and 
kidney of rodents. The mouse ODC promoter region contains an ARE sequence 
(AGAACAagtGGGACT) at position -924 to -910. This sequence binds AR ill vitro and an 
ODC promoter fragment containing this sequence confers a low level of androgen response 
to a reporter gene (Eisenberg & Janne 1989, Crozat et al. 1992). 
The androgen-regulated murine epididymal protein (arMEP24) is an androgen-dependent 
glutathione peroxidase-like protein synthesized and secreted by the mouse epididymis 
(Ghyselinck et al. 1993). An ARE sequence has been found in the upstream promoter region 
(TGTTGAgagAGAACA; -896 to -882). Two or three copies of this sequence are able to add 
limited androgen regulation to a TK promoter. 
Functional transcriptional analysis of a 481 bp region of the mitochondrial aspartate 
aminotransferase (mAAT) gene showed that this region, containing two putative ARE 
sequences (GGAAAAgacTGTTCT at position -1439 to -1424 and TCTCCAtctTGTTCT at-
1465 to -1450) is sufficient for androgen regulated expression of the gene (Juang et al. 
1995). 
From the combined data presented above several general conclusions can be drawn: 
(i) Functional AREs can deviate considerably from the consensus high affinity binding site. 
(ii) Androgen regulated genes in general contain two or more AREs, which act 
synergistically. 
(iii) In addition to AREs, binding sites for ubiquitous transcription factors, and for tissue 
specific transcription factors are essential for high, androgen regulated promoter activity. 
(iv) Different mechanisms of AR specificity can occur, including ARE sequence, binding 
sites for other transcription factors and cell specific factors. 
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1.2.5. REGULATION OF PSA EXPRESSION 
PSA is a single chain glycoprotein with a molecular weight of approximately 33 kDa, first 
isolated by Wang et a!. (1979). The protein was independently isolated by others, and 
therefore is known under different names, as 'Y seminoprotein (Schaller et a!. 1987) and P-30 
(Graves et a!. 1990). PSA is a member of the family of human kallikrein-like serine 
proteases. As mentioned before, other members ofthis family are hGK-l and tissue kallikrein 
KLKl. PSA is synthesized in, and secreted by the luminal epithelial cells of the human 
prostate. Mature PSA is composed of 237 amino acids, its precursor contains a 17 amino 
acid signal peptide. For full proteolytic activity, posttranslational processing is needed 
(reviewed by Clements 1994, and Peehl 1995). III vivo, PSA may function to liquify the 
seminal coagulum by proteolysis of seminogelin and fibronectin (Lilja et a!. 1985). Laminin, 
IGF-BP3, TGF-{3 and cell surface receptors have also been suggested as substrates for PSA 
(Lee et a!. 1989, Cohen et a!. 1992, Killian et a!. 1993, Webber et a!. 1995). 
PSA cDNA (Lundwall & Lilja 1987, Riegman et al. 1988, Henntu & Vihko 1989) and the 
PSA gene (Riegman et a!. 1989a, Lundwall et a!. 1989) have been isolated and completely 
sequenced. The gene consists of five exons, and spans a region of approximately 5 Kb. The 
PSA gene is clustered with the hGK-l and KLK-l genes in the order (KLKl)-(PSA)-(hGK-
I), in an area of 60 Kb on human chromosome 19q13.2-13,4 (Evans et a!. 1988, Riegman 
et a!. 1989b, Schank et a!. 1990, Riegman et a!. 1992). PSA, and also hGK-l, is almost 
exclusively expressed in the human prostate and prostate derived tumors and tumor cell lines 
(Chapdelaine et a!. 1988, Trapman et a!. 1988, Riegman et a!. 1988, 1991a, Henntu et a!. 
1990 and 1992, Helmtu & Vihko 1992, Young et a!. 1991, 1992, Nevalainen et a!. 1993). 
PSA mRNA expression does not only show cell specificity, but is also tightly regulated by 
androgens (Riegman et a!. 1991a,b, Henntu et a!. 1992, Young et a!. 1991, 1995). 
Androgen-stimulated expression is at least partially regulated at the level of transcription 
(Riegman et· a!. 1991b, Wolf et a!. 1992). 
At present, three functional AREs have been identified in the PSA regulatory regions. Two 
functionally active AR binding sites were identified in the proximal PSA promoter, at 
positions -170 (ARE-I; AGAACAgcaAGTGCT) and -394 (ARE-II; 
GGATCAgggAGTCTC), respectively (Riegman et a!. 1991b, Cleutjens et a!. 1996; Chapter 
III). In transient transfection experiments in LNCaP prostate tumor cells, the high affinity 
AR binding site, ARE-l (-170) by itself gave rise to weak (2-fold) stimulation in the presence 
of androgens. ARE-l (-170) had to cooperate with the low affinity AR binding site, ARE-II 
at position -394 to obtain maximal (-6-fold) androgen induction of the proximal PSA 
promoter. A 6 Kb PSA promoter construct showed much higher (-3000-fold) androgen-
induced activity when transfected to LNCaP cells. A high affinity AR-binding site (ARE-III; 
GGAACAtatTGTATC), was identified in this long PSA promoter fragment, -4200 bp 
upstream of the transcription start site (Cleutjens et a!. 1997; Chapter V). ARE-III, like 
ARE-I, closely resembles the ARE consensus sequence; whereas ARE-II, which binds AR 
with lower affinity, deviates more. Although all three AREs contributed to maximal androgen 
inducibility, the presence of ARE-III in the upstream enhancer region was absolutely essential 
for high androgen regulated activity of the 6 Kb PSA promoter. ARE-III (--4200) turned 
out to be part of a complex, very strong androgen regulated enhancer region (Schuur et a!. 
1996, Cleutjens et a!. 1997). 
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The upstream enhancer region showed synergistic cooperation with the proxbnal PSA 
promoter, and was found to be composed of at least three separate, but cooperating 
regulatory regions. Although the presence of ARE-III was a prerequisite, it was not sufficient 
for strong androgen regulated activity of the enhancer region. The bnportance of the 
upstream enhancer for androgen regulated PSA expression was confirmed by the presence 
of a strong, androgen regulated DNase I hypersensitive site at this position in LNCaP cell 
chromatin. 
Transiently transfected PSA promoter constructs were active in cells with endogenous PSA 
expression (LNCaP prostate cells), but inactive in cells without endogenous PSA, with the 
exception of T47D cells (Schuur et al. 1996, Cleutjens et al. 1997, Chapter V). The cell 
specificity was retained within a 440 bp core enhancer region, encompassing the upstream 
ARE-III. (Cleutjens et al. 1997, Chapter V). Interestingly, the 6 Kb PSA promoter did not 
only show largely prostate cell specific activity in transient transfection experbnents, but was 
also capable to direct prostate specific transcription in transgenic mice (Chapter VI). 
PSA promoter activity is not AR specific. In T47D mammary tumor cells, PR stbnulated 
expression of a PSA promoter driven reporter gene could be demonstrated. Similarly, in 
LNCaP cells stably transfected with a GR expression vector, activated GR was able to 
stbnulate endogenous PSA expression, as well as the activity of a transfected, PSA promoter 
driven reporter gene (Cleutjens et al. 1997, Chapters IV and V). 
1.2.6. PSA EXPRESSION IN PROSTATE CANCER 
In Western countries, adenocarcinoma of the prostate is the most frequently diagnosed 
tumor in men, and the second leading cause of male cancer death (Parker et al. 1996). 
Therapeutic approaches for prostate cancer depend on the stage of the malignancy. In 
clinically localized prostate cancer, surgical curability is feasible through complete excision 
of the prostate (radical prostatectomy). First line therapy of locally invasive or metastatic 
disease is generally based upon androgen ablation, or blockade of AR function by anti-
androgens. Unfortunately, the effects of endocrine therapy are only temporary and after a 
variable period of time, a finally hormone refractory tumor continues to grow. 
PSA is expressed in the vast majority of prostate cancers, although its expression level is 
decreased and more heterogeneous in undifferentiated tumors (Keillor & Aterman 1987, 
Gallee et al. 1990, Partin et al. 1993, Ruizeveld de Winter et al. 1994). Incidentally, prostate 
cancers can even be PSA negative (Mai et al. 1996). Although PSA is considered to be the 
best tissue specific marker available, low PSA expression has been demonstrated in some 
male salivary gland derived tumors (vanKrieken 1993), and in mammary tumors, lactating 
breast tissue and in endometrial tissue in women (Diamandis et al. 1994, Yu & Diamandis 
1994, Clements & Muktar 1994). Also in the non-prostatic tissues, expression of PSA lVas 
suggested to be steroid hormone-dependent (Yu & Diamandis 1994, Graves 1995). 
PSA as serum marker of prostate cancer 
Although not per se a tumor marker, increased serum PSA is a strong indication of 
prostate cancer (Catalona et a11991, Oesterling 1991). In spite of its limitations, the serum 
PSA test is now a widely accepted method to screen for prostate cancer. Because occasionally 
inflammation of the prostate and BPH can also give rise to positive serum PSA values, 
additional tests, including a needle biopsy are needed for final proof. 
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Increase of serum PSA during endocrine or other therapy is generally considered as 
evidence for recurrence or progression of the tumor. What determines the increase in serum 
PSA during the development of an apparently hormone refractory tumor? Several alternative 
mechanisms can be proposed. One factor can be that, although PSA expression in individual 
tumor ceBs is decreased, the increase in tumor load leads to a net increase in serum PSA. 
Other hypotheses include hormone independent activation of the AR (Culig et a!. 1994), or 
GR or PR induced PSA expression (this thesis). However, whether prostate tumors contain 
functionally active GR or PR is presently unknown. An alternative explanation could involve 
the induction of hormone independent PSA expression using an unidentified mechanism. 
The currently widespread application of serum PSA-based prostate cancer screening has 
led to a considerable increase in the number of prostate cancer diagnoses, and a concomitant 
decrease in tumor stage at time of diagnosis (Rosen 1995, Bangma et a!. 1995). Early 
detection might provide the opportunity to detect a larger number of prostate confined 
tumors, which might still be curable. On the other hand, it is a real possibility that PSA-
based screening leads to overdiagnosis and subsequent overtreatment. 
Because, like PSA, hGK-l expression is prostate specific, it is a second candidate for 
application in prostate cancer diagnosis. The hGK-1 mRNA level has been estimated to 
amount 10 to 50 percent of PSA mRNA in prostate (Chapdelaine et a!. 1988, Henntu et a!. 
1990, Young et a!. 1992, Young 1996). In serum, the proportion of hGK-l relative to PSA 
seems to be low (Piironen et a!. 1996). Therefore, the clinical significance of serum hGK-l 
tests remains elusive. 
PSA mRNA as marker of circulating tumor cells 
In addition to its role in the early detection of prostate cancer, and as a marker for 
monitoring therapy, PSA expression might have additional clinical relevance. Approximately 
50 percent of patients with clinically localized prostate cancer show extra-prostatic disease 
upon histopathological screening of the prostate and regional Iymphnodes (Epstein et a!. 
1993, Rosen et a!. 1992). A substantial proportion of these patients will, despite radical 
prostatectomy, relapse with locally recurrent or metastatic disease. In patients with clinically 
localized prostate cancer, the detection of prostate cells in the circulation might be an 
indication of the presence of micrometastases, and thus might be a means to discriminate 
between the presence of locally coufmed tumors and tumors with extra-prostatic spreading. 
Establisbunent of otherwise undetectable micrometastases might lead to a different 
therapeutical approach. 
Circulating prostate tumor cells can theoretically be detected by means of RT-PCR for 
mRNAs, specifically expressed by prostate (tumor) cells and not by other cells in the blood. 
Because PSA is ahnost exclusively expressed by prostate epithelial cells, it is a good 
candidate. Several reports, applying PSA mRNA based RT-PCR for detection of circulating 
tumor cells, have now been published (Hambdy et a!. 1992, Moreno et a!. 1992, Israeli et 
a!. 1994, Katz et a!. 1995, Cama et a!. 1995, Jaakola et a!. 1995). There is substantial 
variation in the percentage of patients with proven metastases, in which PSA mRNA is 
detectable in the blood. Because of the very low level of PSA mRNA in the blood, the 
method is prone to false negative and false positive (contamination) values. Therefore, the 
clinical relevance of the assay remains to be established. 
Besides PSA-based RT-PCR, a second related analysis, RT-PCR based upon Prostate 
specific membrane antigen (PSM or PSMA) mRNA for detection of circulating prostate 
tumor cells is currently under investigation. Cloning of the cDNA encoding PSM (Israeli et 
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al. 1993) showed that it is a transmembrane glycoprotein. A high level of expression was 
observed in normal prostate and both primary and metastasized prostate tumors (Israeli et al. 
1994). Recently, the prostate specificity of PSM expression has become a matter of debate. 
Examination of a set of normal tissues revealed the presence of significant PSM expression 
in duodenal mucosa, a subset of renal tubules and certain neurocrine cells in the colon crypts 
(Silver et al. 1997). Leek et al. (1995) suggested the existence of a second, related gene, 
which might further complicate the specificity of PSM. 
1.2,7. THE ANDROGEN RECEPTOR IN PROSTATE CANCER 
One of the most important questions in prostate cancer biology concerns the role of 
androgens. Initially, the growth of the majority of prostate tumors depends, like normal 
prostate development, on androgens. Therefore, as discussed above, therapy of metastasized 
tumors is generally based upon androgen ablation or blockade of AR function. After Ollset 
of endocrine therapy, most prostate tumors show regression. However, essentially all 
originally hormone responsive tumors become apparently hormone independent during time. 
From a clinical point of view it is very important to elucidate the mechanisms involved in 
androgen dependent and androgen refractory prostate tumor growth. 
An important first question concerns the role of the AR. The majority of locally 
progressive, hormone refractory tumors show high AR expression, although more 
heterogeneous than in the normal prostate (van der Kwast et al. 1991, Sadi et al. 1991, Sadi 
& Barreck 1993, Chodak et al. 1992, Ruizeveld de Winter et al. 1994, Tilley et al. 1994, 
reviewed by Trapman & Brinkmann 1996). Interestingly, distant prostatic carcinoma 
metastases in bone express AR (Hobish et al. 1995) and the expression level seems even 
higher and more homogeneous than in locally recurrent tumor (K1einerman, unpublished). 
An increased level of AR expression could allow cancer cells to continue androgen-dependent 
growth in the presence of a low level of semm androgen. AR overexpression could be the 
result of amplification of the AR gene, as recently observed in a proportion of hormone 
refractory prostate tumors (Visakorpi et al. 1995, Koivisto et al. 1997). Importantly, AR 
gene amplification has never been detected in tumors prior to endocrine therapy. 
Additionally, alternative AR activation could play a role in apparently androgen-
independent prostate cancer. In prostate cancer cell lines, growth factors (for example IGF-I 
and KGF) have been found to induce AR mediated, promoter specific transcriptional 
activation (Culig et al. 1994). Furthermore, cross-talk between AR and both the PKA or 
PKC-signalling pathways has been reported (Ikonen et al. 1994, deRuiter et al. 1995, 
Nazareth & Weigel 1996). 
Also, stmctural changes in the AR could account for androgen-independent activation of 
the receptor. A classical example is the point mutation in the AR gene in the LNCaP prostate 
cancer cell line (alanine to threonine substitution at position 868 in the LBD), which renders 
the receptor responsive to anti-androgens, estrogens and progestins (Veldscholte et al. 1990). 
Mutations in the AR gene have been detected in both primary prostate cancer and in 
metastases. Their prevalence in locally progressive, hormone dependent or refractory prostate 
tumors is low according to most studies (Newark et al. 1992, Culig et al. 1993, Suzuki et 
al. 1993, Gaddipati et al. 1994, Peterziel et al. 1995, Quigly et al. 1995, Koivisto et al. 
1997). The proportion of mutations seems highest in late stage tumors (Taplin et al. 1995). 
For a limited number of tumors, it has been shown that the mutation can lead to altered 
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ligand specificity (Culig et al. 1993, Ris-Stalpers et al. 1993, Pieterziel et al. 1995, Taplin 
et al. 1995). At present the prevailing explanation for AR mutations in prostate cancer is, 
that they represent a mixture of functional and random mutations resulting from genetic 
instability (Trapman & Brinkmann, 1996). 
In AR negative prostate tumors, none of the previously described mechanisms can account 
for the androgen-independent growth of the tumor. In these tumors, alternative tumor specific 
pathways must have bypassed the AR dependent process of growth stinmlation. These 
pathways may implicate inactivation of tumorsuppressor genes and activation of oncogenes 
(Thompson 1990). However, the genes involved in the majority of prostate cancers have not 
been identified as yet. 
Although in general AR stimulates prostate cancer growth, AR mediated tumor cell growth 
repression was recently also shown (Zhau et al. 1996). Whether the androgen-repressed 
phenotype is an incidental occurrence or may represent a larger subpopulation of hormone 
refractory prostate tumors remains to be established. 
In conclusion, several not mutually exclusive mechanisms for the growth of hormone-
refractory prostate tumors have been proposed. Elucidation of the mechanisms involved in 
hormone-refractory prostate tumor growth can ultimately lead to the improvement of the 
currently available therapeutic regimens. 
1.2,8, PROSTATE SPECIF1C PROMOTERS IN PROSTATE CANCER MODELS 
Progress towards a better understanding of the biology of prostate cancer, including its 
escape from regulation by androgens would benefit enormously from animal models 
displaying the full range of clinical stages of this disease. These models will also be 
indispensable for the development of new therapeutic approaches. Prostate cancer is 
essentially unique to humans. Generally spoken two different prostate cancer model systems 
can be envisaged: serial transplantable human xenografts and transgenic animal models. Both 
model systems display their own specific favorable and unfavorable features. Serially 
transplantable prostate cancer xenografts, although in an athymic nude mouse host, are of 
human origin (Nagabhushan et al. 1996, van Weerden et al. 1996). A major disadvantage 
of xenograft models is the variation of tumor take and growth rate and metastatic capacity, 
dependent on the site of transplantation. Furthermore, the effect of the immune system on 
turuor progression calmot be studied. Essentially, transgenic animals constitute a useful model 
for the study of multistep tumor progression and may serve as experimental system to 
develop and evaluate new therapeutic approaches. They provide a source of reproducible 
tumors with known genetic make-up. Major drawbacks of these models are the limitation to 
tumors of rodent origin (e.g. mouse), and the lack of knowledge of the most important genes 
involved in human prostate cancer, which can be applied to build the model. 
A prerequisite of the establishment of a transgenic prostate cancer model is a promoter 
to target a heterologous gene with oncogenic properties to the appropriate prostate epithelial 
cells. Several attempts to generate inbred mouse prostate cancer models have been made. 
Schaffner et al. (1995) explored the capacity of the proximal 632 bp PSA promoter to induce 
prostate cancer in transgenic mice. However, mice carrying a Ha-rasT24 oncogene driven 
by the proximal PSA promoter, developed salivary gland and gastrointestinal tract tumors. 
Mutant Ha-ras expression was confirmed in salivary gland tumors, but not in gastrointestinal 
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tumors. Tumors arose in animals over 44 weeks of age. The late onset of tumorigenesis 
could indicate that the proximal PSA promoter driven oncogene expression was a secondary 
event. 
A C3(l) promoter fragment was successfully applied to direct prostate tumor development 
in mice. Transgenic mice carrying a 5.7 Kb C3(l) promoter fragment linked to the SV40 
large T antigen (Tag) developed prostate adenoma or adenocarcinoma in almost all males 
surviving to the age of 7 months (Maroulakou et al. 1994). All female mice carrying this 
transgene acquired mammary adenocarcinomas. Besides prostate and mammary 
adenocarcinomas, the mice developed other phenotypic changes including several 
proliferative lesions and malignancies leading to premature death. So this model seems not 
the most promising to generate a prostate cancer model. 
Transgenic mice carrying the 426 bp probasin promoter driven SV40 large T antigen 
oncoprotein (TRAMP mice), develop progressive forms of prostatic cancer (Greenberg et al. 
1995, Gingrich et al. 1996). Tumors have been detected specifically in the prostate as early 
as 10 weeks of age, and distant metastases can be found at 12 weeks (Gingrich et al. 1996). 
It is important to note that expression of Tag precedes the histological appearance of 
carcinomas. Furthermore, not all Tag expressing cells became hyperplastic or cancer cells 
(Gingrich et al. 1996). The same observation was made in the transgenic mouse model usiug 
the SV40 large T antigen oncogen, driven by the C3(l) promoter (Maroulakou et al. 1994). 
Cells expressing the transgene seem to be initially in a preneoplastic state and additional 
events are probably needed to confer the cells to the full malignant state. In all presently 
available transgenic prostate cancer models, strong viral oncogenes are targeted to the 
prostate. In the future, additional transgenic animal models, targeting gene products 
implicated in clinically important human prostate cancer might reveal extra information about 
the mechanisms underlying the different stages of prostate cancer initiation and progression. 
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I.3. SCOPE OF TIDS THESIS 
The goal of the present study was the identification and characterization of prostate specific 
transcription factors involved in growth and differentiation of the prostate. It was 
hypothesized that these factors could also play a role in the initial development and 
progressive growth of prostate cancer. To reach the target, two complementary experimental 
approaches were employed. The first approach included a search for novel, prostate specific 
members of known families of transcription factors, based upon the homology in the DNA 
binding domains. Using PCR techniques, expression in the prostate of the C/EBP 
transcription factor family was studied. The C/EBP family was selected as a potentially 
interesting candidate, because of literature data, suggesting the involvement of C/EBP in the 
prostate specific activity of the rat C3(1) promoter. As a result of this attempt, the C/EBPIi 
gene was cloned. C/EBPIi found to be the major C/EBP expressed in LNCaP cells (Chapter 
II), however, C/EBPIi expression appeared not to be prostate specific. 
The second approach focussed on the mechanism of PSA expression. PSA is one of the 
main products of luminal prostate epithelial cells, the cell type which prostate cancer cells 
resemble most. Furthermore, high levels of PSA expression are only observed in prostate and 
prostate derived tumors. At the time of initiation of the work described in this thesis, one of 
the factors involved in the regulation of PSA expression was already identified, the AR. In 
the prostate, the AR is not only involved in the regulation of PSA expression, but is also 
essential for its development and maintenance of function. Although the AR is not prostate 
specific, AR expression is also high in other cells of the male urogenital tract, it was 
considered as an hnportant candidate for further study. So, knowledge on molecular 
mechanisms involved in PSA gene expression would provide information on mechanisms of 
androgen regulated, and prostate-specific gene expression. As additional spin off, the 
knowledge on regulatory elements involved in prostate specific PSA expression might be used 
to direct high, prostate specific expression of a therapeutic gene to the prostate, and to 
develop anhnal prostate cancer models. 
The analysis of the regulatory regions involved in androgen regulated and prostate specific 
expression of the PSA gene was initiated by transient transfection experiments in PSA and 
AR positive LNCaP prostate cells. The studies resulted in the identification of three 
functionally active androgen response elements in the PSA promoter, two (ARE-I and ARE-
II) in the proximal promoter (Chapter III), and one (ARE-III) in a far upstream enhancer 
region (Chapter V). Because the sequence for high affinity DNA binding of the AR and 
several other steroid hormone receptors including the GR is identical, the mechanism 
underlying the apparent androgen specific induction of PSA promoter activity in LNCaP 
prostate cells was investigated (Chapter IV). The far upstream enhancer region, 
encompassing ARE-III, showed mainly LNCaP prostate cell activity in transient transfection 
experhnents (Chapter V). In order to test whether a 6 Kb PSA promoter fragment containing 
both the upstream enllancer region and the proxhnal promoter, was able to direct prostate 
specific and androgen regulated activity ill vivo, transgenic mice with the 6 Kb fragment and 
the proxhnal PSA promoter fragment linked to the LacZ reporter gene were generated. The 
results presented in Chapter VI clearly indicate that the 6 Kb promoter fragment is indeed 
capable to direct prostate specificity. Chapter VII summarizes our findings, reviews them in 
light of recent literature data and indicates future directions for research. 
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ABSTRACT 
In an attempt to identify C/EBP-like transcription factors expressed in the prostate, a 
cDNA homologous to the mouse C/EBPo (CRP3) and the rat CELF gene was isolated. A 
genomic clone containing the entire C/EBPo gene was isolated using a cDNA fragment as 
a probe. The gene was characterized by restriction mapping and sequence analysis. By 
fluorescent in situ hybridization, using the biotinylated genomic clone as a probe, the C/EBPo 
gene was assigned to the pericentromeric region of human chromosome 8, most probably to 
8qIl. This chromosomal localization was confirmed by analysis of a panel of human x 
hamster somatic cell hybrid DNA samples with a C/EBPo specific STS. As a result, the 
C/EBPo gene could be positioned between the PLAT and MOS locus. 
INTRODUCTION 
The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors is important 
for regulation of the expression of many different genes (2). C/EBP-like proteins are 
members of the family of leucine zipper (bZIP) transcription factors, characterized by a basic 
DNA binding domain linked to heptad leucine repeats, which mediate dimerization. The 
DNA binding domain is well conserved between the different C/EBP-like proteins, but 
further structural homology is limited (14). 
Expression of C/EBP-like proteins can be cell type dependent, and can vary during 
differentiation. C/EBP (13), hereafter called C/EBPa, is primarily expressed in liver and fat 
tissue, and at lower levels in intestine and lung (2,22). C/EBPa expression in these tissues 
is restricted to terminally differentiated cells. C/EBPiJ (6) [also named CRP2 (24), AGP/EBP 
(4), IL-6DBP (16), NF-IL6 (1) and LAP (9)], C/EBP'Y (6) [Ig/EBP (18)], and C/EBPo (6) 
[CRP3 (24) or CELF (11)] are almost ubiquitously expressed in different tissues, but at 
varying levels. C/EBPo expression is most abundant in kidney and testis. 
To identify C/EBP-like transcription factors which are expressed in prostate, first strand 
cDNA of poly(A)+ RNA from LNCaP cells, a human prostate carcinoma cell line, was 
prepared with a Tl2SITE primer (3' TTTTTTTTTTTTCCTAGGCTTAAGCGTACG 5'), 
using standard conditions. The first strand cDNA was then amplified by PCR using the SITE 
primer (3' CCTAGGCTTAAGCGTACG 5') and a primer specific to the DNA binding 
domain of C/EBP-like transcription factors (5' CAACATCGCGGTGCGCAAGAGC 3'). 
Both primers contain a restriction site (underlined; EcoRI and FspI, respectively), which 
were used to insert the PCR products in the pTZI9 vector (Pharmacia, Uppsala, Sweden). 
Twenty seven independent clones were isolated. Subsequent sequence analysis identified four 
clones containing an insert encoding a heptad leucine repeat. The four clones showed the 
same sequence, which turned out to be closely related to the 3' region of the mouse C/EBPo 
(CRP3) gene (24) and the rat CELF gene (1 I), indicating the isolation of the human C/EBPo 
(CELF) homoloque. The selective isolation of the C/EBPo cDNA, and no other known or 
unknown C/EBP-like cDNAs, could implicate that the C/EBPo mRNA is the most abundant 
C/EBP-like transcript in human prostate. Alternatively, the PCR conditions might have been 
in favour of this specific eDNA. 
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-120 CCCCCGCGGTGCCGGAGTCGGGGCGGGGCGTGCACGTCAGCCGGGGCTAGAAAAGGCGGC 
-60 GGGGCTGGGCCCAGCGAGGTGACAGCCTCGCTTGGACGCAGAGCCCGGCCCGACGCCGCC 
M S A A L F S L D G PAR GAP W P A E 
1 ATGAGCGCCGCGCTCTTCAGCCTGGACGGCCCGGCGCGCGGCGCGCCCrGGCCTGCGGAG 
PAP F YEP G RAG K P G R G A E P G 
61 CCTGCGCCCTTCTACGAACCGGGCCGGGCGGGCAAGCCGGGCCGCGGGQCCGAGCCAGGG 
A L G E P G A A A PAM Y D DES A I D 
121 GCCCTAGGCGAGCCAGGCGCCGCCGCCCCCGCCATGTACGACGACGAGAGCGCCATCGAC 
F SAY IDS M A A V P T L E L C H D E 
181 TTCAGCGCCTACATCGACTCCATGGCCGCCGTGCCCACCCTGGAGCTGTGCCACGACGAG 
L FAD L F N S N H K A G GAG P L E L 
241 CTCTTCGCCGACCTCTTCAACAGCAATCACAAGGCGGGCGGCGCGGGGCCCCTGGAGCTT 
LPG G PAR P L G P G P A APR L L K 
301 CTTCCCGGCGGCCCCGCGCGCCCCTTGGGCCCGGGCCCTGCCGCTCCCCGCCTGCTCAAG 
REP D W G D G D A P G S L L P A Q V G 
361 CGCGAGCCCGACTGGGGCGACGGCGACGCGCCCGGCTCGCTGTTGCCCGCGCAGGTGGGC 
P C A Q T V V S L A A A G Q P T P P T S 
421 CCGTGCGCACAGACCGTGGTGAGCTTGGCGGCCGCAGGGCAGCCCACCCCGCCCACGTCG 
PEP P R SSP R Q T PAP G PAR E K 
481 CCGGAGCCGCCGCGCAGCAGCCCCAGGCAGACCCCCGCGCCCGGCCCCGCCCGGGAGAAG 
SAG K R G P D R G S P E Y R Q R R E R 
541 AGCGCCGGCAAGAGGGGCCCGGACCGCGGCAGCCCCGAGTACCGGCAGCGGCGCGAGCGC 
N N I A V R K S R D K A K R R N Q E M Q 
601 AACAACATCGCCGTGCGCAAGAGCCGCGACAAGGCCAAGCGGCGCAACCAGGAGATGCAG 
Q K L VEL S A ENE K L H Q R V E Q L 
661 CAGAAGTTGGTGGAGCTGTCGGCTGAGAACGAGAAGCTGCACCAGCGCGTGGAGCAGCTC 
T R D LAG L R Q F F K Q L P S P P F L 
721 ACGCGGGACCTGGCCGGCCTCCGGCAGTTCTTCAAGCAGCTGCCCAGCCCGCCCTTCCTG 
P A A G TAD C R 
781 CCGGCCGCCGGGACAGCAGACTGCCGGTAACGCGCGGCCGGGGCGGGAGAGACTCAGCAA 
841 CGACCCATACCTCAGACCCGACGGCCCGGAGCGGAGCGCGCCCTGCCCTGGCGCAGCCAG 
901 AGCCGCCGGGTGCCCGCTGCAGTTTCTTGGGACATAGGAGCGCAAAGAAGCTACAGCCTG 
961 GACTTACCACCACTAAACTGCGAGAGAAGCTAAACGTGTTTATTTTCCCTTAAATTATTT 
1021 TTGTAATGGTAGCTTTTTCTACATCTTACTCCTGTTGATGCAGCTAAGGTACATTTGTAA 
1081 AAAGAAAAAAAACCAGACTTTTCAGACAAACCCTTTGTATTGTAGATAAGAGGAAAAGAC 
1141 TGAGCATGCTCACTTTTTTATATTAATTTTTACAGTATTTGTAAGAATAAAGCAGCATTT 
1201 GAAATCGCCCCTGCTTCCTATATTCGCAGTGACTCCCGCCCGCCCGCCGCCGCCGGTCGG 
1261 AGGACCCGGCTCGGAAGGGCGTTCCGGACCGCAGCCAGCCAGCACCTAGGGAGCCCGGGC 
1321 GCCAGGTGTGTGTGTGGGGGGQGCGGGGGGATGGGCGCAGCGGCGAGCTACTCAGGAGAG 
1381 AGGGTCTGTCGCTTTTAAAACGCATTAAAGGCTCTCTCCTGGCCTTATTTAACTTGCCTA 
1441 AGCTAGGTGGAGCACGGCTGAGCTC 
Figure lI.l. (A) Restriction JJlap of the genomic clolle (J\2KJ) containillg the CIEBPli sequellce. A 
more detailed restriction map oJ a region of 5.5 kb encompassing the entire gene is showJI below. The 
open readillg frame is shown as a dark box. 171e 5'- alld 3'-lllltrallslated regions are represemed by 
open boxes. 17w horizollfal arrow indicates the direction of transcription. B=BamHl; E=EcoRl; 
H=HilldlII; S=Ssll; Sp=Splll; P=Psll. (B) Nllcleotide alld deduced amillo acid sequellce of tile 
human CIEBPli gene. 17,e presumed TATAAA box alld the polyadenylatioll signal are llIiderlillea. l7le 
position of the transcriptional start site, as indicated by all arrow, is drawn 011 basis of similarity to 
the mouse CIEBPli gene. l71e poly(A) attachmelll site is indicated by all asterisk. l71e primer ill the 
DNA binding domam. llsed for amplification of first strand cDNA is double underlined. 171e latter 
oligo and the reverse of the 962 to 983 sequence were used as STS for chromosomal mapping. 
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A human genomic library (Sau 3A partial digest in EMBL3) was screened with the 
C/EBP6 eDNA fragment as a probe. This resuited in the isolation of one clone (A2KI), 
which contains the complete C/EBP6 gene (Fig.IA). The gene was characterized by 
restriction mapping and sequence analysis (Fig.IA,B). The human C/EBP6 turned out to be 
a one exon gene with a large open reading frame encoding a protein of 269 amino acids. 
Southern blot hybridization of genomic DNA with a human C/EBP6 probe showed the human 
C/EBP6 gene to be single copy (data not shown). The homology with the mouse C/EBP6 
(CRP3) gene is 80% on nucleotide level and 85% on amino acid level. The homology with 
the rat CELF gene is 75% and 86%, respectively. When this work was in progress Kinoshita 
et al. reported the isolation of the human NF-IL6{3 gene (12). Although there is a difference 
of two amino acids (amino acid residues 2 and 13, respectively) and a homology of only 95% 
in the 3' untranslated region, the NF-IL6{3 and the human C/EBP6 gene most probably are 
two different allelic forms of the same gene. 
Figure II. 2. (AJ Competitive III Situ hybridization o/Jlllmalllllelapltase chromosome spreads witlt the 
genomic CIEBP5 clone X2Kl. TIle position of the j7uorescelltly labeled CIEBPfJ gelle at chromosome 
8 is indicated by Gn arrow. (B) Comparison of chromosome 8 III Situ hybridization with probe )"'2Kl 
(B1) with R-balldillg (B2). 
To determine the chromosomal localization of the C/EBPo gene, simultaneous fluorescent 
in situ hybridization (FISH) and R-banding on metaphase chromosome spreads were 
performed (7,8). The biotinylated genomic clone A2KI was used as a probe. By comparison 
of the FISH results with the R-banding, the human C/EBP6 gene could be assigned to 
chromosome 8 (Fig.2). The resuits are very suggestive for an 8qll localization, very close 
to the centromere (Fig.2B), however, mapping to the short arm at 8pll cannot completely 
be ruled out. 
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Figure 1I.3. Regional assignment a/the CIEBP5 gel/e, lIsing a human.\" hamster somatic hybrid cell 
panel. (A) Schell/atical representation of the chromosome 8 /ragmellfs preseflf ill the mappillg pallel 
(see also ref. 23). (B) Mapping of the CIEBP5 gellomic fragment all the chromosome 8 pallel. 
Radioactive peR alld PAGE analysis of the amplified CIEBPo!ragmellf were essellfiallyas described 
(19). 
To confirm the chromosomal localization, and to determine in more detail the regional 
position of the human C/EBPS gene at the chromosomal map, a panel of human x hamster 
somatic cell hybrids, containing chromosome 8 as the single human chromosome (CL17), 
or chromosome 8 fragments (see Fig.3 and ref.23) was analyzed with a C/EBPO specific STS 
(see legend to Fig.I). The results obtained are summarized in Figure 3. As expected, CLl7 
gave a positive signal of the correct size. All data obtained with hybrids containing 
chromosome 8 fragments are in agreement with the assignment of the C/EBPS gene to the 
pericentromeric region of chromosome 8. Most importantly, the amplified C/EBPS fragment 
was present in clone ISHL3 and absent in ISHL27 and 20xP0435-2 (Fig.3B). This positions 
the C/EBPS gene between MOS at 8ql1 and PLAT, which has been mapped to 8p12-q11.2 
(23, and refs therein). The pericentromeric localization of the C/EBPO gene links it to the 
autosomal dominant retinitis pigmentosa locus (RPI) (3). 
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Two other C/EBP genes, C/EBP", and DBP (15) are located at human chromosome 19 
(10,20). The C/EBPiJ gene is assigned to human chromosome 20 (10,21). So, with possibly 
one exception, the C/EBP gene family, as mapped so far, is scattered over the human 
genome. The murine C/EBPIi gene has recently been linked to chromosome 16 (cited in 24). 
The mouse MOS locus is at chromosome 4 (17); PLAT at chromosome 8 (5). This shows 
that the pericentromeric region of human chromosome 8 (8pll-qll) is not conserved in one 
specific mouse chromosomal segment. 
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SUMMARY 
Transcription of the Prostate-specific Antigen (PSA) gene is androgen regulated. The PSA 
promoter contains at position -170 the sequence AGAACAgcaAGTGCT, which is closely 
related to the ARE (androgen response element) consensus sequence GGTACAnnnTGTTCT. 
This sequence is a high affinity androgen receptor (AR) binding site and acts as a functional 
ARE in transfected LNCaP cells. A 35 bp segment starting at -400 (ARR: Androgen 
Response Region; GTGGTGCAGGGATCAGGGAGTCTCACAATCTCCTG) cooperates with 
the ARE in androgen induction of the PSA promoter. A construct with three ARR copies lin-
ked to a minimal PSA promoter showed a strong (104-fold), androgen induced activity. The 
ARR was also able to confer androgen responsiveness to a minimal thymidine kinase (TK) 
promoter. Both AR binding and transcriptional activity resided in a 20 bp ARR subfragment: 
CAGGGATCAGGGAGTCTCAC (2S). Mutational analysis indicated that the sequence 
GGATCAgggAGTCTC in the 2S fragment is a functionally active, low affinity AR binding 
site. Like AR, the glucocorticoid receptor (GR) was able to stimulate PSA promoter activity. 
Both the ARE and ARR are involved in dexamethasone regulatin of the PSA promoter. Both 
the AR and GR promoter constructs were 20- to 100- fold more active on ARR-PSA and 
ARR-TK promoter constructs than in other cell types (COS, HeLa, Hep3B and T47D cells), 
indicating (prostate) cell specificity. 
INTRODUCTION 
Androgens exert their function via the intracellular androgen receptor (AR), which is a 
member of the family of the steroid hormone receptors (see for reviews 1,2). Upon ligand 
binding, steroid receptors interact with specific DNA sequences and regulate the 
transcriptional activity of target genes (1-3). The DNA structures to which steroid receptors 
bind with high affinity are imperfect palindromic sequences, separated by a 3 bp spacer. The 
consensus sequence of the response element for the glucocorticoid receptor (GR), progeste-
rone receptor (PR) and AR is identical: GGTACAnnnTGTTCT (HRE: hormone response 
element) (1-6). However, in natural target genes, the binding site can deviate considerably 
from the consensus sequence. Analysis of natural and synthetic promoters has shown that 
steroid receptors are able to act synergistically with a variety of other transcription factors 
(2,7-9). Synergistical interaction of two HREs has also been observed (7,8). At present it is 
unclear how specificity of the ARIGR/PR response operates. Several mutually not exclusive 
mechanisms have been proposed, including subtle differences in sequences flanking the HRE, 
differences in affmity to general or specific transcription factors, interaction with specific 
accessory proteins, or differences in cellular concentration of the specific receptors and 
ligands. 
We use the Prostate-specific Antigen (PSA) gene as a model for androgen regulated gene 
expression. PSA is expressed at high level in the luminal epithelial cells of the prostate, and 
is absent or expressed at very low levels in other tissues. PSA is a member of the human 
kallikrein gene family, and is well known as a prostate-specific tumor marker (10,11). 
Further members of the kallikrein gene family are the hGK-I gene and the tissue kallikrein 
gene (KLK-I) (12-15). The three genes are clustered in an area of 60 kb on chromosome 
19q13.2-13.4 (15-18). In previous studies we and others have shown that PSA mRNA 
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expression is androgen-regulated (19-22). Androgen-stimulated expression of PSA is at least 
partially regulated at the level of transcription (22,23). A functional ARE (androgen 
responsive element) was defmed at -170 which closely resembles the ARE consensus 
sequence (23). 
In the present study we address the following questions: (i) which PSA promoter elements, 
additionally to the ARE (-170) are the major contributors to its androgen regulation, (ii) is 
PSA promoter regulation AR specific, and (iii) is steroid hormone regulation of the PSA 
promoter cell type specific. 
MATERIALS AND METHODS 
Cell culture 
LNCaP cells were cultured in RPMI 1640, supplemented with 5 % fetal calf serum 
(Boehringer, Mannheim, Germany) and antibiotics. For transfection, cells were grown in 
Dulbecco's Modification of Eagle's Medium supplemented with 5 % steroid-depleted 
(dextran-charcoal treated) fetal calf serum. For examination of androgen-driven promoter 
activation by transfection, the synthetic androgen R1881 (New England Nuclear, Boston, 
MA) was added to a final concentration of 1 nM. For examination of glucocorticoid-regulated 
activation, a final concentration of 10 nM of the synthetic glucocorticoid dexamethasone 
(Sigma, St. Louis, MO) was used. 
Construction of plasmids 
All plasmid constructs were prepared using standard methods (24). The human AR 
expression plasmid pARO, the rat GR expression plasmid PSTC GR 3-795 and the plasmid 
pRlTlTAR to produce AR(DBD) were described previously (25-27). The promoter-less basic 
plasmid pLUC, which was used for cloning of PSA promoter fragments in front of the LUC 
reporter gene, was derived from pSLA3 (28) by insertion of an oligonucleotide containing 
a multiple cloning site (MCS) (HindIII, PvuII, Nhel, BglII and Ncol) in the HindIII and Ncol 
sites ofPSLA3. PSA-LUC constructs, PSA-4-LUC (EcoRl/HindIII; -6321 + 12), PSA-S-LUC 
(BglII/HindIII, -539/+12), PSA-6-LUC (XhoII/HindIII; -324/+12) and PSA-7-LUC 
(NheIlHindIII; -1571+ 12) were generated by ligation of the appropriate fragments in the 
MCS ofpLUC. 
Constructs PSA-8 to PSA-Il-LUC were obtained by exonuclease III digestion of PSA-2-
CAT (-6321 + 12)(23) from the Sail site. After exonuclease III incubation according to the 
'Erase a base' protocol (Promega, Madison, WI), the plasmid was digested with HindIII and 
the derived promoter fragments were ligated in the MCS of pLUC. This resulted in the 
constructs PSA-8-LUC, starting at -488, PSA-9-LUC, starting at -456, PSA-IO-LUC starting 
at -395 and PSA-II-LUC, starting at -376. Construct PSA-12-LUC was prepared by 
introduction of a Pst! site at position -174 by PCR. The PCR product was digested with Pst! 
and HindIII ( + 12) and isolated from a 1.5 % agarose gel. The isolated fragment was ligated 
in the Pst! and HindIII sites of the pLUC MCS. One and three copies of the -400 to -366 
oligomer were cloned in front of the PSA-12-LUC and the TK-LUC construct. Double-
stranded oligonucleotides spanning ARR (-400 to -366) 
S'GATCCGTGGTGCAGGGATCAGGGAGTCTCACAATCTCCTG 3' were inserted in the 
BamHI site of PSA-12-LUC and TK-LUC. Double stranded oligonucleotides spanning three 
copies of the ARR-1S; GTGGTGCAGGGATCAGGGAG, ARR-2S; 
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CAGGGATCAGGGAGTCTCAC, ARR-3S region; GAGTCTACAATCTCCTG and the 
ARR-2S mutants (mutations are underlined) ARR-2S-1; CAGGGGATQAGGGAGTCTCAC, 
ARR-2S-2; CAGGGATCAGGGACTCTCAC and ARR-2S-3; 
CAGGGATCAG£:GAGTCTCAC, containing Sail compatible ends were inserted in the Sail 
site of PSA-12-LUC. All constructs were verified by sequencing. 
Transfections 
LNCaP cells were transfected according to the calcium phosphate precipitation method 
essentially as described (29), using 1 x 10' cells per 25cm' flask, 5 I'g of the appropriate 
PSA-LUC construct, and where indicated 2.51'g pARO or PSTC GR 3-795 (GR expression 
vector). After overnight incubation with the precipitate, the culture medium was removed and 
replaced by phosphate buffered saline (PBS), containing 15% glycerol (incubation for 90 sec 
at room temperature). Subsequently, transfected cells were incubated in culture medium in 
the absence or presence of the appropriate hormone (R1881 or dexamethasone) for at least 
24 h. Transfections were performed at least three times in duplicate, using at least two 
independent plasmid isolates. 
Luciferase activities were corrected for variations in protein concentrations within the 100 
pi cell extracts. Luciferase activities and relative induction factors are expressed as mean and 
standard error of the mean (SEM). 
Luciferase assay 
Cells were washed once with PBS and lysed in 300 1'1 lysis buffer (25 mM Tris-phosphate 
pH 7.8, 8 mM MgCI" 1 mM DTT, 1 % Triton X-lOO, 15 % glycerol). Next, 1001'1 
Luciferin (0.25 I'M) (Sigma)! 0.25 I'M ATP was added to 100 1'1 of each extract, and 
luciferase activity was measured in a LUMAC 2500 M Biocounter (LUMAC, Landgraaf, 
The Netherlands). After a delay of 2 sec (according to supplier), the light emission during 
5 sec was recorded. 
Gel retardation analysis 
Nuclear extracts were prepared as described by Dignam et al. (30). Coupled 
transcription/translation of human AR cDNA cloned in BluescriptII-KS (31) was carried out 
according to the protocol of the manufacturer of the system (Promega). AR synthesis was in 
the presence of 10 I'M ZnCI,. Production in E. coli, and purification of AR(DBD) was done 
as described previously (27). 
Double stranded oligonucleotide probes used in gel retardations: 
ARE: 5' GATCCTTGCAGAACAGCAAGTGCTAGCTG 3 ' 
GAACGTCTTGTCGTTCACGATCGACCTAG 
ARR: 5' GATCCGTGGTGCAGGGATCAGGGAGTCTCACAATCTCCTG 3' 
GCACCACGTCCCTAGTCCCTCAGAGTGTTAGAGGACCTAG 
ARR-1S: 5' GATCCGTGGTGCAGGGATCAGGGAG 3' 
GCACCACGTCCCTAGTCCCTCCTAG 
ARR-2S: 5' GATCCAGGGATCAGGGAGTCTCACG 3' 
GTCCCTAGTCCCTCAGAGTGCCTAG 
ARR-3S: 5' GATCCGAGTCTCACAATCTCCTGAG 3' 
GCTCAGAGTGTTAGAGGACTCCTAG 
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ARR-2S-1: 5' GATCCAGGGATGAGGGAGTCTCACG 3' 
GTCCCTACTCCCTCAGAGTGCCTAG 
ARR-2S-2: 5' GATCCAGGGATCAGGGACTCTCACG 3' 
GTCCCTAGTCCCTGAGAGTGCCTAG 
ARR-2S-3: 5' GATCCAGGGATCAGCGAGTCTCACG 3' 
GTCCCTAGTCGCTCAGAGTGCCTAG 
ARR-2S-4: 5' GATCCAGGGATCAGGGAGTTCCACG 3' 
GTCCCTAGTCCCTCAAGGTGCCTAG 
ARR-2S-S: 5' GATCCAGGGAACAGGGTGTTCCACG 3' 
GTCCCTTGTCCCACAAGGTGCCTAG 
Probes were filled in with MMLV -reverse transcriptase in the presence of a-32P-dATP, 
and subsequently isolated from non-denaturing polyacrylamide gel. For gel retardation 
assays, 20-50xlO' cpm of each probe was added to 20 1'1 reaction mixture, containing 2 I'g 
poly dldC, 2 I'g BSA, 10 I'M ZnCI, I mM DTT and 2 1'1 lOx binding buffer (100 mM 
Hepes pH 7.6, 300 mM KCI, 62.5 m'M MgCI, and 30 % glycerol), and in indicated cases 
10 I'g LNCaP nuclear protein, in vitro translated AR (7-10 finol) or AR(DBD) (5 pmol). In 
experiments using the AR antibody Spl97 (epitope amino acid residues 1-20),0.11'1 portions 
of antiserum were added to the reaction mixture (32). Incubation was for 30 min at RT. In 
addition to oligonucleotides described above, (100-fold excess of) double-stranded 
oligonucleotides containing a C/EBP binding site, 5'-
GACCTTACCACTTTCACAATCTGCTAG-3' (33) and a GRE 5'-
TCGACTGTACAGGATGTTCTAGCTACT-3' (Promega) were used in competition 
experiments. Samples were loaded on a 4 % polyacrylamide (19: 1) gel and electrophoresed 
in a 50 mM Tris.HCI, 41.5 mM Boric acid, 0.5 mM EDTA buffer for 2 h at 150 V and RT. 
Subsequently, gels were fixed, dried and exposed to X-ray film. 
RESULTS 
Deletion manping of the PSA promoter: effect of androgen receptor overexnression 
In a previous study we analyzed androgen regulation of the PSA promoter in COS cells 
which were co-transfected with several different PSA promoter-chloramphenicol 
acetyltransferase (CAT) reporter gene constructs and the AR expression vector pARO (23). 
This resulted in the functional characterization of an ARE (AGAACAgcaAGTGCT), which 
is closely related to the consensus sequence, at position -170, and the identification of a 
second region, from -539 to -324, important for PSA promoter activity. 
Essentially the same data were obtained in LNCaP cells which endogenously express the 
AR and PSA gene (Figure IA). Transfection of PSA-4-LUC (-6321 + 12) or PSA-5-LUC 
(-5391 + 12) resulted in an approx. 7-fold higher LUC activity in the presence of RI881 than 
in its absence. Similar results were found with constructs containing longer promoter 
fragments [up to approx. 4 kb (data not shown)]. Removal of the -539 to -324 fragment 
(PSA-6-LUC) caused a 3.5-fold drop in relative induction. Subsequent removal of the -324 
to -157 region (containing the ARE sequence at position -170), resulted in the complete 
abolishment of androgen induction (construct PSA-7-LUC). 
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Figure IIl.I. ill/drogell regulatioll of the PSA promoter ill LNCaP cells. (AJ LNCaP cells were 
trallsfected with PSA-LUG COllstmcts (left panel) alld with PSA-LUC COllstruCts plus the AR expression 
plasmid pARD (right pallel) as described ill Materials alld Methods. Start positions of PSA promoter 
constructs are indicated below the figure alld ill Figure lB. After owmight incubation with the 
precipitate, transfected cells were further illcubated in the presence or absence of il1M Ri88] for 24 
h. The absolute activity and relative induction factor were calculated as the llleall of five or more 
indepelldelll trallsfectioll experimellts, which were all done ill duplicate. Closed bar: Activity ill the 
presence of Ri88],' open bar: activity in the absence of Ri88]. Hormone illducr/on is given at tile top 
of the bars. SEM of absolute activity is represented by a vertical stripe,' SEM of illduction is given ill 
parelllheses. The TATA box ;s represellted by a hatched box,' the ARE by a black box. (8) Sequence 
of the proximal PSA promoter. Transcriptioll start sites are indicated by asterisks. Arrows indicate 
starting poillts of constructs used ill transfections. 111e ARE sequence starting at position -170 is 
double underlined, the ARR(-400) ;s single underlined and the TATA box is indicated by stripes. 
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To investigate in more detail sequences in the -539 to - 324 region important for PSA 
promoter activity, a series of exonuclease III deletions was generated (see Figure IB for PSA 
promoter fragments in different constructs). Transfection of LNCaP cells with constructs 
PSA-8-LUC, PSA-9-LUC and PSA-lO-LUC resulted in a high (6- to 7-fold), androgen-
regulated PSA promoter activity, which is comparable to that of the PSA-5 construct. 
Importantly, construct PSA-ll-LUC, starting at -376, showed a low (2.2-fold), androgen-
induced activity, which is identical to that of PSA-6 (starting at -324). These results 
indicated sequences in the region -395 to -376 to be essential for high androgen-induced PSA 
promoter activity. 
Co-transfection with the AR expression plasmid pARO resulted in considerable higher PSA 
promoter activity, both in absolute values as well as in relative induction levels without 
affecting the significance of the -324 to -157 region containing the ARE at position -170, and 
the -395 to -376 region (Figure IA). The co-transfection experiments showed again that 
truncation of the promoter from -395 to -376 gives rise to a markedly lower androgen-
induced activity (compare PSA-lO and PSA-ll); deletion of the -324 to -157 region again 
resulted in a complete loss of androgen inducibility of the PSA promoter (compare PSA-6 
and PSA-7). 
Mutations in the ARE at -170 in construct PSA-4-LUC resulted in an ahoost complete 
inhibition of androgen activation of the PSA promoter (23, and data not shown), indicating 
cooperativity between the -395 to -376 region and the ARE sequence at position -170. 
Androgen receptor binding to the ARE(-170) motif 
To confirm that the sequence AGAACAgcaAGTGCT (-170) was able to interact directly 
with the AR, gel retardation experiments were done with LNCaP nuclear extracts, in vitro 
synthesized AR, and AR DNA-binding domain [AR(DBD)] produced in E. coli (Figure 2A-
C). Using LNCaP nuclear extract, addition of an AR-specific antibody (SpI97) to the 
incubation mixture resulted in the visualization of a stable, specifically supershifted AR-
ARE(-I70) complex (compare Figure 2A, lanes 1-4). The retarded complexes visible in the 
absence of antibody Spl97 (lane 1) are considered to be non-specific because a 100-fold 
molar excess of unlabelled ARE( -170) did not inhibit the formation of these complexes (lane 
3). Additionally, none of these bands was supershifted after adding the specific AR antibody 
(lane 2). 
A specific AR-ARE(-170) retarded complex could be observed, ifin vitro synthesized AR 
was used, addition of the SpI97 antibody again resulted in the formation of a much more 
stable supershifted complex (Figure 2B). Application of the AR(DBD) in the gel retardation 
assay revealed a clear AR(DBD)-ARE( -170) complex in the absence of antibody (Figure 
2C). 
Effect of the - 400 to -366 fragment (ARR) on basal PSA and TK promoter activity 
To further elucidate the properties of the -395 to -375 region, one and three copies of an 
oligonucleotide, spanning this region [-400 to -366; 
GTGGTGCAGGGATCAGGGAGTCTCACAA TCTCCTG (denotedARR, androgenresponse 
region) underlined in Figure IB] were inserted in front of a "minimal" PSA promoter, 
starting at position -174. The "minimal" PSA promoter (PSA-I2-LUC), which contains the 
TATA-box and ARE(-I70), was approx. 6 times more active in RI881-treated, pARO co-
transfected LNCaP cells than in the absence of hormone (Figure 3A). Constructs PSA-I2.1s-
LUC and PSA-I2.Ias-LUC, containing one ARR copy in sense and anti-sense orientation, 
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respectively, gave rise to an increased RI881-induced activity of the promoter (22- to 23-fold 
induction). PSA-12.3-LUC, with three ARR copies, showed a 18S-fold higher promoter 
activity in the presence of RI88I, clearly indicating cooperativity between the ARR motifs. 
Importantly, even tbree ARR copies did not affect basal PSA promoter activity in the absence 
of hormone. This suggested that ARR activity could be directly androgen regulated. 
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Figure III.2. Gelretardatioll allalysis of ARlARE(-170) complexes. (A) 2OxIa' cpm ARE(-I70) was 
incubated willi LNCaP lluclear extract, alld complexes were analyzed by PAGE as described ill 
Materials and Methods. Incubations were ill tile absence (lane 1) or ill the presence of antibody Sp197 
(lalles 2-4). Incubation of ARE with Sp197, without Iluclear extract did 1I0( give rise to a complex 
(data 1101 showll). Specific, slIpershifted ARIARE comple.x:es are indicated by all arrow (lalles 2 and 
4), Sequences of the oligoJlucleotides camainillg t/le ARE(-170) alld the lIoll-specific CIEBP competitor 
(lalle 4) are given ill Materials alld Methods (see for the -170 ARE also the underlined sequellce below 
the figure). (B) 4Qr1(f cpm ARE(-170) was incubated with ill vitro sYllthesi'l.ed full length AR, alld 
ARIARE(-170) complexes were analyzed by PAGE as described ill Materials alld Methods. ume 1 alld 
2: ARE 'with reticulocyte lysate, contailling ill vitro synthesized AR. Incubations were ill the absence 
(Ialle 1) alld ill tile presellce 0/ alllibody Sp197 (lalle 2). Arrows illdicate the positioll of the ARIARE 
complex (Ialle I) alld sllpershifted ARIARE complex (Ialle 2). (C) Gel refardatioll analysis of 
AR(DBD)IARE(-I70) compleres. Lane I: Free ARE(-I70) probe (5OxIa' cpm). 77le arrow indicates 
the positioll of the AR(DBD)IARE campIer. ume 2: 50x1rJ cpm ARE(-170) was incubated with 
AR(DBD) erpressed ill E. coli, and purified as described ill Materials and Methods. Subsequemly, 
fhe reactioll mixture was analyzed by PAGE. 
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Figure III.3. (A) Effect of the -400 to -366 regiou (ARR) 011 basal PSAprollloter activity ill LNCaP 
cells overexpress;llg the AR. The ARR is represemed by a hatc/zed triangle, fhe ARE by a black box, 
alld the TATA elemellf by a hatched box. (B) Effect of tire -400 to -366 region a/the PSA promoter 
(ARR) Oil TK promoter activit)' ;11 LNCaP cells overexpressing AR. 17le ARR is represented by a 
hatched triangle. 17Je mean of [uci/erase activity alld relative illductioll levels are from four 
independent, duplicate e:tperiments. Experimellfai details are identical to those described ill Figure 
lA. The ARR sequellce is single underlined ill Figure lB. 
To investigate this further, one or three ARR copies were inserted in front of a minimal 
Thymidine Kinase (TK) promoter linked to the LUC gene and co-transfected with pARO to 
LNCaP cells. Basal TK promoter activity was hardly inducible by androgen (Figure 3B). The 
construct containing one ARR (TK-I-LUC) showed a 4.7-fold higher LUC activity in the 
presence of RI88I than in the absence of hormone. TK-3-LUC (with three ARR copies) 
showed a 104-fold induction. In the absence of hormone, the ARR-TK-LUC reporters had 
the same activity as the TK-LUC basal construct. 
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Figure IlI.4. Gel retardatioll allalysis of ARiARR complexes. (A) 4Oxlo' cpm ARR was iucubated 
with LNCaP nuclear extract, and completes were analyzed as described ill Materials alld Methods. 
COII/plex formalion was in the absence (lane I) or in the presence of alllibody SpI97 (lanes 
2-4). Incubation of ARR with SpI97, without lIuclear extract did 1I0t give rise to a retarded 
balld (data 1I0t showlI). COli/petition experill/ellls were ill the presence of a IOO-jold excess 
ARR(-400) (lane 3) and ARE(-I70) (lane 4). ARR and ARE sequences are presellled below 
the jigure. (B) 40xlri cpm ARR was illcubated with lIuclear extract of LNCaP cells grown 
ill steroid depleted medium for 6 days alld all additiollal 24 h ill the presence (Ialle 2) or 
absence (Ialle I) of I nM RI88I. (C) 20xlri cpm ARR was incubated with ill vitro 
SYlllhesized full length AR. in the absence (lane I) alld ill the presence of antibody SpI97 
(lane 2), and subsequently analyzed by PAGE as described in Materials and Methods. Lanes 
3 to 6: 40xlri cpm ARE illcubated with ill vitro sylllhesized AR. Complexes were analyzed 
by gel retardation assay as described in Materials alld Methods. Incubations were in the 
presence of antibody SpI97. Competition was with IOO-fold excess ARE(-I70) (lane 4), ARR 
(lane 5), CIEBP (Ialle 6). T7le atTOW indicates the position of supershifted ARIARR alld 
ARIARE complexes. (D) Gel retardatioll analysis of AR(DBD)IARR complexes. Lane I: Free 
ARR probe. Lane 2: 50xlri cpm ARR was incubated with AR(DBD) expressed in E.coli alld 
purifted as described in Materials alld Methods alld subsequently allalyzed by PAGE. T7le 
atTOW indicates the positioll of the AR(DBD)IARR cOlI/plex. 
Gel retardation analysis of the androgen response region (ARR) 
To find out whether the AR could directly interact with the ARR(-400 to -366), a series 
of in vitro protein-DNA interaction experiments was carried out. First of all, nuclear extract 
of LNCaP cells grown in the presence of Rl881 was used to study proteins interacting with 
the ARR. Gel retardation analysis with this extract revealed the presence of at least three 
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specific complexes (Figure 4A, lanes 1-3). Incubation with antibody Sp197, did not result 
in a visible supershift [Figure 4A, lane 2; compare Figure 2A for ARE(-170) shifts], nor 
could one of the complexes be competed with an excess of unlabeled ARE(-170) (Figure 4A, 
lane 4). Identical complexes were formed with extracts from cells grown in the absence or 
in the presence of hormone, indicating that the expression or activity of none of the proteins 
visualized in Figure 4B is androgen regulated. 
If in vitro synthesized AR was used in AR-ARR gel retardation assays, in the presence of 
Spl97 a very weak retarded complex could be detected (Figure 4C), suggesting the presence 
of a low affinity AR binding site in the ARR. In agreement with this observation, a 100-fold 
excess ARR could partially compete the formation of an AR-ARE( -170) complex (Figure 4C, 
lanes 3-6). A similar excess of unlabeled ARE completely inhibited the formation of the AR-
ARE complex. The unrelated C/EBP oligo had no effect on AR-ARE complex formation. 
The most sensitive assay, gel retardation with AR(DBD) produced in E. coli clearly revealed 
the formation of an AR(DBD)-ARR complex (Figure 4D). 
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Figure 111.5. Allalysis of the AR bi1lding segmeJlt ill ARR. (A) Gel retardation analysis of 
AR(DBD)/ARR stlbfragmellt completes. 5Ox10' cpm ARR-1S (lalles 1,2), -2S (lalles 3,4) alld -3S 
(lalles 5,6) were incubated with AR(DBD) Gild analyzed by gel retardatioll assay as described ;11 
Materials and Methods. IS, 2S and 3S sequellces are showll below thejigure. 171e arrow indicates 
Iile position oflile AR(DBD)/ARR-2S complex. (B) EffeCI oflile ARR-/S (-40010 -381), -2S (-394 to-
375) alld -3S (-383 to -366) Oil PSA basal promoter activity ill LNCaP cells overexpressillg the AR. 
TIle ARR-sllbfragmellls are represented by Irial/gles, tile ARE(-170) by a black box alld tile TATA box 
by a hatched box. Mean values and SEM are from three independent, duplicate experiments. Further 
experimellfal details are identical to those described ill Figure lA. 
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Next, three copies of IS, 2S and 3S were inserted in front of the minimal PSA promoter 
construct PSA-I2-LUC and co-transfected with pARO to LNCaP cells. The construct 
containing three copies of the IS region (PSA-IS-LUC) gave rise to a 9.6-fold higher activity 
in the presence of RI88I than in the absence (Figure 5B). Construct PSA-2S-LUC, 
containing three copies of 2S gave rise to a 128-fold higher activity upon RI88I treatment. 
The construct with three copies of 3S (PSA-3S-LUC) produced a 7. I-fold higher activity in 
the presence of RI88!. So, there is complete concordance between the presence of AR 
binding and functional, hormone dependent enhancer activity in 2S, and the absence of these 
activities in IS and 3S. 
Analysis of the AR binding site in ARR-2S 
Sequence aligrunent showed that in 2S the highest percentage of homology to the ARE 
consensus sequence is in the sequence GQATCAgggAGTCIC. This sequence deviates in 2 
out of 6 most essential positions, (positions 2,3 and 5 in each half-site, underlined) and 
overall in 6 out of 12 positions from the ARE consensus GGTACAnnnTGTTCT. To test 
whether this sequence could indeed be responsible for low affinity AR binding, gel 
retardation analyses were performed with five ARR-2S mutants (mutations are underlined). 
Two mutants expected to decrease AR affinity to the putative AR binding site ARR-2S-1 
(GGATQAgggAGTCTC) and ARR-2S-2 (GGATCAgggAl:TCTC) and one presumed silent 
mutant ARR-2S-3 (GGATCAg£gAGTCTC) were tested for their AR binding capacity (Figure 
6A). Gel retardation experiments confirmed our hypothesis: AR binding to ARR-2S-1 and 
ARR-2S-2 was ahuost completely abolished; ARR-2S-3 did not show a marked difference 
in AR affinity as compared to ARR-2S. AR(DBD) gel retardation with mutants with a higher 
homology to the consensus ARE sequence (ARR-2S-4 and ARR-2S-5: 
GGATCAgggAGTTCC and GGAACAgggIGTTCC, respectively) substantiated these 
findings. 
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Figure 111.6. MU/lltion a1lalysis oflhe ARR-2S segment. (A) Gel retardation analysis of ARR-2S alld 
ARR-2S mutallts with AR(DBD). 5Ox10' cpm ARR-2S (Ialles 1,2) ARR-2S-1 (Ialles 3,4), - 2S-2 (Ialles 
5,6) -2S-3 (Ialles 7,8), -2S-4 (Imles 9,10) alld - 2S-5 (Ialles II alld 12) were illcubated with AR(DBD) 
alld allalyzed by gel retardatioll assay as described ill Materials alld Methods. Sequences of ARR-2S 
alld ARR-2S mutants are shown below the figure. 17le arrow indicates the POSU;OIl of the 
AR(DBD)/probe complex. (B) Effect of the ARR-2S-1, -2S-2 alld -2S-3 sequellces 011 PSA basal 
promoter activity ill LNCaP cells overexpressillg the AR. ARR-2S alld mutallf ARR-2S oligo's are 
represellted by triallgles, the ARE(-170) by a black box alld the TATA box by a hatched box. Meall 
values of (ucijerase activit)' alld induction levels and their respective SEM are/rom three independent, 
duplicate experiments. E>.perimellfal details are as described ill Figure lA. Closed bar: Activity ill the 
presence of Rl88l (1 nM); Open bar: activity ill the absence of hormone. 
Next, mutated 2S-elements were tested in LNCaP cells for enhancer activity. To this end, 
three of the mutant oligonucleotides, 2S-I, 2S-2 (both abolishing AR-binding) and 2S-3 
(spacer mutation), were cloned in front of the minimal PSA promoter construct PSA-12-
LUC. PSA-2S-I-LUC and PSA-2S-2-LUC were hardly more active than PSA-12-LUC upon 
RI881 induction in AR co-transfected LNCaP cells (Figure 6B). Construct PSA-2S-3-LUC 
showed a 100-fold higher activity in the presence than in the absence of R 1881. These data 
strongly suggest the importance of the GGATCAgggAGTCTC motif in androgen-regulated 
activity of the ARR in the PSA promoter. 
Effect of glucocorticoid receptor overexpression on PSA promoter activity 
Because on the one hand the DNA motif for high affinity AR and GR binding is identical 
and on the other hand AR and GR might show specificity on individual promoters, we 
investigated whether GR was able to mediate PSA promoter activity. LNCaP cells were co-
transfected with the GR expression plasmid PSTC-GR and selected PSA-LUC constructs. 
Without GR co-transfection, no response of the different PSA promoters to dexamethasone 
was observed (data not shown). As depicted in Figure 7 A, the pattern of PSA promoter 
activity induced by dexamethasone in the presence of GR turned out to be identical to AR 
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Figure III. 7. Effect oj glucocorticoid receptor overexpress;oJl 011 PSA promoter activity ill LNCaP 
cells. (A) LNCaP cells were transfeeted with PSA promoter constructs ill the presellce of the GR 
eJ..pressioll plasmid PSTC-GR (see Materials alld Methods/or experimelllal details), After tralls/eetioll, 
cells were cultured ill the presellce or absence of 10 11M dexamethasoJle. Closed bar: activity ill the 
presellce of dexamethasolle,' open bar: activity ill the absence of hormone. Induction value of the 
various promoter constructs is indicated to the right of each black bar. Absolute luciferase activity 
alld induction values are the means of at least four illdepelldellf e\perimems pelformed ill duplicate. 
SEM of luciferase activity is givell by the horizoJltal bar; SEM of illduction factor is given ill 
parentheses. (B) Effect of the -400 to -366 region (ARR) olllllinimai PSA alld TK promoter activity 
ill LNCaP cells overe:tpressillg the GR. The ARR is represellted by a hatched triangle, the ARE by a 
black box and the TATA box by a !latclzed box. Further e.'perimelltai details are as described ill 
Figure 7A. 
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mediated activity (compare with Figure IA): the ARE at position -170 could function as a 
GRE (glucocorticoid response element) and the ARR(-400 to -366) was needed for maximal 
dexamethasone inducibility. 
Co-transfection of LNCaP cells with PSTC-GR and the constructs containing one and three 
copies of the ARR( -400) linked to the minimal PSA promoter or TK promoter showed a very 
strong synergistic, dexamethasone induced activity (Figure 7B). So, the GR seems to act 
exactly identical to the AR in activation of the PSA promoter. In fact, under the conditions 
used, the GR is an even more potent stimulator of PSA promoter activity than the AR. 
Cell specificity of ARR activity 
To investigate whether or not steroid hormone induced activity of ARR(-400) was LNCaP 
specific, PSA-12-LUC and TK-LUC constructs (see Figures 3 and 7B) and pARO or PSTC-
GR were co-transfected to several non-prostate cell lines: COS, HeLa, Hep3B and T47D. 
In the non-prostate cell lines, the minimal PSA promoter construct PSA-12-LUC containing 
the ARE(-170), is at least 2.5-fold less induced by RI881 and dexamethasone as compared 
to LNCaP cells. Essentially identical results were obtained in comparising AR and GR 
induction of ARR-PSA and ARR-TK constructs. Both activated receptors were able to induce 
these promoters far better in LNCaP cells than in other cell types (ARJPSA-12.3-LUC: 42-
to 97- fold; GRJPSA-12.3-LUC: 26- to 48-fold; ARJTK-3-LUC: IS- to 54- fold; GRJTK-3-
LUC: 27- to 7S-fold). Our data indicate that LNCaP cells contain one or more factors, which 
affect PSA minimal promoter activity and ARR( -400) activity. It is tempting to speculate 
that this factor(s) directly or indirectly interacts with the steroid receptors bound to its 
response elements. 
Table lII,l. Effect of RISSI (A) and dexamethasone (B) on ARR(-400) PSA promoter and ARR(-
400) TK promoter activity in COS, HeLa, Hep3B, T47D and LNCaP cells co-transfected with (A) 
the androgen receptor expression plasmid pARO and (B) glucocorticoid receptor expression plasmid 
PSTC-GR. 
CONSTRUCT RELATIVE INDUCTION 1+/- hormone) • 
LNCaP COS HeLa Hep38 T47D 
PSA-12-LUC" 4.4 ± 1.7 1.1 ± 0.1 1.1 ± OA 1.8 ± 0.4 1.1 ± 0.2 
PSA-12.3-LUC 127 ± 28 2.0 ± 0.3 3.1 ± 0.8 3.1 ± 0.8 1.3 ± 0.2 
TK-LUC 1.5 ± 0.2 1.1 ± 0.1 1.1 ± 0.3 1.1 ± 0.3 0.8 ± 0.1 
TK-3-LUC 81 ± 22 2.1 ± 0.4 2.0 ± 0.9 4.4 ± 2.0 1.5 ± 0.3 
PSA-12-LUC 8.9 ± 2.3 1.3 ± 0.3 3.5 ± 0.8 3.6 ± 1.2 1.8 ± 0.4 
PSA-12.3-LUC 361 ± 83 9.7 ± 1.0 7.5 ± 1.3 )-4 ± 3.0 13 ± 4.7 
TK-LUC 1.7 ± 0.4 0.8 ± 0.2 1.7 ± 0.7 1.0 ± 0.1 1.1 ± 0.1 
TK-3-LUC 468 ± 101 13 ± 1.7 6.3 ± 1.9 17 ± 3.4 8.2 ± 2.6 
') Induction factor is the mean of three to seven independent, duplicate 
experiments ± SEM. 
") Constructs are as described in Materials and Methods. 
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DISCUSSION 
In the present study, analysis of prostate-specificity and androgen-regulation of the PSA 
promoter is performed in LNCaP cells, the only available prostate derived cell line, that 
endogenously expresses the PSA gene in an androgen-dependent fashion (34). Two regions 
in the PSA promoter were identified, which are essential for androgen stimulation in LNCaP 
cells. 
The first region (ARE) encompassed the imperfect palindromic sequence 
AGAACAgcaAGTGCT at -170 to -156 (see Figures 1B and 2). Comparison of this sequence 
with a GGTACAnnnTGTTCT AREIGRE consensus sequence (4-6) revealed four deviations. 
However, none of these was at one of the six positions (positions 2,3 and 5 in each half-site), 
most critical for high affinity AR binding andlor functional activity (4,6). The ARE(-170) 
by itself gave rise to a weak activation of the PSA promoter (approx. 2-fold without pARO 
co-transfection). It had to cooperate with the second androgen response region: ARR (-400 
GTGGTGCAGGGATCAGGGAGTCTCACAATCTCCTG -366) for high, androgen induced 
activity. This ARR contains a low affinity AR binding site. Results of both gel retardation 
and transfection experiments indicate an important role of the sequence 
GGATCAgggAGTCTC, which is a degenerated palindromic sequence (6 out of 12 positions 
are identical to the consensus ARE: GGTACAnnnTGTTCT). Low AR affinity can probably 
be explained by deviation from the consensus sequence at position 3 in the 5' -part (T instead 
of A) and at position 5 (T instead of C) in the 3'-part of the palindromic sequence. 
Although several androgen-regulated genes have been described, only few functional AREs 
have been studied in detail. The mechanism of PSA promoter regulation by androgens seems 
different from other genes studied in this respect. In the MVDP gene promoter, two ARE 
sequences are present (35). Only the proximal ARE is functionally active, and no synergism 
between the two AREs was detected. In the probasin promoter, also two fragments, which 
are in,portant for androgen-regulation of the promoter and which bind AR, can be found 
(36,37). Although both sequences are able to interact with AR outside the probasin promoter 
context, both AR binding sites are individually functionally inactive, even three copies of the 
two separated AR binding sites fail to give rise to androgen-induced reporter gene activity. 
This is in contrast to the AR binding sites in the PSA promoter, ARE(-170) and ARR-2S, 
which are clearly independently active, and when multimerized act synergistically (23, and 
this study). 
Three candidate AREs have been found in the C3 gene; only one of them, Core II, C is 
functionally active in transfection experinlents (38,40). Activity of Core II is strongly 
enhanced by surrounding sequences including candidate OCT-l and NF-I binding sites (41). 
Functional synergism between multiple ARE-like sequences and binding sites for other 
transcription factors has been found in the complex enhancer elements of the 20 kDa protein 
and SIp genes. In the androgen responsive enhancer in the promoter of the SIp gene, three 
tandemly repeated HRE-like sequences are present (42). Additionally, several non-receptor 
binding elements contribute to the characteristic androgen response of this complex enhancer 
(43). The first iIuron of the 20 kDa protein gene contains a cluster of three ARE-like half 
sites spanning a 39 bp fragment (N39) which shows AR binding and confers weak androgen 
responsivity to a heterologous promoter. Additional sequences surrounding this cluster of 
ARE-like sequences are needed for full activity of this enhancer (44). These additional 
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sequences include a region (D2) that shows high AR binding affinity and androgen induced 
transcriptional activity, but no candidate ARE sequences were identified. Taking into 
consideration the results obtained in our present study, which show that multiple weak AR 
binding sites can give rise to strong androgen inducibility, weak AREs might be postulated 
to be present in the D2 region. Like the Sip and C3 promoter, non-steroid receptor factors, 
including OCT-I are supposed to be involved in establishment of the full AR specific 
response of the 20 kDa Protein promoter. 
The complex promoters of the Sip and 20 kDa protein genes show an AR, but no GR 
response in transfection assays, although both AR and GR are able to bind and induce 
activity of smaller enhancer fragments (42,44). Both AR and GR are able to stimulate 
probasin promoter activity however AR is markedly more potent than GR in this respect 
(36). This in contrast to results on the PSA promoter presented in this study. Co-transfection 
of LNCaP cells with PSA-LUC constructs and a GR expression plasmid showed that GR can 
replace AR in high, steroid hormone regulated PSA promoter activation. This is not only 
related to the ARE(-170), but is also true for the ARR at -400. Preliminary evidence 
indicates that GR is also able to activate the promoter of the endogenous PSA gene in LNCaP 
cells (Cleutjens, unpublished). From these findings we conclude that the apparent AR 
specificity of the PSA promoter in LNCaP cells is due to the absence of other members of 
the steroid receptor family in this particular cell line. The absence of PSA expression in GR 
or AR positive, non-prostate cells must be explained by additional, inhibitory mechanisms 
in these cells or absence of other essential regulatory proteins involved in PSA expression. 
Transfection experiments further indicated that ARR(-400) and minimal PSA promoter 
activity [including ARE(-170)] are cell dependent. We studied this aspect in more detail for 
ARR (-400). Even in the presence of high levels of AR and GR, ARR(-400) activity in 
LNCaP cells is much higher than in the non-prostate cell lines tested (Table I). This indicates 
that in addition to AR or GR, other factors are involved in steroid receptor regulated PSA 
promoter activation. These factors might be present in a higher concentration in LNCaP cells 
than in the non-prostate cell lines tested. Candidates regarding ARR(-400) could be the 
proteins detected in gel retardation experiments with the ARR(-400) and LNCaP nuclear 
extract (Figure 4A). However, these factors are not androgen regulated (Figure 4B) and in 
gel retardation experiments using nuclear extracts from the non-prostate cell lines COS, 
T47D, HeLa and Hep3B essentially the same protein complexes could be found (data not 
shown). The absence of LNCaP specific ARR(-400)/ protein complexes may be due to a 
relative weak or unstable interaction of these factors with the ARR(-400). Alternatively, 
specific factors affect AR and GR activity by protein-protein interaction. 
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SUMMARY 
Androgen receptor (AR) positive LNCaP cells were stably transfected with a rat 
glucocorticoid receptor (OR) expression plasmid. Ligand binding studies in the generated cell 
lines revealed high affinity binding of the cognate ligands to their receptors. Transfection 
experiments with the newly derived cell lines showed that, like AR, OR can induce activity 
of a PSA promoter fragment linked to the luciferase gene. Similarly, dexamethasone can 
stimulate expression of endogenous PSA mRNA. Cell proliferation could be induced by 
R1881. In contrast, dexamethasone treatment of the OR positive sub-lines had no stimulatory 
effect on cell growth. In conclusion, the newly generated cell lines form together with the 
parental LNCaP cell line an attractive system to study the mechanism of specificity of steroid 
hormone regulation of gene expression. In addition, these cells can be applied to identify 
novel, steroid hormone-specific regulated gene(s). 
INTRODUCTION 
Steroid hormones affect many biological activities of the cell by modulating gene activity 
via interaction with specific nuclear receptors (1-3). Upon ligand binding, steroid receptors 
interact with specific DNA sequences and regulate the transcriptional activity of target genes 
(1-4). The glucocorticoid receptor (OR), mineralocorticoid receptor (MR), progesterone 
receptor (PR) and androgen receptor (AR) bind with high affinity to a DNA element 
composed of an inverted repeat, separated by a 3 bp spacer sequence. The consensus high 
affinity binding site for OR, MR, PR, and AR (HRE: hormone response element) is identical 
(5-8). Although there are genes which can be regulated by more than one specific steroid 
hormone receptor, the biological function of the different receptors is quite distinct. This 
presents the problem of specific gene activation in case multiple receptors, which recognize 
the same DNA binding site, are present in one and the same cell. At present it is essentially 
unknown how this mechanism operates. Several mutually not exclusive mechanisms, 
including subtle differences in receptor-DNA interaction, specificity of the interaction of the 
receptor with other proteins, receptor levels and ligand availability have been proposed (1-3). 
LNCaP is an androgen-sensitive human prostatic carcinoma cell line (9), which expresses 
AR, but lacks OR and PR (10, \1). It was previously shown that growth of LNCaP cells, 
maintained in steroid-depleted culture medium, is stimulated by the addition of androgens 
(ll). The synthetic androgen RI881 at a concentration of 10-10 M increases the growth rate; 
a higher RI881 concentration is suboptimal to cell proliferation, and might even have no 
stimulatory effect at all. Androgen treatment of LNCaP cells increases the mRNA level, 
production and secretion of prostate specific antigen (PSA) (12-14). 
In the present study we describe the generation and initial characterization of LNCaP 
snblines, in which the OR was stably expressed. In this way a system lVas established for 
comparison of AR and OR molecular and biological functions. 
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MATERIALS AND METHODS 
Cell culture 
LNCaP prostate cells were cultured in RPMI 1640 supplemented with 5 % fetal calf serum 
(Boehringer, Mannheim, Germany) and antibiotics. For transfection, cells were grown in 
Dulbecco's Modification of Eagle's Medium supplemented with 5 % fetal calf serum. 
Plasmids and probes 
The rat GR expression plasmid PSTC-GR(3-795) and the selection plasmid pSV,Neo were 
described previously (15,16). PSA-61-LUC was generated by integration of a 6 Kb HindIII-
HindIII (-60001 + 12) fragment of the PSA promoter in the multiple cloning site of pLUC 
(17). Southern and Northern blots were hybridized with a rGR cDNA fragment (nucleotide 
2256-2543) obtained by PCR amplification with primers: 
5'-GAGTCTCACAAGACACTTCG-3' and 5'-GAAACATCCATGAGTACTG-3' and 
plasmid PSTC-GR(3-795) as template using standard methods. Northern blots were 
hybridized with the 320 bp EcoRI-ClaI fragment of PSA 75 cDNA (IS), and a 1.2 Kb Pst!-
Pst! hamster actin cDNA fragment as a control. 
Transfections 
Stable tl'ansfectioll 
LNCaP cells were transfected according to the calcium phosphate precipitation method 
essentially as described (19), using 3 x 10' cells per 10 cm dish, 10 "g PSTC-GR(3-795) and 
2 "g pSV,Neo. After overnight incubation with the precipitate, the culture medium was 
replaced by phosphate buffered saline (PBS), containing 15% glycerol (incubation for 90 sec 
at room temperature). Subsequently, transfected cells were incubated in culture medium for 
24 h. Next, culture medium was replaced by maintenance medium supplemented with G41S 
(Gibco BRL, Grand Island, NY) at a concentration of 1.2 mglml. The resulting G41S-
resistant clones were seeded into 96-well plates, and selected for GR expression by 
immunohistochemistry (see below). 
Transient transfectioll 
The GR positive clones LNCaP-IB7 and LNCaP-IF5, and the parental LNCaP cells were 
transiently transfected according to the calcium phosphate method using I x 106 cells per 
25cm' flask and 5 "g PSA-61-LUC. After overnight incubation with the precipitate, the 
culture medium was removed and cells were shocked in phosphate buffered saline (PBS), 
containing 15% glycerol (90 sec at room temperature). Subsequently, transfected cells were 
incubated in culture medium in the absence or presence of 10 nM of the synthetic 
glucocorticoid dexamethasone (Dex) (Sigma, SI. Louis, MO) or I nM RISSI (DUPoIlt NEN, 
Boston, MA) for 24 h. Transfections were performed three times in duplicate, using two 
independent plasmid isolates. Luciferase activities were corrected for variations in protein 
concentrations in 100 "I cell extract samples. 
Luciferase assay 
Cells were washed once in PBS, and subsequently lysed in 300 "I lysis buffer (25 mM 
Tris-phosphate pH 7.S, S mM MgCl" ImM DTT, I % Triton X-100, 15 % glycerol). Next, 
100 "I O.I"M luciferin (Sigma)1 0.25"M ATP was added to 100 "I extract, and luciferase 
activity was measured in a LUMAC 2500 M Biocounter (LUMAC, Landgraaf, The 
Netherlands). After a delay of 2 sec (according to the supplier), the light emission during 5 
sec was recorded. 
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Inununohistochemistry 
Immunostaining for GR was performed with the monoclonal anti-GR (rat) antibody Mab 
7 (20). Cells were seeded at a density of 3 x 10' cells per well on sterile micro slides in four-
well tissue culture plates (Heraeus Instruments, Hanau, Germany) ill maintenance medium 
supplemented with G418, and cultured until 50-60% confluence. Next, 10 nM Dex was 
added, and the incubation was continued for 24 h. Cells were washed in PBS, and fixed for 
10 min in 10% phosphate-buffered formalin (pH 7.4). Subsequently, the slides were rinsed 
in PBS (pH 7.4) and attached cells were made permeable in methanol (-20'C, 5 min), and 
acetone (-20'C, 2 min). After rehydration in PBS, the slides were incubated in 5% non-
immune rabbit serum in PBS followed by overnight incubation in I: 1000 diluted monoclonal 
antibody Mab7 at 4'C. Excess antibody was removed and rGR immunoreactivity was 
visualized using rabbit anti-mouse immunoglobulin (DAKO, Glostmp, Denmark) as 
secondary antibody, and mouse monoclonal PAP complexes (DAKO) as third-step reagent. 
After three PBS washes, the slides were incubated with diaminobenzidine. The reaction was 
stopped in water. Cells were counterstained with Mayers hematoxylin. 
Southern and Northern blot analysis 
Total cellular DNA ofLNCaP and GR positive sublines LNCaP-IF5 and LNCaP-1B7 was 
isolated using standard procedures (21). 10 I'g DNA was digested with EcoRI for 16 h, 
electrophoresed on 0.8 % agarose gel and transferred to a H ybond N + membrane 
(Amersham, Cardiff, UK). Filters were hybridized at high stringency with random primed 
32P-labeled probes. Both DNA transfer and filter hybridization were carried out according 
to the protocol of the manufacturer. 
Isolation of total cellular RNA from the different cell lines was carried out by the 
guanidinium thiocyanate method (22). Glyoxal denatured RNA (10 I'gllane) was separated 
by electrophoresis on a I % agarose gel and transferred to a nylon membrane (Gene Screen, 
DuPont NEN, Boston, MA). The blot was hybridized with random primed 32P-labeled rGR, 
PSA or actin cDNA probes in 50 % formamide at 42'C, using standard conditions. 
Radio ligand binding assay 
Cells were cultured in maintenance medium until 50-60% confluence. To deplete for 
steroids, cell culturing was continued in RPMI 1640 supplemented with dextran-charcoal-
stripped (dcc) semm for 48 h. 
['H)-RI881 (87 Ci/mmol) and unlabeled RI881 (methyl-trienolone) were purchased from 
DuPont NEN. ['H)-Dex (94 Cilmmol) was obtained from Amersham. For radio ligand 
binding analysis, cells were rinsed in PBS and harvested as a single-cell suspension by 
trypsinization. Cells were washed four times, counted and resuspended in ice cold PBS. In 
order to measure the cellular AR and GR content and ligand affinity of both receptors, cells 
were incubated with serial ['H)-RI881 dilutions (0.125-16 nM, in the absence and presence 
of a 100-fold molar excess of unlabeled R1881) or ['H)-Dex dilutions (0.5-32 nM, in the 
absence and presence of a 100-fold molar excess of unlabeled Dex) for 90 min at room 
temperature. Free steroid was removed by extensive washing of the cells in ice cold PBS. 
Radioactivity was measured in a scintillation counter. Specific binding of ['H)-RI881 and 
['H)-Dex was calculated by subtraction of non-specifically bound radioactivity from total 
bound radioactivity, and used for Scatchard analysis with the radioligand binding analysis 
program 'Ebda/Ligand' by GA Pherson from Elsevier-BiOSOFT. All assays were performed 
in triplicate. 
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Cell growth studies 
Cells were trypsinized, seeded in RPMI medium containing 5% fetal calf serum in 25 cm' 
tissue culture flasks at a density of 5 x 10' cells, and cultured for three days, Subsequently, 
medium was replaced by medium containing 5 % dcc serum, and the incubation was 
continued for an additional 3 day period. At this time point (t=O), medium was replaced by 
RPMI medium containing 5 % dec serum and indicated hormones at different concentrations. 
RI881 was added to final concentrations of 10-", 10-10 and 10-' M; Dex was added to final 
concentrations of 10'10, 10-' and 10" M, respectively. Control cultures without steroids were 
supplemented with 0.1 % (v/v) ethanol. At day 4, medium was renewed. At day 8, cells 
were washed in PBS, trypsinized and the cell number in each tissue culture flask was 
determined using a BUrker's cell counting chamber. Experiments were performed in 
triplicate. 
RESULTS 
Generation of GR expressing LNCaP transfectants 
LNCaP cells were transfected with the GR expression vector PSTC-GR and the pSV,Neo 
selection plasmid. Cells were grown in medium supplemented with G418 to select for 
transfected cells. After 3 weeks, G418 resistant clones were picked. Clones were 
immunohistochemically stained with the GR antibody MAb 7. Out of sixty G418 resistant 
clones, five showed strong reactivity with the antibody, indicating high GR expression. 
Thirty-two clones showed low or heterogeneous GR expression, whereas in the remaining 
clones, no GR inmmnoreactivity was observed. Staining of two clones with high levels of 
GR expression (LNCaP-IB7 and LNCaP-IF5), is shown in Figure IA,B; staining of the 
parental LNCaP cells for GR was negative (Figure IC). Note that the morphology of GR+ 
sublines is different from that of the parental cells, indicating a so far unexplained specific 
effect of the activated GR on cell physiology. LNCaP-IB7 and LNCaP-IF5 were selected 
for more detailed studies. 
Characterization of LNCaP-IB7 and LNCaP-IF5 
Southern blot analysis of EcoRI digested genomic DNA isolated from the LNCaP-IB7 and 
LNCaP-IF5 transfectants, demonstrated the presence of one or more copies of the complete 
CMV-GR cDNA fragment in both clones (lanes 2 and 3, Figure 2A; indicated by an arrow). 
The rat GR probe showed cross-hybridization to two fragments corresponding to the 
endogenous human GR gene (bands a and b; see also lane I, containing parental LNCaP 
DNA). Both LNCaP-IB7 and LNCaP-IF5 DNA contained also at least one incomplete 
PSTC-GR fragment (bands c and d). Densitometric scanning of the blot revealed the presence 
of 6 to 7, and 2 complete copies of CMV-GR eDNA in LNCaP-IB7 and LNCaP-IF5, 
respectively. 
Northern blot analysis of LNCaP-IB7 and LNCaP-IF5 RNA showed expression of GR 
mRNA of the expected size (2.7 Kb) in both clones, no hybridization signal was observed 
in the parental LNCaP cell line (Figure 2B). 
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Figure IV.I. Imlllllllohistochemical staining of GR posWve LNCaP sub-lines LNCaP-IB7 (A), 
LNCaP-IFS (B) al/d the parel/tal LNCaP cells (C) with the allti rat-GR 1II01l0c/01lal alltibody Mab7, 
utilizing the i"direct PAP technique. Cells were counterslailled with Mayer's hemato:tylill. Prior to 
immunohistochemical analysis, cells ·were cultured/or 24 hill tlte presence of Dex. 
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Figllre IV,2, SOllthem alld Northern blot allalysis of the illtegrated GR cDNA (A), alld GR IIIRNA 
expression (n) ill GR+ LNCaP sublilles and parental LNCaP cells. (A) Southern blot analysis of 
EcoRl digested gellolllie DNAfrolll LNCaP (talle i), LNCaP-iB7 (Ialle 2), al/d LNCaP-iF5 (Ial/e 3), 
DNA (10 p.gllane) was hybrid;zed with a rat GR eDNA probe, h01ll0[ogous to human GR eDNA. 
Ballds a and b: endogenolls human GR gene; ballds c alld d: i1lfegrated, partial rGR cDNAjragmellfs. 
17le arrow indicates the positioll of illlegrated, complete CMV-GR eDNA copies. (B) Northern blot 
allalysis of 10 I'g total RNA from LNCaP (talle I), LNCaP-IB7 (talle 2), alld LNCaP-IF5 (talle 3) 
hybridized with a rat GR eDNA probe. 17le lower panel shows {J-actill IllRNA expressioll. 
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Radio-ligand binding assays on LNCaP, LNCaP-1B7 and LNCaP-IF5 cells were 
performed to establish the number of GR and AR molecules per cell, and the respective 
dissociation constants for both receptors (Figure 3). The parental LNCaP cell line showed 
for RI881 a B~ of75 pM, which is equivalent to approximately 15,000 AR molecules per 
cell (see legend to Figure 3). LNCaP-1B7 and LNCaP-IF5 contained approximately 30,000 
and 32,000 AR molecules per cell, respectively, which is comparable to parental LNCaP 
cells (see above). All three cell lines showed an identical binding affinity for RI881 (K. 1.1 
oM). 
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Figure IV.3. Analysis of glucocorticoid amI androgen billdillg activity ;11 parelltal LNCaP alld the 
GR tralls/ectant IB7 alld IFS cells. Scatcl/ard represelltatioll of RI881 bindillg activity (panel A) alld 
Dex binding activity (pallel B) of LNCaP, LNCaP-iB7 alld LNCaP-iF5 cells. Cellular AR and GR 
cOllcentrations were deduced from (Bmu (M) x Na>J/tlfllllber of cells per liter (3x1rJ ill pallel A, and 
5x J(I ill pallel B). Receptor boulld fHJ-steroid was measllred by a whole cell assay ill the presence 
and absellce of a lOO10ld molar ex.cess of unlabeled hormone. 17le values shown are fhe mean of a 
triplicate experiment, alld represent specific billding after subtractioll of nonspecific binding. 
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As expected, in the parental LNCaP cell line, binding of Dex could not be detected. From 
the B=, values it could be deduced that LNCaP-lB7 contains approximately 31,000 GR 
copies per cell, and LNCaP-IF5 115,000 copies. The K. for Dex binding was 3.1 nM in 
both LNCaP sublines. 
GR activity in GR positive LNCaP sublines 
To investigate whether the GR present in LNCaP-lB7 and LNCaP-IF5 cells was 
functionally active, the cells were transiently transfected with PSA-61-LUC, which contains 
a 6 Kb PSA promoter fragment. This promoter contains a strong androgen dependent 
enhancer region, approximately 4.2 Kb upstream of the transcription start site of the PSA 
gene (17,23). As expected, PSA-61-LUC showed clear, R1881 induced luciferase activity 
in transfected parental LNCaP cells. No luciferase activity was detected upon incubation of 
the PSA-61-LUC transfected parental LNCaP cells with Dex (Figure 4). Transient 
transfection of LNCaP-lB7 and LNCaP-IF5 cells with the PSA-61-LUC construct resulted 
in a comparable R1881 induced luciferase activity, both in absolute luciferase activity and 
in induction level (1310- and 1940-fold, respectively). Dex induced a slightly higher PSA-61-
LUC activity, clearly indicating the transactivating capacity of the GR encoded by the stably 
integrated rGR expression vector (Figure 4). 
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Figure IVA. RIB81 alld Vex regulalioll of the PSA promoter activity in LNCaP and GR positive 
LNCaP sub!il/es, LNCaP, LNCaP-IB7 al/d LNCaP-I F5 cells were lral/sleeled witll Ille PSA-6J-LUC 
reporter gene COllstruet as described ill Material alld Methods. After ovemight incubation with 'he 
precipitate, cells were incubated/or 24 h either ill the presence or absellce of 111M RiB81 or 10 11M 
Dex. Activity ill the absence of hormolle is indicated by a solid bar, activity ill the presence of RIBS1 
with a hatched bar alld ill the presence of Dex by a grey bar. Fold- i1lduction is displayed Oil top of 
the bars. 
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Regulation of endogenous PSA mRNA expression 
In previous studies we and others (12-14) have shown that PSA mRNA expression is 
induced upon androgen incubation of LNCaP cells. To investigate whether GR can replace 
AR in induction of tbe endogenous PSA gene, we performed Northern blot analysis with 
RNAs isolated from the parental LNCaP cell line, and from LNCaP-IB7 and LNCaP-IF5 
cells, grown in the absence and in the presence of hormone (Dex or RI881). Hybridization 
with a PSA specific cDNA probe demonstrated that GR can replace AR in higb, steroid 
hormone induced expression of the PSA gene (Figure 5). In the parental LNCaP cell line, 
PSA mRNA expression was induced by RI881 but not by Dex. In contrast, in tbe two GR 
positive clones, Dex treatment clearly resulted in stimulation of PSA mRNA expression, 
although to a slightly lower level (approximately 3-fold) than RI881 upregulated PSA 
mRNA. 
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Figure IV.S. Expression of the ral GR rellders the endogenolls alldrogen-regulated PSA gelle 
illdllcible by Dex ;11 lite LNCaP sllbUlles IB7 alld IFS. Nortltem blot allalysis of 10 ~g tOlal RNA 
ofLNCaP-lB7, LNCaP-1F5 alld LNCaP cells Itybridhed witlt a PSA cDNA probe. Cells were treated 
for 24 It with Dex, RI881 or were groWIl ill the absence of hormone. flle lower pallel shows 
hybridization of the {3-actill eDNA probe as a contro/. 
Regulation of cell proliferation 
Growth of LNCaP cells depends on androgens in a concentration dependent fashion. 
Previous studies indicated a bell shaped dose-response curve for the stimulatory effect of 
androgens (11). Maximal growth stimulation of RI881 was observed at a concentration of 
0.1 nM. To find out whether GR was able to replace AR in growth regulation of LNCaP 
cells, we compared the effects of different RI881 and Dex concentrations on growtb of 
LNCaP cells, and of the two GR positive LNCaP sublines. At day 8 after addition of 
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hormone, all three cell lines showed a clear growth sthnulation upon treatment with 0.1 nM 
RI881, and to a somewhat lower extent at I nM R188!. However, at none of the tested Dex 
concentrations a growth stimulatory effect was observed (Figure 6). Similar negative results 
were obtained with hydrocortisone (data not shown). These results clearly indicated that GR 
was unable to replace AR in growth sthnulation of LNCaP cells. 
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Figure IV. 6. Effects of Dex aud R1881 all cell growtll of pare uta I LNCaP, aud tile GR+ IB7 alld 
IFS cells. At day 0, alld at day 8 of incubation ill the absence or presence of hormone, cells were 
washed, trypsillized and counted. The values showll (lre the mean of experiments ill triplicate. 
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DISCUSSION 
In this paper we describe the generation and properties of LNCaP sublines, that express 
not only AR but also GR. These novel cell lines facilitate the direct comparison of GR and 
AR effects on cellular functioning. Furthermore, they can be employed for investigation of 
interference between GR and AR activated molecular and biological processes. We 
demonstrated that AR and GR positive cells behave identically in up-regulation of the 
expression of a transfectcd PSA promoter driven reporter gene, and the expression of the 
endogenous PSA gene. Interestingly, they were found to differ in hormone induced effects 
on cell proliferation. 
At least part of the effects of steroid hormone receptors on gene expression is on 
transcription initiation. Upon ligand binding, steroid receptors interact with specific DNA 
sequences (HREs) , and regulate the transcription of target genes. The 
GGT/AACAnnnTGTTCT consensus sequence for high affinity DNA binding of GR, MR, 
PR and AR is identical (5-8). Despite this common DNA binding site, the different receptors 
mediate distinct cellular responses. Many independent mechanisms to achieve specificity of 
the steroid hormone response have been proposed (see for reviews 3 and 24). These include 
differential affinities to natural receptor binding sites, or to binding sites in their natural DNA 
context (25-27), differential affinity to general and specific transcription factors (28-31), 
differences in interaction with receptor specific accessory proteins, or coactivators (32-34), 
differential modification of specific chromatin structures (35,36), differences in cellular 
concentration of the specific receptors (37), and variations in ligand availability (38,39). 
The observation that PSA mRNA was Dex inducible in the GR expressing LNCaP sublines 
showed that the steroid receptor content determines at least in part the specific activation of 
the PSA gene in wild type LNCaP cells. Transient transfection of the 6 Kb PSA promoter 
to the LNCaP sublines resulted also in activation by both AR and GR. In contrast, in case 
of the MMTV promoter, differences have been reported on the effect of GR and PR on 
transiently transfected reporter gene constructs and stably integrated plasmids (35,36). It 
appears that the native chromatin structure can prevent PR activation, and permits GR 
stimulation of the stably integrated target gene. 
AR activation of the PSA promoter involves at least three AREs, two in the 600 bp 
proximal promoter region, and one in a far upstream enhancer region (17,40). Although 
ultimate PSA promoter induction is comparable for AR and GR, it cannot be excluded as yet, 
that AR and GR affect the individual regulatory regions differentially. Such an observation 
has been made for GR and PR activation of the MMTV promoter, which contains four 
HREs. Differences might be accounted for by distinct chromatin structures over the 
individual HREs, and the ability of the different receptors to affect these structures, andlor 
the interaction with other specific transcription factors (31). 
As shown above, GR expression cannot be detected in wild type LNCaP cells, this in 
contrast to normal human prostate tissue (41). However, in normal prostate highest GR 
expression is in the stromal compartment. In epithelial cells expression of AR appears much 
higher than GR expression. In prostate cancer, GR expression seems even to decrease. 
Therefore, GR might not be a major factor in PSA expression. No data are available about 
PR expression in prostate tissue, another candidate for regulation of PSA expression (17). 
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The stimulatory effect of androgens on LNCaP cell proliferation shows a bell-shaped dose-
response curve (11,42). At low androgen concentrations (up to J()'IO M R1881), LNCaP cells 
proliferate in a dose dependent maoner; at higher hormone concentration, the proliferation 
rate is less. The molecular mechanism of growth stimulation by androgens, including the 
remarkable dose response is not fully understood, although it has been proposed that TGF-{31 
mediates at least part of the growth arrest observed at high androgen concentration (43). The 
cell growth studies clearly demonstrated that Dex was unable to induce proliferation of 
LNCaP-IB7 and LNCaP-IF5 cells. The molecular mechanism responsible for the differential 
effects of glucocorticoids and androgens on growth remains to be investigated. In a probably 
oversimplified view it can be hypothesized that a limited number differentially expressed 
genes are involved. Differential AR and GR regulated TGF{3 and other growth factors or 
inhibitors, and their corresponding receptors should be considered in this regard. 
Using a differential display PCR approach, we initiated a search for differentially 
expressed genes in the AR +GR + LNCaP sublines. Although many genes appeared to be 
regulated by both GR and AR, so far one novel mRNA was detected, that could be up-
regulated by AR, but not by GR (44). This observation demonstrates the validity of the 
model here presented. We expect that further analysis of the regulation of expression of this 
gene will provide information about the mechanism of AR specificity. 
ACKNOWLEDGEMENTS 
We thank Dr S. Rusconi for providing us with PSTC-GR(3-795), and Dr M. Bronnegard 
for the gift of Mab7. We are indebted to Dr F.T. Bosman for critical reading of the 
manuscript, Dr. M. Verheggen for technical advice, and to Mr F. van der Paone for 
photography. This work was supported by a grant from the Dutch Cancer Society. 
REFERENCES 
I. Carson-Jurica MA, Schrader WT, O'Malley BW 1990 Steroid receptor family: 
Structure and functions. Endocr Rev 11:201-220 
2. Beato M, Herrlich P, SchOtz G 1995 Steroid hormone receptors: many actors in 
search of a plot. Cell 83:851-857 
3. Beato M, Chavez S, Truss M 1996 Transcriptional regulation by steroid hormones. 
Steroids 61:240-251 
4. Yamamoto KR 1985 Steroid receptor regulated transcription of specific genes and 
gene networks. Arum Rev Genet 19:209-252 
5. Nordeen SK, Suh B, KOimel B, Hutchinson III CA 1990 Structural determinants of 
a glucocorticoid receptor recognition element. Mol EndocrinoI4:1866-1873 
6. Lieberman BA, Bona BJ, Edwards DP, Nordeen SK 1993 The constitution of a 
progesterone response element. Mol Endocrinol 7:515-527 
7. Roche PJ, Hoare SA, Parker MG 1992 A consensus DNA-binding site for the 
androgen receptor. Mol Endocrinol 6:2229-2235 
8. Lombes M, Binart N, Obin M-E, Joulin V, Baulieu EE 1993 Differential intracellular 
localization of human mineralocorticosteroid receptor on binding of agonists and 
antagonists. Biochem J 292:577-583 
116 
Differential effects of AR and GR in LNCaP cells 
9. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Ming Chu T, Mirand 
EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 
43: 1809-1818 
10. Berns EMJJ, Boer W de, Mulder E 1986 Androgen-dependent growth regulation of 
and release of specific protein(s) by the androgen receptor containing human prostate 
tumor cell line LNCaP. Prostate 9:247-259 
11. Schuurmans ALG, Bolt J, Voorhorst MM, Blankenstein RA, Mulder E 1988 
Regulation of growth and epidermal growth factor receptor levels of prostate tumor 
cells by different steroids. Int J Cancer 42:917-922 
12. Riegman PHJ, Vlietstra RJ, Korput JAGM van der, Brinkmann AO, Trapman J 1991 
The promoter of the Prostate-specific antigen gene contains a functional androgen 
responsive element. Mol EndocrinoI5:1921-1930 
13. Young CY-F, Montgomery BT, Andrews PE, Qiu S, Billhartz DL, Tindall DJ 1991 
Hormonal regulation of Prostate-specific Antigen messenger RNA in human prostatic 
adenocarcinoma cell line LNCaP. Cancer Res 51:3748-3752 
14. Henntu P, Liao S, Vikho P 1992 Androgens upregulate the human prostate specific 
antigen messenger ribonucleic acid, but down regulate the prostatic phosphatase 
mRNA in LNCaP cells. Endocrinol 130:766-772 
15. Severne Y, Wieland S, Schaffner W, Rusconi S 1988 Metal binding 'finger' 
structures in the glucocorticoid receptor defined by site-directed mutagenesis. EMBO 
J 7:2503-2508 
16. Southern PJ, Berg P 1982 Transformation of mammalian cells to antibiotic resistance 
with a bacterial gene under control of the SV40 early gene promoter. J Mol Appl 
Genet 1:327-341 
17. Cleutjens KBJM, Van der Korput HAGM, Van Eekelen CCEM, Van Rooij HCJ, 
Faber PW, Trapman J 1997 An androgen response element in a far upstream 
enhancer region is essential for high, androgen-regulated activity of the prostate-
specific antigen promoter. Mol Endocrinol 11:148-161 
18. Riegman PHJ, Klaasen P, Korput JAGM van der, Romijn JC, Trapman J 1988 
Molecular cloning and characterization of novel prostate-specific antigen cDNAs. 
Biochem Biophys Res Conunun 155:181-188 
19. Chen C, Okyama H 1987 High efficiency transformation of manunalian cells by 
plasmid DNA. Mol Cell Bioi 7:2745-2752 
20. Okret S, Wikstrom A-C, Wrange 6, Andersson B, Gustafsson J-A 1984 Monoclonal 
antibodies against the rat liver glucocorticoid receptor. Proc Nat! Acad Sci USA 
81:1609-1613 
21. Blin N, Stafford DW 1976 A general method for isolation of high molecular weight 
DNA from eukaryotes. Nucleic Acids Res 3:2303-2308 
22. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ 1979 Isolation of biological 
active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-
5299 
23. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG and Henderson 
DR 1996 Prostate-specific Antigen expression is upregulated by an upstream 
enhancer. J Bioi Chem 271:7043-7051 
117 
Chapter IV 
24. Katzenellenbogen lA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid 
hormone receptor pharmacology: interaction with multiple effector sites as a basis 
for the cell- and promoter-specific action of these hormones. Mol EndocrinollO: 119-
131 
25. Baer I, Yamamoto KR 1994 Analysis of the DNA-binding affinity, sequence 
specificity and context dependence of the glucocorticoid receptor zinc finger region. 
I Mol Bioi 239:664-688 
26. Rundlett SE, Miesveld RL 1995 Quantitative differences in androgen and 
glucocorticoid receptor DNA binding properties contribute to receptor-selective 
transcriptional regulation. Mol Cell Endocrinol 109:1-10 
27. Claessens F, Alen P, Devos A, Peeters B, Verhoeven G, Rombauts W 1996 The 
androgen-specific probasin response element 2 interacts differentially with androgen 
and glucocorticoid receptors. I Bioi Chern 271:19013-19016 
28. Adler AI, Schuller A, Robins DM 1993 The stringency and magnitude of androgen-
specific gene activation are combinatorial functions of receptor and nonreceptor 
binding site sequences. Mol Cell Bioi 10:6326-6335 
29. Adler AI, Danielsen M, Robins DM 1992 Androgen-specific gene activation via a 
consensus glucocorticoid responsive element is determined by interaction with 
nomeceptor factors. Proc Nat! Acad Sci USA 89:11660-11663 
30. Pearce D, Yamamoto KR 1993 Mineralocorticoid and glucocorticoid receptor 
activities distinguished by nonreceptor factors at a composite response element. 
Science 259:1161-1165 
31. Le Ricousse S, Gouilleux F, Fortin D, Ioulin V, Richard-Foys H 1996 Glucocorticoid 
and progestin receptors are differently involved in the cooperation with a structural 
element of the mouse mammary tumor virus promoter. Proc Nat! Acad Sci USA 
93:5072-5077 
32. Oilate SA, Tsai SY, Tsai M-I, O'Malley BW 1995 Sequence and characterization of 
a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357 
33. Voegel JJ, Heine MIS, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa 
transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear 
receptors. EMBO I 15:3667-3675 
34. Yeh S, Chang C 1996 Cloning and characterization of a specific coactivator, ARA,o, 
for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-
5521 
35. Archer TK, Zanieuwski, Moyer ML, Nordeen SK 1994 The differential capacity of 
glucocorticoids and progestins to alter chromatin structure and induce gene expression 
in human breast cancer cells. Mol Endocrinol 8:ll54-ll62 
36. Archer TK, Lee H-L, Cordingley MG, Mymryk IS, Fragoso G, Berard DS, Hager 
GL 1994 Differential steroid hormone induction of transcription from the mouse 
manmlary tumor virus promoter. Mol Endocrinol 8:568-576 
37. Strahle U, Boshart M, Klock G, Stuwart F, SchUtz G 1989 Glucocorticoid- and 
progesterone-specific effects are determined by differential expression of the 
respective hormone receptors. Nature 339:629-632 
38. Funder JW 1993 Mineralocorticoids, glucocorticoids, receptors and response 
elements. Science 259: I 132-ll33 
ll8 
Differential effects of AR and GR in LNCaP cells 
39. Kralli A, Bolmen SP, Yamamoto KR 1995 LEMI, an ATP-binding-cassette 
transporter, selectively modulates the biological potency of steroid hormones. Proc 
Nat! Acad Sci USA 92:4701-4705 
40. Cleutjens KBJM, Eekelen vall CCEM, Korput van der HAGM, Brinkmann AO, 
Trapman J 1996 Two androgen response regions cooperate in steroid hormone 
regulated activity of the prostate specific antigen promoter. J Bioi Chern 271:6379-
6388 
41. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, French FS, Sar 
M 1996 Androgen and glucocorticoid receptors in the stroma and epithelium of 
prostatic hyperplasia and carcinoma. Clin Cancer Res 2:889-895 
42. Lee C, Sutkowski PM, Sensibar JA, Zeiner D, Kim I, Amsel I, Shaw N, Prins GS, 
Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific 
antigen in androgen-sensitive prostate cancer cells LNCaP by hydrotestosterone. 
Endocrinol 136:796-803 
43. Kim IY, Kim J-H, Zeiner DJ, Ahn H-J, Sensibar JA, Lee C 1996 Transforming 
Growth Factor-lll is a mediator of androgen-regulated growth arrest in an androgen-
responsive prostatic cancer cell line, LNCaP. Endocrinology 137:991-999 
44. Steketee K, Cleutjens CBJM, van Eekelen CCEM, van der Korput JAGM, Trapman 
J A specifically androgen up-regulated mRNA isolated from an androgen receptor and 
glucocorticoid receptor positive LNCaP subline. Program of the 10th International 
Congress of Endocrinology, San Francisco, 1996, PI-226 (Abstract) 
119 

Chapter V 
AN ANDROGEN RESPONSE ELEMENT IN A FAR UPSTREAM ENHANCER 
REGION IS ESSENTIAL FOR HIGH, ANDROGEN-REGULATED ACTIVITY 
OF THE PROSTATE-SPECIFIC ANTIGEN PROMOTER 
Kitty BJM Cleutjens, Hetty AGM van der Korput, Conny CEM van 
Eekelen, Henri CJ van Rooij, Peter W Faber, and Jan Trapman 
Department of Pathology, Erasmus University, Rotterdam, The Netherlands 
Molecular Endocrinology (1997) 11: 148-161 
121 
Chapter V 
ABSTRACT 
Prostate-specific antigen is expressed at a high level in the luminal epithelial cells of the 
prostate, and is absent Of expressed at very low levels in other tissues. PSA expression can 
be regulated by androgens. Previously, two functional androgen response elements were 
identified in the proximal promoter of the PSA gene. In order to detect additional, more 
distal control elements, DNase! hypersensitive sites (DHSs) upstream of the PSA gene were 
mapped in chromatin from the prostate derived cell line LNCaP grown in the presence and 
absence of the synthetic androgen RISSI. In a region 4.S to 3.S kb upstream of the 
transcription start site of the PSA gene, a cluster of three DHSs was detected. The middle 
DNAseI hypersensitive site (DHSII, at approximately - 4.2 kb) showed strong androgen 
responsiveness in LNCaP cells, and was absent in chromatin from HeLa cells. Further 
analysis of the region encompassing DHSII provided evidence for the presence of a complex, 
androgen responsive and cell specific enhancer. In transient transfected LNCaP cells, PSA 
promoter constructs containing this upstream enllancer region showed approximately 3000-
fold higher activity in the presence than in the absence of RISSI. The core region of the 
enllancer could be mapped within a 440 bp fragment. The enhancer showed synergistic 
cooperation with the proximal PSA promoter, and was found to be composed of at least three 
separate regulatory regions. In the center, a functionally active, high affinity androgen 
receptor binding site (GGAACATATTGTATC) could be identified. Mutation of this element 
almost completely abolished PSA promoter activity. Transfection experiments in prostate and 
non-prostate cell lines showed largely LNCaP cell specificity of the upstream enhancer 
region, although some activity was found in the T47D manlll13ry tumor cell line. 
INTRODUCTION 
Prostate-specific antigen (PSA) is a kallikrein-like serine protease, that is almost 
exclusively synthesized by the luminal epithelial cells of the human prostate. It is well known 
as a prostate tumor marker (1,2). The PSA gene is a member of the human kallikrein gene 
family. Further members of the kallikrein gene family are the hGK-I gene, which is also 
expressed in the prostate, and the tissue kallikrein gene (KLKI), which is expressed in the 
pancreas and kidney (3-6). The tlnee genes are clustered in the order [KLK-I]-[PSA]-[hGK-
I], in an area of 60 kb on human chromosome 19q13.2-13.4 (7). The PSA and hGK-l genes 
are separated by 12 kb, the distance between KLKI and PSA, which are transcribed from 
opposite strands is approximately 31 kb (7). PSA expression does not only show cell 
specificity, but is also tightly regulated by androgens, as mediated by the androgen receptor 
(AR) (S-12). The strong tissue specificity makes the PSA promoter a good candidate through 
which to deliver therapeutic genes in prostate cancer. 
Two functionally active AR binding sites (androgen response elements, or AREs) were 
identified in the proximal PSA promoter, at positions -170 (ARE-I) and -394 (ARE-II), 
respectively (1l,13). Although the proximal PSA promoter, including ARE-I and ARE-II, 
is more active in LNCaP prostate cells than in non-prostate cells, its activity is relatively 
low. This low level of activity suggested that the proximal PSA promoter is not sufficient to 
account completely for androgen regulation of the endogenous PSA gene, as observed in 
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LNCaP cells (11). This indicated to us that additional cis-acting control elements residing 
outside the proximal promoter might contribute to androgen regulated PSA gene expression. 
For several strong, tissue specific promoters, like those of the beta-globin and tyrosine amino 
transferase (TAT) genes, it has been well established that important control elements are 
located in regions far upstream of the proximal promoter (14-16). These distal enhancers 
cooperate with the proximal promoter for high expression of the specific gene. 
To identify putative regulatory elements upstream of the PSA gene, DNaseI hypersensitive 
sites (DHSs) were mapped in chromatin from LNCaP prostate cells. Functional analysis of 
a DNaseI hypersensitive region far upstream of the PSA gene showed the presence of a 
complex, androgen regulated enhancer. In this study we present a detailed analysis of this 
strong enhancer, which contains a functionally active, high affinity AR binding site (ARE-
\II). Furthermore, we compare the AR binding affinity and the functionality of this novel 
ARE with that of the previously identified AREs -I and -II (11,13). An abstract describing 
parts of tWs work has been published previously (17). 
While this work was in progress, Schuur et at. (18) reported the identification of a 1.6 Kb 
upstream enhancer fragment (-3.7 to -5.3). This fragment encompasses the 440 bp core 
enhancer region, which is the basis of the present study. 
RESULTS 
Mapping of DNaseI hypersensitive sites in the PSA upstream region 
In a previous study we identified two regions ill the PSA proximal promoter which are 
involved in androgen regulation (13). A functional active, high affinity, AR binding site, 
ARE-I (AGAACAgcaAGTGCT), was found to be present at position -170. ARE-I by itself 
gave rise to a weak (2-fold) stimulation of the PSA promoter activity in the presence of 
RI881. ARE-I had to cooperate with a second, low affinity AR binding site, ARE-II 
(GGATCAgggAGTCTC) at position -394 for maximal (approximately 6-fold) androgen 
induction of proximal PSA promoter activity in transfected LNCaP cells. 
To identify additional regulatory elements, we mapped DHSs in the 31 kb region between 
the PSA and KLKI genes in chromatin from the prostate derived cell line LNCaP, grown in 
the presence and absence of androgens, and in HeLa cell chromatin. DNA from DNaseI 
treated nuclei was digested with EcoRI and evaluated for location of DHSs by Southern blot 
analysis with the appropriate hybridization probes. With two different probes, DHSs could 
be found (Figure I). No other DHSs were detected over the 31 kb region with any of the 
probes tested (data not shown). Hybridization of EcoRI digested DNA from LNCaP cells 
with a 1.1 kb HindIlI-EcoRI fragment, spanning exon 1 and intron 1 of the PSA gene, 
showed one DHS (DHSIV), which was most prominent in the presence of Rl881 (Figure 
lC). This DHS mapped to the proximal promoter region. Hybridization of genomic DNA 
from R1881 treated LNCaP cells with a 0.5 kb EcoRI-HindIII probe (-6 kb) revealed the 
presence of a cluster of three DHSs, approximately 4 kb upstream of the PSA gene (Figure 
lA). The position of this cluster of DHSs could be confirmed by hybridization with a more 
downstream located probe (data not shown). Analysis of the same region ill chromatin from 
LNCaP cells grown in the absence of hormone showed that DHSII at -4.2 kb is clearly 
androgen regulated. Intensity of DHSI, at approximately -4.8 kb, is also influenced by the 
presence of R1881 during LNCaP culturing. The weak DHSIII (at - 3.8 kb) could be found 
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both in the absence and presence of R188I. Although weak, DHSI and DHSIII might also 
be present in chromatin from HeLa cells, which do not express PSA (Figure IB). In contrast, 
DHSII was clearly absent in HeLa cell chromatin, indicating cell specificity. 
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Figllre V.I. DNAsel hypersellsitive sites ill chromatillllpsiream of lite PSA gelle. SOlilltem 
blot allalysis of gellomic DNAfro/ll 1Iliciei of LNCaP (A, C) alld HeLa (B) cells illcubated lVilh 
illcreasillg alllOllllls of DNase! (lalles 2-7, alld 9-14 ill A; 2-6 ill B; alld 2-7, alld 9-14 ill C; 
Lalles 1 alld 8 ill A; 1 ill B; 1 alld 8 ill Care cOlllrols lVilholil DNAse! treatmelll), alld 
digested lVitlt EcoRI. Hybridizatioll was lVillt all EcoRI-HilldIlI probe al -6 kb (A,B) or a 
HindIII-EcoR! probe at + 1 kb (C). Nllclei lVere isolaled from LNCaP cells grolVn ill lite 
absellce (A, lalles 1-7; C, lalles !-7) or presellce of R1881 (A, lalles 8-14; C, lalles 8-14), 
or (B) from HeLa cells grolVlI ill 5% complele foetal calf sel'l/m. (D) Scltemalical 
represelllatioll of tlte PSA gelle. Black boxes represelll tlte jive exolls of tlte PSA gelle. 
Hybridizatioll probes are illdicated by "orizolltal bars ill the panial restriction map. Positiolls 
of DHSs are indicated by arrows (DHSI-IV). 
Functional analysis of the DnaseI hypersensitive region upstream of the PSA gene 
To identify the function of the DNA segment containing the upstream DHSs, a 6 kb PSA 
promoter fragment was inserted upstream of the luciferase reporter gene (PSA-61-LUC), and 
the activity of this fragment was compared with that of 2.2 kb (PSA-I-LUC) and 632 bp 
(PSA-4-LUC) PSA promoter fragments. Transient transfection to LNCaP cells showed for 
PSA-61-LUC a much higher (3000-fold) activity in the presence than in the absence of 
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RI88I (Figure 2A). PSA-I-LUC and PSA-4-LUC gave rise to a 6-foid and 4-fold induction, 
respectively, upon hormone treatment. These experiments clearly indicated the presence of 
a very potent enhancer between -6 and -2.2 kb. 
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Figllre V.2, Alldrogell reglllalioll of tfle PSA promoter ill LNCaP cells. (A) LNCaP cells lVere 
transiently tralls/eeted with PSA-LUC COltstructs as described ill Materials alld Methods. Following 
4 " incubation with the plasmid precipitate, trans/eeted cells were cultured for 24 It in the absellce 
or ill the presence of R1881 (1 11M). 17le absolute activity and relative inductioll jactor were 
calculated as tlte mean of /ollr or more illdepelldelll experimellfs, whicll were dOlle ill duplicate. 
Closed bar: Activity ill tile presellce of RiB8i; open bar: activity ill the absence of RiB8i. The SEM 
of tile absolute activity is represented by a Ilorizontal stripe. Tile induction level is indicated at tile 
right side of the bars. Positiol1s of ARE-I and ARE-II ill PSA promoter constructs are represented by 
black boxes. Positions of DHS I, 1I and 111 are indicated by arrows. (B) Partial restrictioll map of the 
PSA promoter. "SolI" represellts the positioll of all artificial SolI site derived from the border of a 
IllIman gellomic DNA fragmelll ill lambda EMBL3. 
To map this upstream region in more detail, a 2.2 kb Xbal-StuI fragment (see Figure 2B 
for a partial restriction map of the PSA promoter), encompassing the three upstream DHSs, 
was inserted in front of the proximal PSA promoter in PSA-4-LUC, which starts at the 
EcoR! site at -632, and which contains ARE-I (-170) and ARE-II (-394) (13) (Figure 3A), 
giving rise to construct PSA-64-s-LUC. Transfection of PSA-64-s-LUC to LNCaP cells 
resulted in an even higher (over 6000-fold) induction of promoter activity upon RI88I 
activation (Figure 3A), indicating that the upstream enhancer activity resides within this 2.2 
kb fragment. The 2.2 kb Xbal-Stul fragment in the opposite orientation gave rise to a similar 
high activity (PSA-64-as-LUC in Figure 3A). 
125 
Chapter V 
A CONSTRUCT RELATIVE LUCIFERASE ACTIVITY (%) 
PSA·4 
.e, 
'" liE 
. ." []}§ 4 
I!:eolt! 
3000 
6060 
PSA·.'·, V22/ft~ .............. ---; )(bal Siul ,. 
PSA·64·as ~~
Siul )(bal 
!joao 
PSA-73  , ••••• 11-< 2640 
".0 BamHI ,. 
PSA-74 L?-4-4l .. ________ LLU~C I7777L ...rn= ~ ••••• ., 3420 
p.n "&11 
PSA·78 ~~ Poll l!"eoRV 
PSA·83 C777L --fTT1.fLUC sall~~ l.L.Uc:..::: c:::J • R1661 
~~~~~~~~~"~'=O ____ .o.-__ -:"'::_+~"~":'~'. 6o\~11 pon f 
o 50 100 150 200 2:>0 
PSA·85 
B 1 
BstEII ggtgaccaga gcagtctagg tggatgctgt 
61 
cctgagatta ggaatcctca atcttataot 
121 "SaIl" 
tctctgatga agatattato ttcatgatct 
181 CiaI 
CAtatTGTAT Cgattgtcct tgacagtaaa 
241 
tatctaggac agtaagcaag cctggatctg 
301 
tttacaaaca tcottgaaac aacaatccag 
361 Nco! 
aagacacaca gatacgtgac agaaccatgg 
421 PstI 
gccttccacc cttgtctgca 9 
c CONSTRUCT 
TKLUC :::---E 
-105 
ARE ([[ 
90a9a09999 tttgtgccac tggtgagaaa 
gggacaactt gcaaaoctgc tcagcctttg 
tggattgaaa acagacctac tctggaGGAA 
caaatctgtt gtaagagaca ttatotttat 
EcoRV 
agagagatat catottgcaa ggatgcotgc 
aaaaaaaaag gtgttgctgt ctttgctcag 
agaattgcct cccaacgctg ttcagccaga 
LUCIFERASE ACTIVITY 
1.4 c:::J - R1881 
_ + R1681 
~1I1I1I1I1I1I1I1I1I1-'~63 TK-85-s-LUC It " z "k z z z zr-----E BstEIi Pstl 
TK-85-as-LUC lSSSS~SSS~ >49 
Pstl BstEIl 
o 5 10 15 x 10 4 20 
Figure V.3. Identification of the androgen regulated core enhancer region, upstream of the PSA 
gelle. (AJ Detailed deletioll mapping of the upstream region of the PSA gene ill trallsfected LNCaP 
cells. E:tperimelltal details of the trallsfectiolls are described ill Materials alld Methods, alld ill the 
legend to Figure 2A. T1le activity of the PSA-6I-LUC construcl ill the presence of RI88I is set at 100 
%. 17le mean of the luciferase activity alld tile relative inductioll levels are from at least four 
il1depel1dellf experimellfs. (B) Sequel1ce of tile 440 bp BstEII-Psi/upstream core el1i1aucer fragmel1t. 
Importam restrictioll sites are indicated above 'he sequence. 171e ARE-Ill sequence is underlined, with 
the two half sites ill capitals. (C) Effect of the core enllancer region 011 TK promoter activity ill 
LNCaP cells. T1le hatched box represellfs the 440 bp core ellhallcer. E:"perimemai details are as ill 
Figure 2A. 
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To determine the borders of the upstream enhancer region, a series of truncated fragments 
was linked to the proximal PSA promoter in LUC reporter gene constructs. Both PSA-73-
LUC (1 kb PstI-BamHI) and PSA-74-LUC (0.9 kb PstI-PstI) showed an induction and 
absolute activity, which was approximately 50% of PSA-64 activity. A further 200 bp 3' 
truncation in construct PSA-78-LUC (PstI-EcoRV) resulted in a 4-fold drop of activity upon 
RI881 treatment. Similarly, deletion of the distal end (PSA-83-LUC), resulted in an 8-fold 
reduction in activity. The 440 bp BstEll-PstI fragment (PSA-85-LUC) turned out to be the 
smallest fragment with strong enhancer activity (Figure 3A). We defined the BstEII -PstI 
fragment as the core enhancer. The sequence of this core enhancer is shown in Figure 3B. 
Because further 5'- or 3'- deletion resulted in a partial decrease of core enhancer activity I 
two or more separate enhancer elements must be present in this fragment. Most accurate 
calcnlations of the positions of DHSs -I, -II, and -III showed that DHSII is located within the 
core enhancer fragment, however, this is not the case for DHSI and DHSIII. Most likely, 
DHSI is situated close to the PstI site at -4.8 kb, and DHSIII close to the BamHI site at -3.8 
kb (see Figure 2B). 
To find out whether core enhancer activity was directly androgen regulated, the BstEII-Pst! 
fragment was linked in both orientations to the TK promoter (TK-85-s-LUC and TK-85-as-
LUC, respectively), and LNCaP cells were transfected with these constructs (Figure 3C). 
The result clearly showed that this 440 bp fragment contained orientation independent, 
intrinsic androgen responsive enhancer activity. This observation correlated with the strong 
androgen regulation of DHSlI, linking results of the transient transfection studies with the 
activity of the promoter of the endogenous PSA gene. Additionally, the results indicated 
synergistic cooperation between the upstream enhancer and the proximal PSA promoter, 
because PSA-6I-LUC and PSA-85-LUC were considerably more active than TK-85-LUC 
(Figures 2A, 3A and 3C, and data not shown). 
Identification of an androgen response element in the core enhancer region 
To identify candidate AR binding sites, DNaseI footprints were determined over four 
overlapping core enhancer segments, utilizing the purified AR DNA binding domain (AR-
DBD). The only clear protection that was observed, was located in the middle part of the 
fragment, over the sequence 5'-ACTCTGGAGGAACATATTGTATCGATT-3', directly 
upstream of the ClaI site (Figure 4A). The protected area contained the sequence 
GGAACAtatTGTATC, which shows high homology (overall 9 out of 12 bp), with the 
consensus sequence GGTI AACAnnnTGTTCT for high affinity AR binding (19). Competition 
was found with a lOO-fold excess ARE consensus oligo, but not with an excess of an NF-I 
consensus oligo (Figure 4A, lanes 4 and 5), indicating specificity of the interaction. Although 
both the BstEII-SaII and the EcoRV-Pst! subfragments contributed to maximal activity of the 
core enhancer (Figure 3A), AR binding was not observed in one of these fragments (data not 
shown). Gel retardation analysis of a double stranded oligonucleotide encompassing the 
upstream AR binding site (ARE-III: ggaGGAACAtatTGTATCgat) with AR-DBD confirmed 
that this fragment contains a specific, high affinity AR binding site (Figure 4B). 
To test Whether ARE-III was functionally active, the sequence was mutated to 
G£;ATAAtatTTCAAC in TK-85-s-LUC, resulting in construct TK-85-I-LUC. In transfection 
experiments, the mutated enhancer was no longer Rl881 inducible (Figure 4C). This not only 
indicated that ARE-III was functionally active, but also provided evidence for a pivotal role 
of ARE-III in androgen regulation by the core enhancer region. 
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Figure VA. Identification ofafllllctiollally active AR binding site ill tlte core enhancer region. (A) 
DNAse/footprilit allalysis over ARE-III. 17Ie 10IVer stralld ofpHS2 ("SaII"-EcoRVjragmelll ill the core 
enhalleer) was 32P-eJld labelled, digested with DNase! ill the absence (lalles 1 alld 6) alld presence 
of 10 (Ialle 2) alld 20 pmol (Ialles 3-5) AR(DBD) fusioll proteill, alld subjected to gel electrophoresis 
(see Materials alld Methods). Lalles 4 alld 5: competition with a 1OO10ld excess double stral/ded lion 
specific (NF-l consensus oligo, lalle 4), alld specific oligonucleotide (ARE consel/SUS, lalle 5). Maram 
alld Gilbert sequence reactions are run alongside the footprim (G alld G+A). The sequence of the 
protected area is depicted at the right. 17le two ARE-Ill hal/sites are ill capitals. LS: lower stralld; 
US: upper stralld. (B) Gel retardatioll allalysis of the ARE-Ill*AR(DBD) complex. Experimelltal 
details are as described ill Materials alld Methods. Lane 1: free ARE-Ill probe,' lalles 2-5: ARE-Ill 
probe illcubated with AR(DBD). Lalles 3-5: competitioll with a IOOjold excess ARE-Ill oligo (Ialle 
3), ARE COl/sellSUs oligo (lalle 4) alld NF-J consenslls oligo (lalle 5). 17le arrow indicates the position 
of the AR-Ill*AR(DBD) compler. 171e ARE-Ill sequellce is presellled below the jigllre. (C) 171e effect 
of ARE-III illactivatioll all the alldrogell regulated core ellhallcer activity ill tralisielllly trallsfected 
LNCaP cells. Experimellfal details are as described ill Materials alld Methods, alld ill the legelld to 
Figllre 2A. Closed bar: Activity ill the presellce of RI88I (111M); Opell bar: activity ill the absellce 
of hormone. Meall values of [uciferase activities alld inductionleveis, alld the SEM (horizontal stripe) 
are from three illdepelldellt, duplicate experimellfs. TIle hatched bar in the constructs represellts the 
core enhancer. ARE-Ill is givell as a black box. 171e inactivated ARE-III is represellfed by a cross. 
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Comparison of ARE-I. ARE-II. and ARE-III 
The presence of (at least) three AREs [ARE-I(-170): AGAACAgcaAGTGCT; ARE-I1(-
394): GGATCAgggAGTCTC, and ARE-III (-4200): GGAACAtatTGTATC] in the PSA 
promoter raised the question of relative AR binding affinities of the individual AREs, and 
their separate contribution to overall androgen regulation of PSA promoter activity. To 
compare AR binding to these AREs, gel retardation analyses were performed with serial 
dilutions of purified AR-DBD (Figure SA). ARE-I and ARE-III turned out to be high affinity 
AR-DBD binding sites, with comparable AR binding affinity. The ill vitro interaction of AR-
DBD with ARE-II was much weaker. 
Next, three copies of ARE-III were inserted in front of the minimal TK promoter in TK-
LUC, and the activity was compared with similar ARE-I and ARE-II TK-LUC constructs. 
Transient transfection experiments in LNCaP cells showed ARE-III to be functional active, 
albeit less than ARE-I: to-fold, and 34-fold induction upon Rl881 stimulation, respectively 
(see Figure 5B). However, both ARE-I and ARE-III were more active than ARE-II. 
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Figllre V.S. Comparisoll of ARE-I, ARE-II alld ARE-III ill vitro AR(DBD) billdillg alld filllctiollal 
activity. (A) Gel retardatioll allalysis of ARE-I. ARE-II alld ARE-III complexed witll AR(DBD). ARE-I 
(Ialles 1-5), ARE-II (Ialles 6-10), alld ARE-III (Ialles II-I5) (50xIif cpm) are illcllbated witll all 
increasing omollllt of AR(DBD) alld analyzed by gel retardation assay as described ill Material alld 
Metllods. Lalles I, 6 alld II: free probe. Lalles 2, 7 alld 12: 30 fillol AR(DBD). III eacll pallel, tile 
followillg lalle cOllfah/s jOllr times more AR(DBD}, 11le arrow indicates the POSWOIl of the 
ARE*AR(DBD) complex. ARE-I, ARE-II alld ARE-III sequellces are presellted below tllejigure. (B) 
Effect of ARE-I, ARE-ll alld ARE-Ill 011 minimal TK promoter activity ill transiently trallsfeeted 
LNCaP cells. LNCaP cells were co/ralls/eeted with the illdicated reporter gene COllstruet alld the AR 
e;.pressioJl vector pSVARo (2.5 I(g). The ARE-/ragmellfs are represented by triallgles, mean values 
and SEM are from three illdependent, duplicate e).perimellts. Further experimellfai details are 
described in Materials and Methods and in the legend to Figure 2A. 
Mutational analysis of AREs -l, -II. and -III 
To investigate the role of the individual AREs in overall androgen induced transcriptional 
responsiveness of the 6 kb PSA promoter, for each individual ARE two different knock out 
mutations were introduced in PSA-61-LUC (see Materials and Methods for sequences of 
mutated AREs). Transient transfection of LNCaP cells with the resulting mutated PSA 
promoter-LUC constructs showed that all three AREs contributed to androgen regulation. 
ARE-I(-170) mutations resulted in an 80% reduction of promoter activity (Figure 6). Both 
mutations in ARE-II(-394) had a limited effect (50% or less reduction). Mutations in ARE-III 
had by far the most dramatic effect. As compared to wild type PSA-61-LUC, less than 1 % 
of activity was retained in the mutated promoter. This finding indicated that ARE-III is not 
only a key element in the 440 bp upstream core enhancer, as shown in Figure 4C, but also 
in the context of the 6 kb PSA promoter. 
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Figure V.6. The effect oflhe illactivation of ARE-I, ARE-II alld ARE-III 011 androgen regulation 
of the PSA promoter. Et:perimellfai details are as described ill Materials alld Methods, alld ill the 
legelld to ill tile legelld to Fig 2A. PSA·61·LUG activity ill LNCaP cells cultured ill tile presellce of 
Ri881 is set at 100%. TIle ARE mutations ill the 6 Kb PSA-61~LUC COtlstruct are indicated by 
crosses. Mean values alld SEM arejromfour independent, duplicate e:tperimellts. Hormolle inductioll 
values are givell at the right side of the bars. 
Tissue specificity of the PSA promoter 
Previous work in our laboratory showed that the proximal PSA promoter is more active 
in LNCaP prostate cells than in non·prostate cells (13). To study whether the androgen 
induced activity of the upstream core enhancer also showed cell specificity, reporter 
constructs PSA·61·LUC (Figure 2), TK·85·s·LUC and the TK-LUC control (Figure 3C) 
were cotransfected with the AR expression plasmid pSY ARo to a series of AR negative 
prostate and non·prostate cell lines. In contrast to the high activity in LNCaP cells, TK-85·s· 
LUC showed hardly any activity over basal TK promoter activity in the androgen 
independent prostate cell lines PC·3 and DU145, and in COS (monkey kidney) and Hep3B 
(human hepatoma) cells (Table I), Furthermore, the 6 kb PSA promoter was hardly active 
in these cells. For comparison, MMTY·LUC was transfected to the same set of cell lines. 
In PC3 and DU145 cells, a low RI881 induced activity was detected. In COS, Hep3B and 
LNCaP cells, the MMTY promoter was strongly induced. Interestingly, in COS and HeLa 
cells, induction of MMTV promoter activity was 40·60 times higher than that of PSA·61. 
In contrast, in LNCaP cells, PSA·61·LUC was 6 times more active than MMTY·LUC. These 
findings clearly indicate cell specificity of the PSA promoter. 
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Table V.I. Effect of RI88I 011 PSA-6I-LUC, TK-85-LUC alld MMTV-LUC activity ill PC3, DU145, 
COS, Hep3B cells, co-Iralls/eeled with the AR expressio1l plasmid pSVARo, as compared to LNCaP 
cells. 
CONSTRUCT RELATIVE INDUCTION (+/- R1881) • 
PC3 OU145 COS Hep3B LNCaP 
TK-85-s-LUC" 1.5 ± 0.2 1.2 ± 0.1 1.8 ± 0.3 1.3 ± 0.4 163 ± 17 
TK-LUC 1.5 ± 0.2 1.1 ± 0.3 1.3 ± 0.4 1.1 ± 0.3 1.4 ± 0.2 
PSA-61-LUC 1.7 ± 0.5 1.2 ± 0.1 1.4 ± 0.3 2.1 ± 0.8 3000 ± 224 
NNTV-LUC 2.8 ± 1.5 2.6 ± 0.9 58 ± 20 115 ± 36 476 ± 64 
') Induction is the mean of three independent, duplicate experiments ± SEM. 
") Constructs are described in Materials and Methods. 
The only tested celis, besides LNCaP cells, in which the PSA promoter was active was 
the human mammary carcinoma cell line T47D. Transfection of TK-85-s-LUC to T47D cells 
resulted in a 25-fold induction of luciferase activity upon RI881 stimulation, even in the 
absence of pSVARo cotransfection (Table IIA). PSA-6I-LUC could be stimulated 
approximately lOG-fold by RI88I. Because T47D cells are known to contain the progesterone 
receptor (PR), and a low level of AR, and because RI881 can activate both AR and PR, 
experiments were repeated with the pure androgen dihydrotestosterone (DHT) and the pure 
progestin R5020. DHT stimulation ofT47D cells transfected with TK-85-s-LUC and PSA-6I-
LUC resulted in a 4-fold and 15-fold induction of LUC activity, respectively. R5020 
stimulation of T47D cells transfected with TK-85-s-LUC and PSA-6I-LUC gave rise to 
induction levels, comparable to RI881 stinlUlation. Cotransfection of T47D cells with 
pSV ARo slightly increased DHT induced PSA promoter activity (Table lIB). These results 
indicate that the PSA promoter is not completely cell specific, and also, that PSA promoter 
activity is not completely AR specific. However, comparison of PSA (PSA-61 and TK-85) 
and MMTV promoter activity in T47D cells with that in LNCaP cells (Tables I and II) still 
indicates a strong preference of the PSA promoter for LNCaP cells. 
Table V.II. Effect of RI88I, DHT alld R5020 011 PSA-6I-LUC, TK-85-LUC alld MMTV-LUC 
activity ill T47D cells, withoul (A) alld with co-transfee/ioll o/the AR expression plasmid pSVARo 
(B). 
CONSTRUCT RELATIVE INDUCTION (+/- hormone) • 
A RIBBI DHT R5020 B DHT 
TK-85-s-LUC" 25 ± 4 4.3 ± 0.4 26 ± 3 8.2 ± 1.7 
TK-LUC 1.3 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 1.3 ± 0.3 
PSA-61-LUC 97 ± 21 17 ± 4 157 ± 29 25 ± 7 
MMTV-LUC 504 ± 50 228 ± 21 512 ± 60 478 ± 45 
') Induction is the mean of three independent, duplicate experiments ± SEM . 
.. ) Constructs are described in Materials and Methods. 
132 
Androgen regllla!ioll by the PSA upstream enhancer 
DISCUSSION 
It is well established that PSA expression is directly androgen regulated, and cell specific. 
Previously, in transient transfection experiments with PSA promoter constructs, combined 
with in vitro protein-DNA interaction assays, two AREs were identified in the proximal PSA 
promoter: ARE-I at position -170, and ARE-II at -394 (11,13). Activity of a 632 bp proximal 
promoter was approximately 6-fold induced by RIBBI in LNCaP cells. Cotransfection with 
an AR or glucocorticoid receptor (GR) expression plasmid resulted in an increase of absolute 
activity and induction level of the proximal promoter upon RIBBI treatment. The low level 
of induction obtained with the endogenous AR suggested that the proximal PSA promoter was 
not sufficient to account completely for the androgen induction as observed for the 
endogenous PSA gene (11). In the present study we characterized a strong upstream 
enhancer, which is required for high, androgen regulated and cell specific expression of the 
PSA gene. The results described extend our own previous work, and the recent work of 
Schuur et al. (lB). As compared to the latter study, two major differences seem obvious: (i) 
In the experiments described in the present study, approximately 50% of the activity of the 
upstream eollancer region is retained within the 440 bp BstEII-Pst! (-4.3 to -3.9) fragment 
(see Figure 3A), whereas in the work of Schuur et al. essentially all activity is lost by 
deletion of sequences downstream of the XbaI site at -5.3 Kb. At the 3' -border of the 
enhancer region the differences are less dramatic. Deletion from the Pst! site to the EcoRV 
site in constructs PSA-73 and PSA-74 results in an approximately 5-fold loss of activity (see 
Figure 3A); the comparable constructs in ref. IB (CN70 and CN71) show a 2-fold drop in 
activity. Summarizing, we found the minimal region with high enhancer activity to be 
approximately I Kb smaller at the 5'-border. Although it can always be argued that different 
LNCaP sublines and culture conditions have been used, there is no obvious explanation for 
the differences observed. (ii) A second difference between the data in ref. IB and our 
findings concerns the induction level of the 6 Kb PSA promoter (3000 as compared to 3B). 
Part of the difference in induction might be accounted for by the reporter genes used (LUC 
and CAT, respectively). The higher sensitivity of the LUC assay enabled us to compare the 
properties of ARE-III in the upstream enhancer with those of ARE-I and ARE-II in the 
proximal promoter. 
An important goal of the present study was the analysis of the chromatin structure in a 31 
kb region upstream of the PSA gene by the identification of DHSs. Although other 
explanations are possible, DHSs in chromatin, which reflect structural alterations, are a 
strong indication for the interruption of Ihe nucleosome slructure due 10 binding of 
Iranscription faclors 10 Ihe DNA. In chromatin from LNCaP cells, Ihree DHSs were found 
cluslered in Ihe area from 3.B 10 4.B kb upslream of Ihe PSA gene. DHSIII (at -3.B kb) is 
weak and also presenl in chromatin from HeLa cells, which do nol express PSA. DHSI (at -
4.B kb) is clearly androgen induced in LNCaP cells. DHSII (al -4.2 kb) is by far Ihe most 
prominent: it is slrongly androgen induced in LNCaP cells and absent in HeLa cells. The 
differences in structure between chromatin froIll LNCaP cells, grown in Ihe presence and 
absence of RIBBI, and from HeLa ceUs indicated to us a functional role of Ihe DHS cluster 
in androgen regulated and cell specific expression of the endogenous PSA gene. 
In Iransient lransfection experiments, Ihe -4.B to -3.B region showed slrong, androgen 
regulaled eollancer activily (PSA-64-s-LUC and PSA-64-as-LUC in Figure 3A). It is not 
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clear whether sequences corresponding to DRSI and DRSIII are present in the shorter active 
enhancer construct PSA-73-LUC. Most likely, DRSI maps very close to the Pst! site, which 
is at the 5' border of PSA-73-LUC; DRSIII maps close to the BamHI site, which determines 
the 3' border of PSA-73-LUC. An even shorter fragment, PSA-85-LUC, lacks both DHSI 
and DHSIII, but contains DRSII, which maps close to the ClaI site. The rmding that PSA-85-
LUC still shows approximately 50% of the enhancer activity suggests that, in transient 
transfections, DHSI and DHSIII sequences play no or only a minor part in PSA promoter 
activity. Whether they are required for proper expression of the endogenous PSA gene 
remains to be determined. The finding that ARE-III at -4.2 kb corresponds to DHSII in the 
chromatin suggests that ARE-III is not only essential in the PSA promoter in transient 
transfections, but also in androgen regulated expression of the endogenous PSA gene. 
The upstream core enhancer most probably has a complex structure. We were unable to 
narrow down the size of the core enhancer to less than 440 bp without loosing substantial 
activity. Combined with the essential role of ARE-III in the enllancer, at least three separate 
active regions can be identified in the core enllancer: ARE-III, and the 5'- and 3'- end 
fragments (see Figure 3). In each of the two end fragments, one or more binding sites of 
ubiquitous or prostate specific transcription factors might be located. The possibility that 
these fragments contain one or more weak, so far not identified, AR binding sites cannot be 
excluded. In cooperation with ARE-III, and additional cis-acting sequences within the 130 
bp SalI-EcoRV fragment, a complex enllancer might be formed with cooperative interactions 
between the different components. Further experiments are obviously required to elucidate 
the detailed composition of this core enhancer. 
A functional ARE-III is a prerequisite for high activity of the upstream enhancer. 
Inactivation of ARE-III almost completely abolished core enhancer activity. In contrast, 
truncation of the 5'- and 3'-fragments resulted only in a partial reduction of enhancer 
activity. However, there is little doubt about a synergistic cooperation of ARE-III with other 
cis-acting elements in the core enhancer: when hooked to the TK promoter, the core 
enhancer, containing one ARE-III, is superior to even three copies of ARE-III coupled to the 
TK promoter. A mechanism explaining the central role of ARE-III could be AR induced 
DNA bending, enabling the direct or indirect interaction between other transcription factors 
in the core enhancer. Alternatively, ARE-III bound AR might be a key element in the 
interaction of the upstream enhancer with the proximal promoter region, Of recruitment of 
the RNA polymerase II holoenzyme to the PSA promoter (20,21). In this respect the PSA 
upstream enhancer might function as a classical complex, steroid hormone regulated control 
region. Similar upstream glucocorticoid regulated enhancers, composed of GR binding sites, 
binding sites for the liver enriched transcription factors HNF-3 and HNF-4, and binding sites 
for more ubiquitous transcription factors have been identified for the TAT gene, which is 
highly expressed in liver parenchymal cells (15,16). The enhancer motifs restrict the 
hormonal activation of the TAT gene to liver cells, not only in cultured cells, but also in 
transgenic mice (22). The PSA gene is the first example of an androgen-regulated, prostate 
specific gene for which such a potent upstream enhancer is documented. Further study of this 
enhancer can be of great help for the identification of prostate specific transcription factors, 
and for the elucidation of the mechanism of cooperative interaction between the AR and other 
transcription factors. 
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The identification of three AREs in the PSA promoter in the present, and in our previous 
studies (11,13) readily raised the question of relative AR binding affntities and functional 
activities. ARE-I and ARE-III were found to be of similar potency, whereas ARE-II was less 
active. Mutational analysis indicated a clear synergistic cooperativity between ARE-I and 
ARE-III, and to a lesser extent ARE-II. However, inactivation of ARE-III had a far more 
impressive effect on the 6 kb PSA promoter than mutation of ARE-I. From these findings 
it can be concluded that the context in which the ARE is present has a pivotal effect on its 
functional activity. As indicated above, this might involve interactions with other 
transcription factors, including the spacing between specific cis-acting elements. 
Although the PSA gene is the first example of a gene containing a very potent far upstream 
ARE, clear synergistical interaction between multiple ARE sequences has also be found in 
the proximal (600 bp) PSA promoter (see ref. 13, as discussed above) and in the proximal 
(426 bp), prostate specific rat probasin (PB) promoter (23). Both the proximal PSA and the 
PB promoter contain one high affinity and one low affinity, functionally active AR binding 
site (13,23). Although much more active in their natural setting, multimers of the different, 
separate AREs from the PSA promoter are functionally active when fused to a heterologous 
promoter (Figure 5B, and ref. 13). In contrast, cooperative binding of the AR to both AREs 
in the PB promoter is required for androgen induction (24). 
To investigate cell specificity of PSA upstream core enhancer, we compared its activity 
in several prostate and non-prostate cell lines. Transient transfection experiments in (PSA 
negative) PC3, DUI45, Hep3B and COS cells did not reveal any activity, although two of 
the cell lines (PC3, DU145) originate from a prostate background. The MMTV promoter 
showed a very limited activity in AR cotransfected PC3 and DUI45 cells, but was clearly 
active in COS and HeLa cells. Together these findings indicate the absence of one or more 
transcription factor(s) or coactivator(s) essential for PSA promoter activity in these cells. 
Alternatively, a specific inhibitor of PSA promoter activity is present. The specificity of 
DHSII provided additional evidence for cell specific activity of the PSA promoter. 
TK-85-LUC and PSA-61-LUC were both found to be active in T47D cells. In T47D cells, 
PSA promoter activity was not only mediated through the AR but also via the PR (Table II). 
These results indicate that activity of the 6 kb PSA promoter is not entirely prostate and 
androgen specific. However, PSA promoter activity in LNCaP cells is superior to T47D cell 
activity. The issue of receptor specificity should be investigated in more detail in cell lines 
containing comparable amounts of PR and AR, either endogenously or after cotrausfection 
with the respective steroid receptor expression plasmid. In a similar type of experimental 
setup, we generated LNCaP sublines containing a stable transfected GR expression plasmid. 
This resulted in dexamethasone induction of the endogenous PSA gene, and GR regulated 
activity of the 6 kb PSA promoter in transient transfections (K.B.J.M. Cleutjens, in 
preparation). In summary, steroid hormone regulated expression of the PSA promoter 
depends on the properties of the cell line: the presence of AR, PR or GR is an essential, but 
not the only factor. Absence of specific inhibitors or presence of additional transcription 
factors andlor coactivators will also be essential. 
Although PSA expression was originally thought to be strictly restricted to prostate 
epithelial cells, low PSA expression in mammary tumor cells has been recently published 
(25,26). The activity of the PSA promoter in trausfected T47D cells, which are negative on 
Northern blots for endogenous PSA expression, could be in accordance with these findings. 
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It would be of interest to find out whether in mammary tumor tissue PSA expression is 
progesterone regulated, and could be used as a reliable marker for PR positive tumors. To 
obtain more definite information on tissue specificity of the 6 kb PSA promoter in both 
normal and tumor cells, animal studies with PSA promoter constructs are required. If the 
upstream enhancer is able to confer preferential expression of a target gene to prostate cells, 
ill vivo applications in humans, including gene therapy for delivery of pharmaceutical 
reagents to the prostate, can be further explored. 
MATERIALS AND METHODS 
Cell culture 
LNCaP cells (FGC), originally obtained from Dr. Horoszewicz (27), were cultured in 
RPMI 1640 and supplemented with 5% FCS and antibiotics. For transfection, cells were 
grown ill DMEM supplemented with 5 % steroid-depleted (dextran-charcoal treated) FCS. For 
examination of androgen induced DHSs, and androgen driven promoter activity in 
transfection experiments, the synthetic androgen RI881 (DuPont NEN, Boston, MA) was 
added to a final concentration of I nM. In indicated cases, DHT (Steraloids, Wilton, NH) 
and R5020 (DuPont NEN) were added to final concentrations of 100 nM and 10 nM, 
respectively. 
HeLa, T47D and COS cells were grown in DMEM, Hep3B cells were grown in MEM-
alpha, supplemented with 5% FCS and antibiotics. PC3 and DUI45 cells were grown in 
RPMI 1640, supplemented with 7.5% FCS and antibiotics. For transfection, PC3 and DUI45 
cells were grown in DMEM. 
Mapping of DHSs 
Cultured cells (LNCaP cells, grown in the presence and absence of I nM RIB81, and 
HeLa cells) were washed with ice cold phosphate buffered saline (PBS). Cells were 
suspended in 3 ml ice cold HS-buffer (15 mM Tris-HCI pH 7.4, 60 mM KCI, 15 mM NaCI, 
0.2 mM EDTA, 0.2 mM EGTA and 5% glycerol, supplemented with I mM dithiothreitol, 
0.15 mM spermine and 0.5 mM spermidine, directly prior to use). The cells were disrupted 
by passing 5 to 10 times through a 0.5 x 16 llUll (25G) needle. Disruption was monitored by 
light microscopic examination. Nuclei were collected by centrifugation for 5 min at 2500 
rpm, and resuspended in HS buffer to a final concentration of 5 X 107 nuclei/ml. Limited 
DNase! digestion was carried out in a final volume of 0.5 ml HS-buffer containing 5 x 10' 
nuclei, 5 mM MgCl, and DNaseI (O-BOO U; Boehringer Mannheim, Germany). The mixture 
was incubated for 30 min on ice, and the reaction was stopped by addition of 10 1'1 0.5 M 
EDTA, 12.5 1'1 20% SDS and 50 1'1 Proteinase K (10 mg/ml). Next, the sample was 
incubated overnight at 37 'C. Subsequent to phenol/chloroform extraction, the DNA was 
collected by isopropanol precipitation. The DNA was dissolved in 100 "I Tris-EDTA buffer 
and digested with EcoRl. Restriction fragments were separated by electrophoresis in a 1 % 
agarose gel and transferred to a nylon membrane (Hybond N+, Amersham, Cardiff, UK). 
Filters were hybridized at high stringency with random primed "P-Iabeled probes (as 
indicated in Figure 1) using standard procedures (28). 
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Construction of plasmids 
All plasmid constructs were prepared using standard methods (28). The promoterless basic 
plasmid pLUC, PSA-4-LUC, TKLUC, the human AR expression plasmid pSV ARo, the 
AR(DBD) expression plasmid pRITITAR and pMMTV-LUC were described previously 
(13,29-31). PSA-61-LUC was generated by insertion of the Hind II1/HindllI (-6 kbl + 12) 
fragment of the PSA promoter in the MCS (multiple cloning site) of pLUC. PSA-I-LUC was 
generated by ligation of the BamHl/HindllI (-2.2 kbl + 12) fragment in the MCS of pLUC. 
PSA-64-s-LUC and PSA-64-as-LUC (XbaI-StuI, -5.4/-3.2 kb), PSA-73-LUC (PstI-PstI, -
4.7/-3.9 plus PstI-BamHI -3.9/-3.8 kb), PSA-74-LUC (PstI-PstI, -4.7/-3.9 kb), PSA-78-LUC 
(Pstl-EcoRV, -4.8/-4.1 kb), PSA-83-LUC (SalI-BamHI, -4.25/-3.8 kb) and PSA-85-LUC 
(BstEII-Pstl, -4.35/-3.9 kb) were generated by insertion of the appropriate fragments in front 
of the proximal PSA promoter (-6321 + 12) in construct PSA-4-LUC. The artificial Sall site 
(-4.25 kb) was derived from the 5'-end of a human genomic DNA phage insert (4Pl, see 
ref 7). 
Constructs TK-85-s-LUC and TK-85-as-LUC were generated by insertion of the 440 bp 
BstEII-Pstl fragment into the MCS of TKLUC. Constructs ARE-I-TKLUC and ARE-II1-
TKLUC were generated by cloning three copies of ARE-I, and ARE-III oligonucleotides in 
TKLUC, respectively (sequences of oligonucleotides are shown below). ARE-I1-TKLUC was 
generated by ligation of the double stranded 3ARE-II oligonucleotide in the Sail site of 
TKLUC. 
ARE-I 5' GATCCTTGCAGAACAGCAAGTGCTAGCTG 3 ' 
3' GAACGTCTTGTCGTTCACGATCGACCTAG 5' 
3ARE-II 5' TCGACAGGGATCAGGGAGTCTCACCAGGGATCA-
3' GTCCCTAGTCCCTCAGAGTGGTCCCTAGT-
GGGAGTCTCACCAGGGATCAGGGAGTCTCACG 3' 
CCCTCAGAGTGGTCCCTAGTCCCTCAGAGTGCAGCT 5' 
ARE-III 5' TCGACGAGGAACATATTGTATCGAG 3' 
3' GCTCCTTGTATAACATAGCTCAGCT 5' 
pHS I, pHS2, pHS3 and pHS4, which were the starting material for footprint experiments, 
were obtained by insertion of the blunt ended BstEII/ClaI, SalI/EcoRV, EcoRV/Pstl and 
ClallNcoI fragments, respectively, into the SmaI site of pTZI9 (Pharmacia, Uppsala, 
Sweden). 
Generation of ARE mutations 
Mutations were introduced in ARE-I (-170), ARE-II (-394) and ARE-III (-4200) essentially 
according to the PCR method of Higuchi et a1. (32). Standard amplification conditions were 
30 cycles of denaturation for 1 min at 95'C, annealing for I min at 55'C, and extension for 
2 min at 72'C. The oligonucleotides which were used for the generation of the different 
mutations are listed below. Two different sets of outer primers were used, one set for ARE-I 
and -II mutations, and a separate set for ARE-III mutations. Substitutions in complementary 
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sets of inner primers ARE-I-I, -2; ARE-U-I and -2; ARE-III-I and -2 are underlined (see 
below). PSA-61-LUC was used as the template for the first PCR step. In the second PCR 
step, appropriate samples of the purified products of the first amplification reactions were 
mixed at a I: I ratio. The resulting PCR fragments were cloned and after sequencing, 
exchanged with the corresponding fragment of PSA-61-LUC. 
ARE-I and -II outer primers: 
forward primer 5' CCACAAGATCTTTTTATGATGACAG 3' 
reverse primer : 5' GCTCTCCAGCGGTTCCATCCTCTAG 3' 
ARE-III outer primers : 
forward primer 51 CTTCTAGGGTGACCAGAGCAG 3' 
reverse primer : 5' GCAGGCATCCTTGCAAGATG 3' 
Inner primers: 
ARE-I-l: 5' GTAATTGCAQATTAGCAATGGQTAaCTCTCCC 3' 
3' CATTAACGTQTAATCGTTACCQATIGAGAGGG 5' 
ARE-I-2: 5' GTAATTGCATAGTAGCAAAAGQTAaCTCTCCC 3' 
3' CATTAACGTaTCATCGTTTTCQATTGAGAGGG 5' 
ARE-II-l: 5' GGTGCAGGQATaAGGGATGCTCACAATCT 3' 
3' CCACGTCCQTATTCCCTACGAGTGTTAGA 5' 
ARE-II-2 : 5' GGTGCAGGQATIAGGQAACCTQACAATCT 3' 
3' CCACGTCCQTAaTCCQTTGGAQTGTTAGA 5' 
ARE-III-l:5' CTCTGGAGQATAATATTTCAaCGATTGTC 3' 
3' GAGACCTCQTATTATAAAGTIGCTAACAG 5' 
ARE-III-2:5' CTCTGGAGTAGTATATTACAQCGATTGTC 3' 
3' GAGACCTCaTCATATAATGTQGCTAACAG 5' 
Transfections 
Cells were transfected according to the calcium phosphate precipitation method essentially 
as described (33), using I x 10' cells per 25cm' flask and 5 p.g of the appropriate PSA-LUC 
construct. Following 4 h incubation with the precipitate, the culture medium was replaced 
by PBS, containing 15% glycerol (incubation for 90 sec at room temperature). Subsequently, 
transfected cells were incubated in culture medium in the absence or presence of the 
appropriate hormone for 24 h. Transfections were performed in duplicate. Experiments were 
repeated at least three times using two independent plasmid isolates. 
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Luciferase assay 
Cells were washed in PBS and lysed in 300 1'1 lysis buffer (25 mM Tris-phosphate pH 7.8, 
8 mM MgCl" I mM DTT, I % Triton X-100, IS % glycerol). Next, 0.1 ml Luciferin (0.25 
I'M) (Sigma)/ 0.25 I'M ATP was added to 0.1 ml extract, and luciferase activity was 
measured in a LUMAC 2500 M Biocounter (LUMAC, Landgraaf, The Netherlands). After 
a delay of 2 sec (according to supplier), the light emission was recorded during 5 sec. 
Luciferase activities were corrected for variations in protein concentrations of the cell 
extracts. Luciferase activities and relative induction factors are expressed as mean and 
standard error of the mean (SEM) of at least three independent experiments. 
DNAsel footprint analysis 
Production and purification of AR(DBD) IVas done as described previously (13,30). 
Fragments for footprinting were generated by digestion of pHSI, 2, 3 and pHS4 with Xbal 
and Sac!, or with SpbI and EcoR!, to be able to identify protected windows on both the 
upper and lower strand. Subsequently, fragments were filled in with MMLV -reverse 
transcriptase (Boehringer) in the presence of CI-"P-dATP, and isolated from non-denaturing 
polyacrylamide gel. The DNasel footprinting experiments were performed essentially 
according to Lemaigre et al. (34). Labelled probe (50,000 cpm) was incubated with 10-20 
pmol AR(DBD) fusion protein for 30 min at 0 "C, in the presence of 10 I'M ZnCI,. In 
indicated cases, a 100-fold excess competitor oligo's (consensus ARE or consensus NF-I; 
5' -GATCCAGGGAACAGGGTGTTCT ACG-3', and 5' -A TTTTGGCTTGAAGCCAA TATG-
3', respectively» was added. Digestion with 0.04 U DNasel (Boehringer) was for 60 sec at 
20 "C in a final volume of 50 "I. In the absence of AR(DBD), 0.025 U DNAsel was used. 
Following phenol/chloroform extraction and ethanol precipitation, DNA was dissolved in 5 
1'1 formamide-dye-mix (98% formamide, 10 mM EDTA, 0.2% bromophenol blue and 0.2% 
xylene cyanol). After heating to 95"C for 2 min and rapid cooling on ice, the DNA was 
separated on a denaturing (7M urea) 6 % polyacrylamide gel. G and (G+A) sequence 
reactions according to Maxam and Gilbert (35) of the same fragment were run as markers 
alongside each footprint. After electrophoresis, gels were fixed, dried and exposed to X-ray 
film. 
Gel retardation analysis 
The gel retardation experiments were performed as described previously (13). Double 
stranded oligonucleotides used in gel retardations: 
ARE-I 5' GATCCTTGCAGAACAGCAAGTGCTAGCTG 3' 
3' GAACGTCTTGTCGTTCACGATCGACCTAG 5' 
ARE-II 5' GATCCAGGGATCAGGGAGTCTCAG 3' 
3' GTCCCTAGTCCCTCAGAGTCCTAG 5' 
ARE-III 5' TCGACGAGGAACATATTGTATCGAG 3' 
3' GCTCCTTGTATAACATAGCTCAGCT 5' 
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Shortly, probes were filled in with MMLV -reverse transcriptase in the presence of O'_32p_ 
dA TP, and subsequently isolated from non-denaturing polyacrylamide gel. Labeled probe, 
50,000 cpm, was incubated with AR(DBD) (30 fmol to 2 pmol). In indicated cases lOO-fold 
excess ARE or NF-l competitor oligonucleotides was added. Following 20 min incubation, 
samples were run on a 4 % non-denaturing polyacrylamide gel. Subsequently, gels were 
fixed, dried and exposed to X-ray film. 
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ABSTRACT 
Prostate-specific antigen (PSA) is a kallikrein-like serine protease, that is abuost 
exclusively synthesized in the luminal epithelial cells of the human prostate. PSA expression 
is androgen regulated. Previously, we characterized ill vitro the proxbual promoter, and a 
strong enhancer region, approximately 4 Kb upstream of the PSA gene. Both regions are 
needed for high, androgen regulated activity of the PSA promoter in LNCaP cells. The 
present study aims at the ill vivo characterization of the PSA promoter. Three transgenic 
mouse lines carrying the E.coli LacZ gene driven by the 632 bp proximal PSA promoter, and 
three lines with LacZ driven by the 6 Kb PSA promoter were generated. Expression of the 
LacZ reporter gene was analyzed in a large series of tissues. Transgene expression could not 
be demonstrated in any of the transgenic animals carrying the proximal PSA promoter. All 
three lines carrying the 6 Kb PSA promoter showed lateral prostate specific ,,-galactosidase 
activity. Transgene expression was undetectable until 8 weeks after birth. Upon castration, 
,,-galactosidase activity rapidly declined. It could be restored by subsequent androgen 
administration. A search for mouse PSA-related kallikrein genes expressed in the prostate led 
to the identification of mGK22, which was previously demonstrated to be expressed in the 
submandibular salivary gland. Therefore, the 6 Kb PSA-LacZ transgene followed the 
expression pattern of the PSA gene in humans, which is almost completely prostate-specific, 
rather than that of mGK22 in mice. In conclusion, the 6 Kb promoter fragment appears to 
contain most, if not all, information for androgen-regUlation and prostate-specificity of the 
PSA gene. 
INTRODUCTION 
Prostate specific antigen (PSA) is a 30-33 kDa glycoprotein, that is almost exclusively 
produced by the luminal epithelial cells of the human prostate. It is one of the predominant 
proteins secreted into the prostatic fluid. Serum PSA is a well known marker for diagnosis 
and monitoring of prostate cancer (1,2). The PSA gene (or KLK3) is a member of the human 
kallikrein gene family. Other members of the kallikrein gene family are the hGK-I(KLK2) 
gene, which is also expressed in the prostate, and the tissue kallikrein gene (KLKI), which 
is mainly expressed in the pancreas and kidney (3-6). The three genes are clustered within 
the 60 Kb kallikrein locus on chromosome 19 (7,8). PSA expression can be regulated by 
androgens (9-11). Previously, we and others characterized ill vitro the 632 bp proximal 
promoter (11,12), and a strong, 440 bp enhancer region, approximately 4 Kb upstream of 
the transcription start site of the PSA gene (13,14). Both regions are needed for high, 
androgen regulated activity of the PSA promoter in LNCaP cells. Two functionally active 
androgen receptor binding sites (androgen response elements, or AREs) were identified in 
the proximal PSA promoter, at positions -170 (ARE-I) and -394 (ARE-II), respectively 
(11,12). The upstream enhancer showed synergistic cooperation with the proximal PSA 
promoter, and was found to be composed of at least three separate, but cooperating, 
regulatory regions. At -4.2 Kb, the presence of a functionally active, high affinity androgen 
receptor binding site (ARE-Ill) was established (14). Transient transfection of a 6 Kb PSA 
promoter fragment, containing both the proxin131 promoter and the upstream enhancer, linked 
to the luciferase reporter gene, to prostate and non-prostate cell lines showed largely LNCaP 
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prostate cell specific activity (13,14). The strong tissue specificity of the endogenous PSA 
gene ill vivo and the 6 kb PSA promoter fragment in transient transfection experiments makes 
the PSA promoter a candidate to deliver therapeutic genes to prostate cancer cells. To 
explore this view, the present study aimed at the ill vivo characterization of the PSA 
promoter in transgenic mice. 
In mice, the kallikrein gene family is composed of 24 members, half of which are probably 
pseudogenes (15). Although structurally related to the PSA gene, none of the mouse 
kallikreins can be considered as the mouse homolog of human PSA, because of the different 
tissue distribution (16). All functional mouse kallikrein genes are expressed in the 
submandibular salivary gland (SMG). Individual genes show additional expression in 
pancreas, kidney, spleen and/or testis. So far, mouse kallikrein expression in the prostate has 
not been demonstrated. Two members of the closely related rat kallikrein gene family have 
been found to be expressed in both prostate and SMG (17). In order to compare PSA 
promoter specificity in transgenic mice with the promoter specificity of endogenous mouse 
kallikreins we determined which, if any, of the mouse kallikrein genes was expressed in 
prostate. 
RESULTS 
Activity of the PSA promoter LacZ fusion constructs in LNCaP cells 
Previously, we characterized in transfection experiments the proximal promoter, and a strong 
440 bp core enhancer region, approximately 4 Kb upstream of the transcription start site of 
the PSA gene (11,12,14). Two functionally active AREs were identified in the proximal PSA 
promoter, at positions -170 (ARE-I) and -394 (ARE-II), respectively (11,12). In the center 
of the 440 bp upstream enhancer region a third functionally active ARE, ARE-III (-4200) 
could be demonstrated (14). Although both the proximal promoter and the upstream region 
contributed to maximal androgen regulated and cell specific activity of the PSA promoter, 
the upstream enhancer was found to be essential for high activity (12,14). To investigate the 
regulatory regions of the PSA promoter in transgenic mice, two LacZ reporter gene 
constructs were designed (Figure IA). In these constructs, the LacZ gene is driven by the 
632 bp proximal PSA promoter (PSA-4-LACH), or by the 6 Kb PSA promoter fragment 
(PSA-61-LACH). The hormone induced activity of the constructs was tested in transiently 
transfected LNCaP cells. The PSA-4-LACH construct, co-transfected with the human 
androgen receptor expression plasmid pSV ARo, was 7-fold more active in the presence than 
in the absence of the synthetic androgen RI881 (Figure IA). In the absence of pSVARo, 
PSA-4-LACH showed a linlited androgen inducibility (1.8 fold). Under these conditions 
PSA-61-LACH activity was induced 600-fold by R1881. These results are essentially 
identical to those obtained with comparable luciferase reporter gene constructs (12,14). 
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Identification of transgenic mice 
Both PSA-4-LACH and PSA-61-LACH were used to generate transgenic mice. Three PSA-4-
LACH and five PSA-61-LACH founder animals were identified by PCR of tail DNA with 
primers PSA-s and LacZ-as (data not shown}. Transmission of the transgene to their 
offspring was demonstrated for three PSA-61-LACH and all three PSA-4-LACH transgenic 
lines. One PSA-61-LACH male founder did not transmit the transgene; another PSA-61-
LACH male founder was infertile. Comparison of the hybridization signals of the transgene 
and the endogenous mouse protamine-I gene on Southern blots of genomic DNA revealed 
the presence of 4, 2 and 38 copies of the transgene in lines PSA-61 TG2, TG28 and TG31, 
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respectively. PSA-4 TGl, PSA-4 TG2 and PSA-4 TG6 carried approximately 150, 100 and 
126 copies of the transgene (Figure 2A, lanes 4-6, and 1-3, respectively). Note that the 
endogenous mouse protamine-I gene showed a restriction fragment length polymorphism, 
resulting in 6 and/or 8 Kb hybridizing fragments (Figure 2A lanes 7,8). 
The 6 Kb. but not the 632 bp PSA promoter directs lateral prostate specific trans gene 
expression 
To determine the expression pattern of the transgene, male mice were sacrificed at 8 to 16 
weeks of age, and {:l-galactosidase activity was measured in twenty-six different tissue lysates 
(see Materials and Methods). Thorough analysis of all three PSA-61-LACH transgenic mouse 
lines showed exclusive {:l-galactosidase activity in extracts from lateral prostate. In all other 
tissues, including the dorsal, ventral and anterior prostate lobes, LacZ expression was 
undetectable (as shown in Figure 2B for PSA-61 TG28). {:l-Galactosidase activity could also 
not be detected in extracts from tissues of virgin or lactating female transgenic mice (data 
not shown). In none of the tested tissues of PSA-4-LACH mice, {:l-galactosidase expression 
could be found (data not shown, and Figure 2C). For PSA-61-LACH, transgene activity was 
independent of the number of integrations, since {:l-galactosidase activity in the lateral prostate 
was comparable, despite the difference in copy numbers (4, 2 and 38, respectively). The 
level and specificity of transgene expression appeared independent of the integration site. 
To screen for the presence of low levels of transgene expression in the different prostate 
lobes and Submandibular salivary gland (SMG) , a known expression site of mouse 
kallikreins, we performed RT-PCR with transgene eDNA specific primers, and GAPDH as 
a control (See Materials and Methods). Again, transgene expression could only be detected 
ill the lateral prostate (lane 2, Figure 2D). 
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mOllse protamine eDNA probe (see Materials alld Methods). By comparison of the illfellsity of the 
endogenous (see arrow heads) alld tratlsgelle ballds. the number of trallsgelle copies presellf ill the 
llldividual lransgellic lines was determined (numbers Oil top of each lalle). For PSA-4-LACH 
transgenic animals, two different etpOsllre times of the same Southern blot are shown (A 4" e\posure 
of the trallsgene hybridizingfragmelll and a 40 h e:tposure of the endogenous mouse protamine gene). 
Note that the endogenolls protamine fragment is polymorphic. (8) Liquid {3-galactosidase assay of 
tissue extracts of IO-week old PSA-61-LACH T028 male mice. (q {3-Galactosidase activity ill lateral 
prostate Iysates of PSA-4-LACH TO 1, 2 and 6 alld PSA-61-LACH TO 2, 28 alld 31 allimals as 
compared to activity ill COlllral mice. (D) RT-PCR IIlIalysis of LacZ/Prafamille tmllsgelle mRNA ill 
RNA obtailled from dorsal, lateral, velltral and alltel'ior prostate alld submandibular salil'aty gland 
of PSA-61-LACH TG 28 male mice. &perimelltai details are described ill Materials alld methods. Tlle 
lower pallel shows the result of RT-PCR analysis oj ubiquitollsly e\pressed GAPDH mRNA. peR 
products were separated over a 2 % agarose gel. 
148 
The PSA promoter directs prostate specificity ill vivo. 
Figure VJ.3. Trallsgelle expressioll ill the lateral prostale. (A,B) Whole moullt X-gal staining, 
followed by neutral red cOUllterstaillillg of 5 I'Ill paraffille embedded sections of (B) lateral prostate 
of a 10 week PSA-6J-LACH TG 28 male and (AJ lateral prostate of a lIOn-transgenic Iittermate 
(Magnification 400 .\). Blue X-gal stainillg is shown as blue spots ill the cytoplasm of luminal 
epithelial cells. 
Figure VIA. RNA ill situ "lbridizatioll allalysis oJlateral prostate tissue sectiolls oJ II 10 week old 
PSA-6J-LACH TG 28 male IraJlSgellic mouse, Five /Jill secfiolls a/paraffine embedded tissue were 
incubated with a DIG-labeled protamine RNA probe. Hybridization was visualized with alkaline-
phosphatase-conjugated allt/DIG antibody (see Materials alld Methods). (C,D) Tissue sections of a 
14 week old PSA-61-LACH male transgellic mOllse, (B) NOIl-transgellic Iittermate (atllisellse probe; 
400 x magnification) (A) Incubation of a transgenic mouse prostate with a sense protamille riboprobe. 
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PSA-61-LACH expression is restricted to the luminal epithelial cells of the lateral prostate 
Whole mount ,6-galactosidase staining, followed by sectioning of the paraffine embedded 
tissue was performed to investigate the cell type in the prostate expressing the LacZ gene. 
As demonstrated in Figure 3B, ,6-galactosidase staining lVas restricted to the luminal epithelial 
cells. Staining was concentrated at the basal site of the cytoplasm. No staining was found in 
the lateral prostate from age-matched control mice (Figure 3A). To further evaluate PSA-61-
LACH expression, sections of the paraffine embedded lateral prostate of PSA-61-LACH 
positive and control mice, were analyzed by ill situ hybridization using sense and antisense 
DIG-labeled protamine riboprobes. Results obtained with the antisense protamine probe 
revealed that transgene mRNA was localized within the cytoplasm of the luminal epithelial 
cells of the lateral prostate (Figure 4C,D). No hybridization signal was detected in control 
mice, or with a sense protamine riboprobe (Figure 4A,B). The restricted expression of the 
transgene to the luminal epithelial cells is consistent with endogenous PSA expression in the 
human prostate (18). 
Developmental and hormonal regulation of PSA-61-LACH expression 
PSA gene expression has been shown to be developmentally regulated and to follow plasma 
testosterone levels (19). In ill vitro studies, expression of PSA mRNA and protein, and PSA 
promoter activity is strongly androgen regulated (9-14). To determine the pattern of the PSA-
61-LACH transgene expression during development, Iysates of lateral prostate tissues were 
prepared from line 28 males between 2 and 52 weeks of age. As indicated in Figure 5A, the 
dorsolateral prostate of 2 weeks old and the lateral prostate of 4 weeks old mice did not show 
significant ,6-galactosidase activity. In contrast, sexually mature males, ranging from 8 to 52 
weeks of age, showed an almost constant, high level of ,6-galactosidase activity 
(approximately 1500 RLU/ug protein). 
To obtain additional information on androgen inducibility of the 6 Kb PSA promoter in 
transgenic mice, sexually mature PSA-61-LACH males of line 28 were castrated, and ,6-
galactosidase activity in the lateral prostate was determined at 4 days after castration, and at 
2 days following hormone replacement. As demonstrated in Figure 5B, transgene activity 
decreased dramatically following castration, and returned very rapidly to pre-castration levels 
after DHT administration. This finding strongly indicates androgen regulation of transgene 
expression. 
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Lateral prostate of 10 week old PSA-6J-LACH mice served as camra/. 
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Mouse kallikrein expression 
In order to investigate mouse kallikrein gene expression in the prostate, RNA was isolated 
and RT-PCR was performed with primers overlapping highly conserved regions in exon 3 
(KALK-3-s) and exon 4 (KALK-4-as) of all known mouse kallikrein genes (see GenBauk data 
for mouse kallikrein sequences). Thirty-four cloned, 146 bp PCR fragments were sequenced. 
Thirty-two clones turned out to contain a mGK22 fragment (20), the 2 additional cDNA 
fragments were 94% identical, and both contained novel kallikrein sequences, with highest 
homology to mGK16 (91 and 92%, respectively) (21). Previously, mGK22 was found to be 
expressed in both male and female salivary glands, but absent in all other tissues tested (22). 
RT-PCR with mGK22 specific primers confirmed the presence of mGK22 mRNA in lateral 
prostate and SMG. mGK22 was absent in dorsal, ventral and anterior prostate (Figure 6). 
The expression level in SMG was much higher than in lateral prostate. 
mGK22 
!III-__ _ GAPDH 
1 2 3 4 5 
Figllre VJ.6. RT-PCR allalysis ofmollse Glalldlliar Kallikreill 22 expressioll illihe variolls 
lobes of Ihe mOllse proslale and male sllbmandiblliar salivary glalld. TIle RT-PCR prodllcts 
were blotted to Hybond N+ membralle and hybridized lVith a ralldom primed 32P-labeled 
probe specific for the expected 634 bp cDNA fragment. RT-PCR of GAPDH mRNA ill the 
RNA preparations of the different tissues is sholl'lI ill the 10ll'er part. 
DISCUSSION 
Previously, we investigated the properties of the 632 bp proximal promoter, and a strong 
far upstream (-4 Kb) 440 bp enhancer region of the PSA gene in transfected LNCaP cells 
(11,12,14). Although both regions contributed to androgen regulated activity of the promoter, 
the presence of the 440 bp core enhancer was a prerequisite for high activity. A 6 Kb PSA 
promoter fragment, which contains both the proximal promoter and the upstream enhancer 
region, was mainly active in LNCaP prostate cells. However, PSA promoter activity was also 
observed in T47D mammary tumor cells (14). 
In this study we showed that the 6 Kb and not the 632 bp PSA promoter is capable to 
direct reporter gene activity in transgenic mice. In three independent transgenic lines, 
carrying a LacZ reporter gene under control of the 6 Kb PSA promoter, hormonally and 
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developmentally regulated expression of the transgene was exclusively targeted to the luminal 
epithelial cells of the lateral prostate, which mimics the expression pattern of the endogenous 
PSA gene in the human prostate. This strongly suggests that the 6 Kb PSA promoter contains 
most, if not all, information for prostate specific activity. The specific expression of the 
trans gene in the mouse lateral prostate is in agreement with the structural homology between 
the human prostate and the mouse lateral prostate, and the mouse kallikrein expression in the 
lateral prostate. The variable level of PSA expression in human breast cancer (23), and the 
activity of the 6 Kb PSA promoter in transiently transfected T47D human mammary tumor 
cells (14) could not be confirmed in normal breast tissue offemale PSA-61-LACH transgenic 
mice (data not shown). 
Transgene expression was assessed in a liquid iJ-galactosidase assay, by RT-PCR and by 
RNA ill situ hybridization. Additionally, X -gal staining of the different tissues was 
performed. X-Gal staining of adult mouse tissues is complicated due to high endogenous iJ-
galactosidase activity present in many tissues, including testis, epididymis, vas deferens, 
liver, intestine and prostate. This problem was overcome by modification of the standard 
protocols (24,25). Incubation at elevated temperature prior to staining (l h at 50 0 C), and 
a raised pH (8.6) during the various incubation steps (see Materials and Methods) suppressed 
endogenous iJ-galactosidase activity, without noticeable loss of activity of the B.coli derived 
transgene. Only in epididymis, vas deferens and anterior prostate, endogenous iJ-
galactosidase activity could be found at a long (over 16 h) staining period, which precludes 
detection of a low level of transgene expression in the X-gal assay (data not shown). 
iJ-Galactosidase expression was undetectable in the PSA-4-LACH mice, despite the 
presence of 100 or more copies of the transgene in all three transgenic lines. Transient 
transfection of LNCaP cells with PSA-4-LACH (Figure 1) and also PSA-4-LUC constructs 
(12,14) showed a low activity of this 632 bp promoter fragment, especially in the absence 
of a co-transfected androgen receptor expression plasmid. The observation by Schaffner et 
al. (see ref. 26), that transgenic mice carrying a Ha-rasT24 oncogene, driven by the 632 bp 
proximal PSA promoter developed salivary gland and gastrointestinal tract tumors seems to 
be in contrast to our findings for this promoter. However, mutant Ha-ras expression was 
only confirmed in salivary gland tumors, and not in gastrointestinal tumors. Furthermore, 
the late onset of tumorigenesis could indicate that Ha-ras expression was a secondary event. 
This might be related to PSA expression in a subset of salivary gland tumors in humans (27). 
An alternative hypothesis is that Ha-ras intron or exon sequences affect the selectivity and 
level of expression of the oncogenic transgene. 
The three PSA-61-LACH transgenic lines show a comparable level of lateral prostate 
specific, but copy number independent iJ-galactosidase expression. This could indicate that 
the PS"A-61-LACH transgene cassette lacks elements,like matrix attaclmlent regions or locus 
control regions, which might determine boundaries in chromatin structure, leading to copy 
number dependent and position independent activity of transgenes (see 28, and references 
therein). The 6 Kb PSA promoter fragment contains all DNAse! hypersenstive sites (which 
indicate importaot regulatory regions) in the 31 Kb region upstream of the PSA gene (see ref. 
\4). However, it might lack putative, so far unidentified regulatory sequences within the PSA 
gene, or in the flanking region downstream of the PSA gene. or even downstream of the 
hGK-l(KLK-2) gene, which is also prostate specifically expressed, and which is at a distance 
of 12 Kb in the human genome (7,8). Alternative explanations for copy number independent 
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activity are also possible. Although difficult to compare, the RT-PCR, and X-gal staining 
experiments suggest that the expression level of the transgene in PSA-61-LACH mice is not 
as high as that of the endogenous PSA gene in the human prostate. Although this might be 
due to the integration site and the properties of the LacZ and protamine part of the transgene 
cassette, it is a real possibility that one or more trans-acting factors, that direct high level 
PSA expression in the human prostate, are absent, or present in a much lower concentration 
in the mouse prostate. If this is indeed the case, these factors could be limiting factors in the 
expression of the transgene, which corresponds to a comparable activity of the 6 Kb PSA 
promoter in the three independent transgenic lines. This might also explain the low 
expression level of the mouse kallikrein mGK22 in the prostate. On the other hand, the latter 
might be caused by differences in promoter make up. Further analysis of mGK22 mouse 
kallikrein promoter activity in human prostate cell lines should provide additional 
information. In this regard, it is also interesting, that the 6kb PSA promoter driven transgene 
expression pattern was different from that of mGK22, which is expressed at a high level in 
SMGs. The PSA-61-LACH transgene follows the expression pattern of the endogenous PSA 
gene in humans, and not that of mouse kallikreins. 
The 6 Kb PSA promoter is the first human promoter, that directs prostate specific 
expression in transgenic mice. Previously three rat promoters have been studied with respect 
to prostate specificity and applicability in the development of rodent prostate cancer models, 
rKLK8, C3(l) and probasin (29-35). Transgenic rats carrying a 2.5 Kb rKLK8 rat kallikrein 
promoter fragment did not show tissue specificity. Expression of the transgene was 
demonstrated in almost all tissues tested, including prostate, but was absent at the major sites 
of endogenous gene expression, the submandibular and sublingual salivary glands (29). 
Transgenic mice carrying a 6 Kb 5' -flanking region of the rat C3(1) gene linked to the (3-
galactosidase reporter gene (30) or a 9.5 Kb fragment carrying the C3(l) gene with 4 Kb 
upstream and 2 Kb downstream flanking sequences (31) did not direct transgene activity 
strictly to the prostate. Depending on integration site, expression was also detected in testis, 
heart, lung and skeletal muscle. Transgenic mice bearing a 5.7 Kb C3(l) promoter linked 
to the SV 40 large T antigen region developed at 7 months a prostate adenoma or 
adenocarcinoma (32). Female mice carrying this transgene acquired mammary 
adenocarcinomas. The mice developed also other phenotypic changes including several 
proliferative lesions and malignancies leading to premature death. Greenberg et a!. (33) 
reported on a 426 bp promoter fragment of the rat probasin gene directing CAT reporter 
gene expression to the prostate of transgenic mice. These transgenic mice showed CAT 
expression in dorsal, lateral and ventral prostate. Low levels of transgene expression were 
observed il1 the anterior prostate and in the seminal vesicles. Although prostate specific, the 
expression level of the transgene was dependent on the integration site, and did not strictly 
follow the expression pattern of the endogenous rat probasin gene, which is selectively 
expressed in the dorsolateral prostate. Co-integration of chicken lysozyme matrix attachment 
regions resulted in transgene expression in dorsolateral prostate of adult mice. Co-integration 
of matrix attachment sites was insufficient to facilitate high level and copy number dependent 
expression. Transgenic mice carrying the 426 bp Probasin promoter driven SV 40 large T 
antigen oncoprotein, developed progressive forms of prostatic cancer (34,35). 
Progress towards the understanding of the biology of prostate cancer benefits enormously 
from the availability of proper animal models displaying the whole range of clinical stages. 
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The present study provides a baseline for the generation of such models, utilizing the 6 kb 
PSA promoter hooked to the appropriate oncogenes. Because of its tissue specificity, and 
integration site independent, constant activity it might even be preferred above the probasin 
and C3(l) promoter driven prostate cancer models. 
The observations as presented in this study, are not only relevant to the generation of 
mouse prostate cancer models, but also to gene therapy programs of human prostate cancer. 
The PSA gene is not only expressed in the luminal epithelial cells of the normal human 
prostate, but also in almost all prostate cancers. Therefore, the regulatory elements, that 
determine PSA expression in prostate cancer are of potential interest for building a promoter 
to drive expression of therapeutic genes in prostate cancer cells. The strict prostate specificity 
of the 6 Kb PSA promoter fragment strongly supports the applicability of this large promoter 
fragment. or derivatives, in gene therapy of human prostate cancer. Preliminary experiments, 
indicating prostate specificity of the 6 kb promoter driven TK gene in an adenovirus 
construct are in accordance with this view (Gotoh et aI., unpublished results). 
MATERIALS AND METHODS 
Cell culture 
LNCaP prostate cells were culnlfed as described (36). For examination of androgen driven 
promoter activity, the synthetic androgen, RI881 (DuPont NEN, Boston, MA), was added 
to steroid depleted medium to a final concentration of I nM. 
Comtruction of plasmids 
All plasmid constructs were prepared according to standard procedures (37). The human 
androgen receptor expression plasmid pSV ARo and the LacZ containing reporter plasmid 
pLACH were described previously (38,39). A mouse protamine gene fragment (mPI, +95 
to +625, see ref. 24) provides the LacZ casseUe with an intron and the 3' untranslated 
region, including the polyadenylation signal. PSA-61-LACH was generated by integration 
of the blunt ended HindIII/HindIII (-6 kbl + i2) fragment of the PSA promoter into the Smal 
site of the pLACH multiple cloning site (MCS). PSA-4-LACH was generated by integration 
of the EcoRl/HindIII (-632 1+12 bp) PSA promoter fragment into pLACH. 
Transient transfections 
Cells were transfected according to the calcium phosphate precipitation method, essentially 
as described (i4). 
Generation and identification of transgenic mice 
The 632 bp and 6 Kb PSA promoter driven LacZ genes were reieased from vector sequences 
by restriction digestion, purified by gel electrophoresis and prepared for injection according 
to standard methods (40). The appropriate fragments were microinjected into the male 
pronuclei of fertilized eggs of C57BL6xDBA2C (Fi) mice. The presence of the transgene 
was established by PCR amplification on DNA from tail biopsies (40), using oligonucleotide 
prinlCrs PSA-s: 5'-TTGTCCCCTAGATGAAGTCTCCATGA-3' and LacZ-as: 5'-
CGCCAGGGTTTTCCCAGTCACGAC-3' (indicated in Figure i). 
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Transgene copy numbers were quantitated by phospho image analyses of Southern blots 
of tail DNA. To this purpose, 10 I'g DNA was digested with KpnI and Sac!, electrophoresed 
on 0.8 % agarose gel and transferred to Hybond N+ membrane (Arnersham, Cardiff, UK). 
Filters were hybridized at high stringency with a random primed "P-Iabeled protamine probe 
(see RNA ill situ hybridization section). DNA transfer and filter hybridization were carried 
out according to the protocol of the manufacturer. 
In indicated cases, mice were supplemented once a day with 5 mg Dihydrotestosterone 
(DHT) I Kg body weight. DHT in 100% ethanol was mixed with 9 volumes sesame oil, and 
injected subcutaneously. 
Liquid B-galactosidase assay 
/3-Galactosidase activity was measured in Iysates of LNCaP cells and mouse tissues using the 
Galacto-Light Plus"! chemiluminescent reporter assay 
(Tropix Inc., Bedford, MA). Two to 5 mg of mouse tissue was incubated in 100 1'1 lysis 
solution, transfected LNCaP cells were collected in 350 1'1 lysis solution. /3-Galactosidase 
activity in 10 pI extract was corrected for variations in protein concentrations (protein 
microassay, Bio-Rad, Mtinchen, Germany). 
Whole mount B-galactosidase staining 
Immediately after sacrificing, mouse tissues were fixed by perfusion fixation in 2 % 
parafonnaldehyde in a 0.1 M PIPES buffer (pH 6.9), containing 2 mM MgCI, and 1.25 mM 
EGTA. Tissues were dissected and fixed for an additional 60-90 min at RT. To inactivate 
endogenous /3-galactosidase activity, tissues were washed three times for 30 min in PBS (pH 
8.6). Subsequently, tissues were incubated in PBS for 60 min at 50°C. After cooling to RT, 
tissues were incubated in pre-staining solution (containing 2mM MgCI" 5 mM K,Fe(CN)" 
5 mM K.,Fe(CN), and 5 mM EGTA in PBS) for 60 min. After transfer to staining solution 
(pre-staining solution supplemented with 0.5 mg/ml X-Gal), incubation was continued for 6-
24 h at RT. The reaction was stopped by extensive washing in PBS, and tissues were 
postfixed in 4 % paraformaldehyde in PBS prior to paraffine embedding. Five I'm sections 
were counterstained with neutral red. 
RT-PCR 
Isolation of total cellular RNA was carried out according to the guanidinium isothiocyanate 
method (41). Reverse transcription and PCR amplification of LACZ-protamine (primers 
LACZ-s and PROII2-as), mouse kallikreins (primers KALK- 3-s and KALK-4-as), mGK22 
(mGK22-112-sand mGK22-4/5-as) and GAPDH (GAPDH-s and GAPDH-as) were performed 
on I I'g total RNA in the single tube Access RT-PCR' system (Promega, Madison, WI), 
according to the protocol of the manufacturer. Almealing steps were at 58° C, except for the 
kallikrein eDNAs expressed in mouse prostate (primers KALK-3-s and KALK-4-as), which 
was at 50° C. 
RT-PCR primers: 
LACZ-s 
PR01l2-as 
KALK-3-s 
: 5' AGCCATCGCCATCTG 3' 
:5'GACGGCAGCATCTTCGCCTC3' 
: 5'TGCGGATCCTCAGGCTGGGGCAGCA 3' 
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KALK-4-as 
mGK22-1/2-s 
mKG22-4/5-as 
GAPDH-s 
GAPDH-as 
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: 5' TGTCAGATCTCCTGCACACAAlGCAT 3' 
:5'CTAGGAGGGATTGATGCTGC3' 
: 5' CCTCCTGAGTCTCCCTTACA 3' 
: 5' GGTCTACATGTTCCAGTATGACTCC 3' 
: 5' GAGACAACCTGGTCCTCAGTGTAGC 3' 
The resulting PCR products were separated over a 2% agarose gel, and in indicated cases 
transferred to Hybond N+ membrane. Filters were hybridized at high stringency with random 
primed 32P-labeled probes specific for the expected cDNA fragment. The PCR product 
obtained with primers KALK-3-s and KALK-4-as was cloned in PCR-II (Invitrogen, Leek, 
The Netherlands), and resulting clones were sequenced. 
RNA ill silll hybridization 
Sense and antisense digoxygenin (DIG) labeled protamine RNA probes were generated on 
a 175 bp protamine cDNA fragment, obtained by RT-PCR on mouse testis RNA with 
primers PRO-s (5' GAAGATGTCGCAGACGGAGG 3') and PRO-as (5' 
GATGTGGCGAGATGCTCTTG 3'). The PCR fragment was first cloned in pCR-II. After 
sequencing, the EcoRI-EcoRI eDNA fragment was re-cloned in pTZl9 (Pharmacia, Uppsala, 
Sweden). After linearization with HindlII, DIG labeled RNA was transcribed from the T7 
promoter. Hybridization of 5 I'm paraffine embedded sections, and visualization with alkaline 
phosphatase coupled anti-DIG antibodies and indoxil-nitroblue tetrazolium (NBTIBCIP) 
substrate were done essentially as described (42). Sections were counterstained with neutral 
red. 
Experimental animals 
In accordance with the NIH Guidelines for Care and Use of Laboratory Animals, all 
experiments were conducted using the highest standard for humane care. 
ACKNOWLEDGEMENTS 
We thankJ. Vaughan and Dr. G. Lozano (Department of Molecular Genetics, MD Anderson 
Cancer Center, Houston, TX) for their indispensable contribution to the generation of the 
transgenic animals. We are indebted to Dr F. T. Bosman for critical reading of the 
manuscript, M Vermey and C.M.A. de Ridder for skillful technical support, H. Kock for 
animal care and F. L. van der Paone for photography. This study was supported by a grant 
of the Dutch Cancer Society. 
157 
Chapter VI 
REFERENCES 
1. Catalona WJ, Smith DS, RatcliffTL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole 
GL 1991 Measurement of prostate·specific antigen in serum as a screening test for prostate 
cancer. New Engl J Med 324: 1156-1161 
2. Oesterling JE 1991 Prostate specific antigen: a critical assessment of the most useful tumor 
marker for adenocarcinoma of the prostate. J Urol 145: 907·923 
3. Riegman PHJ, Vlietstra RJ, Klaasen P, van dec Korput JAGM, van Kessel AG. Romijn Je, 
Trapman J 1989 Characterization of the prostate-specifc antigen gene: a novel human 
kallikrien like gene. Biochem Biophys Res Commun 159: 95-102 
4. Lundwall A 1989 Characterization of the gene for prostate specific antigen, a human 
glandular kallikrein. Biochem Biophys Res Commun 161: 1151-1159 
5. Schedlich U. Bennets BH, Morris BJ 1987 Primary structure of a human glandular kallikrein 
gene. DNA 6: 429-437 
6. Evans BA, Zhang XY, Close JA, Tregear G\V, Kitamura N, Nakanishi S, Callen DF, Baker 
E, Hyland VJ, Sutherland GR, Richards RI 1988 Structure and chromosomal localization of 
the human renal kallikrein gene. Biochemistry 27: 3124-3129 
7. Riegman PHJ, Vlietstra RJ, Klaasen P, Kerput JAGM van der, Romijn JC, Trapman J 1989 
The prostate-specific antigen gene and the human glandular kallikrein 1 gene are tandemly 
located on chromosome 19. FEBS Letters 247: 123-126 
8. Riegman PHJ, VlietstraRJ, Suurmeijer L, Cleutjens CBJM, Trapman J 1992 Characterization 
of the human kallikrein locus. Genomics 14: 6-11 
9. Henntu P, Liao S, Vikho P 1992 Androgens up-regulate the human prostate-specific antigen 
messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA 
in the LNCaP cell line. Endocrinology 130: 766-772 
10. Young CYF, Andrews PE, Montgomery BT, Tindall DJ 1992 Tissue-specific and hormonal 
regulation of human prostate-specific glandular kallikrein. Biochemistry 31: 818-824 
II. Riegman PHJ, Vlietstra RJ, Korput JAGM van der, Brinkmann AD, Trapman J 1991b The 
promoter of the Prostate-specific antigen gene contains a functional androgen responsive 
element. Mol Bndocrinol 5: 1921-1930 
12. Cleutjens KBJM. Eekelen van CCEM. Korput van der HAGM, Brinkmann AD, Trapman J 
1996 Two androgen response regions cooperate in steroid hormone regulated activity of the 
prostate specific antigen promoter. J BioI Chern 271: 6379-6388 
13. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR 1996 
Prostate-specific antigen expression is regulated by an upstream enhancer. J Bioi Chern 271: 
7043-7051 
14. Cleutjens KBJM, van der Korput HAGM, van Eekelen CCEM, van Rooij HCJ, Faber PW, 
Trapman J 1997 An androgen response element in a far upstream enhancer region is essential 
for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol 
Endocrinol11: 148-161 
15. Evans BA, Drinkwater ce, Richards RI 1987 Mouse glandular kallikrein genes. Structure 
and partial sequence analysis of the kallikrein gene locus. J BioI Chem 262: 8027-8034 
16. Watt KWK, Lee P-J, M'Timkulu T, Chan W-P, Loor R 1986 Human prostate-specific 
antigen: structural and functional similarity with serine proteases. Proc Nat! Acad Sci USA 
83: 3166-3170 
17. Brady JM, Wines DR, MacDonald RJ 1989 Expression of two kallikrein gene family 
members in the rat prostate. Biochemistry 28: 5203-5210 
18. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, ehu TM 1981 Prostate 
antigen: a novel marker for prostatic cancer. Prostate 2: 89-96 
19. Goldfarb DA, Stein BS, Shamsadeh M, Petersen RD 1986 Age-related changes in tissue 
levels of prostatic acid phosphatase and prostate specific antigen. J Urol 136: 1266-1269 
158 
The PSA promoter directs prostate specificity ill vivo. 
20. Fahnestock M, Woo lE, Lpoez GA, Snoe J, Walz DA, Arici MJ, Mobley WC 1991 Beta-
NGF-endopeptidase: stmcture and activity of a kallikrein encoded gene mGK-22. 
Biochemistry 30: 3443-3450 
21. Kim WS, Nakayama K. Nakagawa T. Haragushi K, Murakami K 1991 Mouse submandibular 
gland prorenin-converting enzyme is a member of glandular kallikrein family. J BioI Chem 
266: 19283-19287 
22. Drinkwater ce, Evans BA, Richards RI 1987 Mouse glandular kallikrein genes: Identification 
and characterization of the genes encoding the epidermal growth factor binding proteins. 
Biochemistry 26: 6750-6756 
23. Zarghami N, Diamandis EP 1996 Detection of prostate-specific antigen mRNA and protein 
in breast tumors. Clin Chem 42: 361-366 
24. Peschon JJ, Behringer RR, Brinster RL, Palmiter RD 1987 Spermatid-specific expression of 
protamine 1 in transgenic mice. Proc Natl Acad Sci USA 84: 5316-5319 
25. Young DC, Kingsley SD, Ryan KA, Dutko PJ 1993 Selective inactivation ofeukaryotic beta-
galactosidase in assays for inhibitors of HIV-J TAT using bacterial beta-galactosidase as a 
reporter enzyme. Anal Biochem 215: 24-30 
26. Schaffner, DL, Barrios R, Shaker MR, Rajagopalan R, Huang SL, Tindall DJ, Young CYF, 
Overbeek PA, Lebovitz RM", Lieberman MW 1995 Transgenic mice carrying a PSArasT24 
hybrid gen develop salivary gland and gastrointestinal tract neoplasms. Lab Invest 73: 283-
290 
27. vanKrieken JH 1993 Prostate marker immunoreactivity in salivary gland neoplasms. Am J 
Surg Pathol17: 410-414 
28. Edmondson DG, Roth SY 1996 Chromatin and transcription. FASEB J iO: 1173-1182 
29. Southard-Smith M, Lechago J, Wines DR, MacDonald RJ, Hammer RE 1992 Tissue-specific 
expression of kallikrein family transgenes in mice and rats. DNA Cell BioI 11: 345-358 
30. Buttyan R, Slawin K 1993 Rodent models for targeted oncogenesis of the prostate gland. 
Cancer Metast Rev 12: 11-19 
31. Allison J, Zhang Y-L, Parker MG 1989 Tissue specific and hormonal regulation of the gene 
for rat prostatic steroid binding protein in transgenic mice. Mol Cell Bioi 9: 2254-2257 
32. Maroulakou IG, Anver M, Garret L, Green IE 1994 Prostate and mammary carcinoma in 
transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc 
Nail Acad Sci USA 91: 11236-11240 
33. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, 
Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, Matusik R 1994 The rat probasin 
promoter directs hormonally and developmentally regulated expression of a heterologous gene 
specifically to the prostate of transgenic mice. Mol Endocrinol8, 230-239. 
34. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR 
1995 Prostate cancer in a transgenic mouse. Proc Nail Acad Sci USA 92: 3439-3443 
35. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FI, Finegold MJ, Angelopoulou 
R, Rosen JM, Greenberg NM 1996 Metastatic prostate cancer in a transgenic mouse. Cancer 
Res 56: 4096-4102 
36. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Ming Chu T, Mirand EA, 
Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818 
37. Sambrook, J., Fritsch, E.F., & Maniatis, T. (1989) in Molecular Cloning: A Laboratory 
Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY 
38. Brinkmann AD, Faber PW, van RODij HCJ, Kuiper GGJM, Ris C, Klaassen P, van der 
Korput JAGM, Voorhorst MM, van Laar JH, Mulder E, Trapman J 1989 The human 
androgen receptor: domain structure, genomic organization and regulation of expression. J 
Steroid Biochem 34: 307-310 
159 
Chapter VI 
39. Bou-Gharios G, Garret LA, Rossert J, Niederreither K, Eberspaecher H. Smith C, Black C, 
deCrombrugghe B 1996 A potent far-upstream enhancer in the mouse pro alpha 2 (I) collagen 
gene regulates expression of reporter genes in transgenic mice. J Cell BioI 134: 1333-1344 
40. Hogan B, Beddington R, Costantini F, Lacy E 1994) in Manipulating the mouse embryo: a 
laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 
41. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ 1979 Isolation of biological active 
ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299 
42. DeBlock M, Debrouwer D 1993 RNA-RNA in situ hybridization using digoxigenin-labeled 
probes: the use of high-molecular-weight polyvinyl alcohol in the alkaline phosphatase 
indoxyl-nitroblue tetrazolium reaction. Anal Biochem 215: 86-89 
160 
Chaptet'VII 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
161 
Chapter VII 
In an attempt to identify a candidate prostate-specific transcription factor, a novel member 
of the C/EBP family of transcription factors was cloned, C/EBPo. As a model system, the 
molecular mechanism involved in androgen regulated and prostate specific expression of the 
PSA gene was extensively studied. During the course of the work described in this thesis 
three functionally active androgen response elements were identified in a 6 Kb PSA promoter 
fragment, two in the proximal promoter (ARE-I and ARE-II), and one in the far upstream 
enhancer region (ARE-III). The upstream enhancer region is probably complex and shows 
largely prostate specific activity in transfection experiments. Because the recognition 
sequence for the AR and several other steroid hormone receptors including the GR is 
identical, the mechanism underlying the apparent androgen specific induction of PSA 
promoter activity in LNCaP prostate cells was investigated. Finally, the capacity of two PSA 
promoter fragments in directing androgen regulated and prostate-specific activity of a reporter 
gene ill vivo was studied. 
Cloning of a novel (candidate) prostate specific transcription factor of a known family 
For the isolation of a novel, prostate specific member of a known family of transcription 
factors, we focused on the C/EBP family. Comparison of band shifts of a CCAAT box 
(TTGGGCAAT) in the rat C3(l) promoter with liver, ventral prostate and testis nuclear 
extracts indicated prostate specificity of a member of the C/EBP family, which could be 
involved in the prostate specific expression of the C3(l) gene (Zhang et al. 1990). At the 
time our search for a C/EBP gene expressed in (human) LNCaP prostate cells was initiated, 
only one human member of the C/EBP family, C/EBP/3, had been identified. In rodents four 
different C/EBPs, including C/EBP/3 had been cloned. C/EBP" had been implicated in liver 
and adipocyte specific gene expression. The C/EBP family members showed over 75 percent 
homology in the DNA binding domains, but the homology in the remaining parts of the 
proteins was limited. At present six different rodent C/EBPs have been identified, four of 
which have also been detected in humans (Akira et al. 1990, Kinoshita et al. 1992, Cleutjens 
et al. 1993, Antonson & Xanthopoulos, 1995, Chumakov et al. 1997). In the course of our 
study, we cloned the human C/EBPo gene. Independently, others reported the isolation of 
the human C/EBPo gene by screening of a genomic library with a probe encoding the 
C/EBP/3 DNA binding domain (Kinoshita et al. 1992). C/EBPo expression was detected in 
a variety of tissues, with the highest level of expression in lung, adipocytes and kidney. The 
expression of C/EBPo in lung and kidney is strongly enhanced by inflammatory cytokines, 
whereas the expression in adipocytes is strongly increased by adipogenic hormones, including 
insulin and dexamethasone (Cao et al. 1991). In prostate, C/EBPo expression is low, and 
upregulated by androgens (Cleutjens et al. unpublished results). Until now no evidence for 
a role of C/EBPo in prostate specific gene expression has been obtained. 
Although the cloning of C/EBPo did not result in the identification of a prostate specific 
transcription factor, the approach to identify prostate transcription factors by means of 
cloning a novel member of a kaown transcription factor family is still valid. As explored for 
C/EBP, a prostate specific protein, binding to the consensus sequence for a specific 
transcription factor family in a band shift assay can be a first tool. Ideally, this binding site 
is present in a region kaown to be important for prostate-specific gene expression but this 
is not a prerequisite. Essentially, the approach of cloning a novel member of a kaown family 
of proteins can also be applied for the identification of a putative prostate specific co-
activator. 
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Is the androgen receptor a key player in prostate specific gene expression? 
Possibly, prostate specific gene expression is not dependent upon one single strictly 
prostate specific transcription factor, but will be attained by a cooperative interaction of a set 
of transcription factors and co~activators, all showing partial tissue specificity. As a result, 
the target gene(s) will only be expressed at a high level in those cells which contain all 
essential factors. In this respect the AR might playa major role. AR is mainly expressed in 
cells of the male urogenital tract. Importantly, all genes showing (almost complete) prostate 
cell specific expression (including PSA, hGK-I, C3(1), probasin and prostate specific 
transglutaminase), were shown to be regulated by androgens (Heyns et aJ. 1978, Dodd et aJ. 
1983, Riegman et aJ. 1991a,b, Young et aJ. 1991, 1992, 1995, Henntu et aJ. 1992, Ho et aJ. 
1992, Wolf et aJ. 1992, Dubbink et aJ. 1996). Obviously, AR is not sufficient to direct 
prostate specific expression of these genes, because they are not expressed in other tissues 
of the urogenital tract. Both from endocrine manipulation of rats, and from the AR mutations 
in AIS, it is well established that AR is not only involved in tissue specific gene expression, 
but also essential for prostate development, and maintenance of its structure (Cunha et aJ. 
1987, Cunha 1994, Quigly et aJ. 1995, Gottlieb et aJ. 1997). 
Evidence for cooperative interaction of the AR with other factors was obtained by studying 
the cell specificity of the PSA promoter in transient transfection experiroents. Reporter genes 
driven by the PSA promoter show largely LNCaP prostate cell specificity as compared to 
several other prostate and non-prostate derived cell lines, despite co-transfection of a human 
AR expression vector in these cells (Chapter V). This correlates with the expression of the 
endogenous PSA gene (with the exception of T47D cells). AR might not be able to stimulate 
PSA promoter activity in PSA negative cells due to the absence of essential cooperating 
transcription factors or co-activators. One AR specific co-activator has been claimed, 
ARA 70. ARA 70 was shown to interact with the AR ligand binding domain, and selectively 
enhance AR -dependent transcription (Yeh & Chang 1996). Although ARA 70 is expressed in 
prostate, it is not prostate specific. Expression was demonstrated in almost all tissues tested, 
including AR negative tissues. 
An alternative mechanism of absence of PSA expression in AR positive cells can be the 
presence of specific silencers in these cells, that block AR mediated PSA promoter activity. 
An indication for such a factor might be obtained by deletion mapping experiments in non-
prostate cells. Deletion of the sequence to which the silencing factor binds would result in 
ubiquitous activity of the PSA promoter. Results obtained so far with the different PSA 
promoter constructs demonstrate that if a silencer protein is active, it must act on the 440 bp 
upstream enhancer region, because this fragment still shows prostate specificity (Chapter V) 
Cooperative interaction of multiple AREs 
Synergistic activity of multiple hormone response elements has been identified in many 
genes, including androgen responsive genes. The proximal promoter region of the probasin 
gene shows cooperative interaction of one high affinity and one low affinity AR binding site 
(Rennie et al. 1993, Kasper et aJ. 1994, Claessens et aJ. 1996). Clear cooperative activity 
between a high and a low affinity AR-binding sequence was also observed in the proximal 
PSA promoter (Chapter III). In case of the 6 Kb PSApromoter, the situation is even more 
complex, cooperative activity of three ARE sequences has been observed (Cleutjens et al. 
1997, Chapter V). Figure VII. I. shows a schematical representation of the currently 
identified regulatory elements in the PSA promoter. 
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TIC 
UPSTREAM ENHANCER REGION 
- ·4200 
Figure VII. 1 Schell/alieal represel/talioll of regulatory elemellts ill the promoter of the PSA 
gel/e. AR: al/drogel/ receptor, TF: ttal/scriptiol/ factor, TFE: TF bindil/g elemellt, TrC: 
transcription initiation complex. TSS: transcription start site. 
In this model, interactions between the various AR homodimers and other transcription 
factors in the upstream enhancer region, and presumably in the proximal promoter region 
might be either direct or mediated by co-activators. Looping out of the intervening DNA 
sequences might contribute to the observed communication between the distal enhancer, and 
the transcription initiation complex and regulatory elements in the proximal promoter 
(Gothard et a1. 1996, and references therein). 
The observed cooperative activity of the low affinity AR binding sites ARE-I 
(ATAGCAtctTGTTCT) in the probasin promoter and ARE-II (GGATCAgggAGTCTC) 
present in the proximal PSA promoter revealed the functional relevance of degenerate 
palindromic sequences with limited homology to the consensus ARE sequence and low AR 
binding affinity. Footprint or bandshift analysis with recombinant AR-DBD or the full length 
AR is an attractive experimental approach to identify candidate AREs, with either high or 
low AR binding affmity in the promoter or enhancer region of interest. However, functional 
activity of the candidate ARE can only be demonstrated by experiments in which multiple 
copies of the candidate ARE are shown to be sufficient to confer androgen regulated activity 
to a heterologous promoter and by mutational analysis of the candidate ARE. 
To make the situation even more complex, in addition to palindromic repeats with a 3 bp 
spacer, directly repeated half-sites have been shown to act as response element for steroid 
hormone receptors, although with several fold lower binding affinity and transactivation 
efficiency (Kato et a1. 1992 and 1995, Aumais et a1. 1996). In natural androgen-regulated 
genes, a functional role of directly repeated half-sites has been implicated in the androgen-
regulation of the crpl120 kDa protein gene (Ho et a1. 1993). A 39 bp fragment in the first 
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intron (N39) contains three ARE-like half-sites separated by 6 and 4 bp respectively. This 
fragment shows low AR-binding affinity and confers weak androgen responsivity to a 
heterologous promoter. In the upstream PSA enhancer region several ARE-like half-sites can 
be identified (see Chapter V), cooperativity of these half-sites with ARE-III cannot be 
excluded. However, until now no information about their functional relevance is available. 
A complex upstream enhancer region 
Inactivation of ARE-III, present in the centre of the 440 bp core of the upstream enhancer 
region, almost completely abolished enhancer activity, indicating its central role. Truncation 
of the 440 bp core enhancer region at either the 5' and 3' end resulted in partial reduction 
of androgen induced activity. The reduction in activity might be the result of deletion of 
binding sites for additional transcription factors. Additionally, the spacing between the 
upstream enhancer region and the proximal promoter might be a factor. The nature of the 
transcription factors, acting cooperatively with the AR in maximal androgen induced activity 
of the PSA core enhancer region has not been identified as yet. Although these factors might 
include ubiquitously expressed transcription factors, one or more should contribute to prostate 
specificity of the PSA promoter. Alternatively, a ubiquitously expressed transcription factor 
interacts with a prostate specific co-activator. 
The central role of ARE-III in activity of the upstream enhancer region raises the 
possibility that binding of AR to ARE-III changes the chromatin structure in this upstream 
region, thereby allowing additional transcription factors to bind to the DNA, possibly 
followed by removal of the AR. This mechanism of cooperativity has previously been 
proposed for GR activation of the proximal MMTV-LTR promoter, and in an upstream 
enhancer region of the tyrosine aminotransferase (TAT) gene. The proximal MMTV 
promoter contains a cluster of three degenerated HREs, and NF-l and Oct binding sites. All 
elements are required for optimal induction by steroid hormone receptors, as shown by 
mutational analysis (Cato et al. 1988). Functional studies indicated that the observed 
synergism between steroid hormone receptors and NF-l might be mediated by the 
organization of the DNA in chromatin (Briiggemeier et al. 1991). Binding of the activated 
steroid hormone receptor is supposed to cause a displacement or disruption of the nucleosome 
positioned over the proximal promoter region, thereby enabling free access of NF-l to its 
recognition sequence (reviewed by Beato & Sanchez-Pacheco 1996). In a complex liver 
specific and glucocorticoid regulated enhancer region, 2.5 Kb upstream of the TAT gene, 
functional cooperativity between multiple GREs and the liver enriched transcription factor 
HNF-3 has been observed (Rigaud et al. 1991, Nitsch et al. 1992, Roux et al. 1995). Results 
obtained by ill vivo footprinting experiments over this enhancer region suggested a hit-and-
run mechanism of transcriptional activation by GR (rugaud et al. 1991). Activated GR binds 
to the GRE, which partially overlaps with the binding site for HNF-3, and modifies the local 
chromatin structure. Subsequently, GR leaves the region accessible to HNF-3. Binding of 
both HNF-3 and GR to this site is mutually exclusive. At present it is unknown if such a 
mechanism is also responsible for the activation of the upstream PSA erutancer region. 
However, the presence of a strong androgen regulated DNaseI hypersensitive site in the 
centre of the upstream enhancer region is a strong indication for hormone-induced 
nucleosome removal or disruption (Elgin 1988). Kinetics of protein interactions, as 
determined by ill vivo footprinting is needed to determine whether or not AR binding to 
ARE-III induces chromatin remodelling, followed by binding of additional factors, and if so, 
whether AR is permanently or temporarily associated with the enhancer region. 
165 
Chapter VII 
Besides by remodelling of the chromatin structure by one factor, and subsequent binding 
of additional factors, synergistic activation between multiple transcription factors can be 
obtained by cooperative binding of transcription factors to adjacent DNA-binding sites 
(Ptasbne et aI. 1988, Tsai et aI. 1989, Baniahmad et aI. 1991, Briiggemeier et aI. 1991). 
Cooperative interaction of independently DNA binding transcription factors with a common 
co-activator should also be considered as a mechanism for synergistic activity (Ptashne 1988, 
Bradshaw et aI. 1991, Martinez et aI. 1991). 
As a first start to identify regulatory sequences, that in addition to ARE-Ill contribute to 
maximal androgen regulated and prostate-specific activity of this complex enhancer, ill vitro 
footprinting experinJents can be done using nuclear extracts from LNCaP and T47D cells, 
cultured in presence and absence of androgens and from a cell line in which the PSA 
promoter is inactive. Appropriate small fragments shown to be protected in footprints can 
be used in bandshifts to study in somewhat more detail the proteins binding to this region. 
Subsequently, these fragments can be deleted from the 440 bp enhancer region in reporter 
gene constructs, and activity of the resulting fragment can be compared with activity directed 
by the original fragment. Once regulatory elements involved in maximal enhancer activity 
are identified, the cloning and characterization of the transcription factor(s) binding to such 
an element can be initiated. 
Especially when the observed synergistic activation in the upstream core enhancer is 
attained by AR induced chromatin remodelling, it will not be easy to determine isolated 
regulatory elements, since every small change in distance between AR and the additional 
elements, or minor changes of sequences surrounding these regulatory elements can have an 
effect on enhancer activity. So, results obtained by rather radical deletion mapping need to 
be substantiated by experiments in which the region of interest is replaced by an inert 
unrelated sequence of comparable length and by subtle mutational analysis. 
AR target gene specificity 
The consensus sequence for high affinity binding of all steroid hormone receptors, 
excluding ER is identical, GGT/AACAunnTGTTCT. Despite the shared DNA-binding site, 
these receptors mediate diverse cellular responses. The common high affinity DNA-binding 
site raises the question of target gene specificity. if more than one receptor is expressed in 
one and the same cell. At present the picture emerges that several distinct molecular 
mechanisms may account for target gene specificity. including receptor expression level, 
receptor-DNA interaction, interaction of the receptor with other proteins, and ligand 
availability . 
AR specific regulation of PSA expression in LNCaP cells is caused by the absence of GR 
in these cells (Chapter IV). No indication of differential activity of AR and GR on the 
individual regulatory elements in the PSA promoter has been found. Transient co-transfection 
of proximal PSA promoter constructs and AR or GR expression plasmids revealed an 
approximately 2-fold higher Dex induced promoter activity (Chapter Ill). The 6 Kb promoter 
was also slightly less activated by the AR. AR seemed slightly more active on the 
endogenous PSA gene. A lack of receptor specificity in mediating PSA promoter activity was 
also observed for AR and PR in T47D cells. These data suggest that an AR specific co-
activator, or other AR specific protein-protein interactions are not essential for PSA promoter 
activity. 
In contrast to the stimulation of PSA expression by both AR and GR, cell proliferation 
could only be induced by R188I. This suggests that genes involved in cell proliferation are 
differentially regulated. In a Differential Display search with a limited number of primers one 
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novel mRNA was detected, that could be up-regulated by AR, but not by GR (Steketee, 
unpublished results). In case the observed difference on the mRNA level is a reflection of 
a difference of transcription initiation, further analysis of the regulation of expression of this 
gene might provide information about the mechanism of AR specificity. 
Recently, Claessens et ai. (1996) reported on a selective ARE sequence. AR and GR 
DBDs bind to most functional AREs in natural androgen regulated genes, including core II 
of the C3(l) gene, HRE-3 of the SIp gene, PSA ARE-I and the AREs present in the hGK-1 
and factor IX genes, with comparable affinity (Rundlett & Miesfeld 1995, Claessens et ai. 
1996). Furthermore both ARE-II and ARE-lII of the PSA gene were found to interact with 
both AR and GR DBD (Cleutjens et aI., unpublished results). However, ARE-2 
(AGTACTccaAGAACC) in the probasin promoter region selectively interacts with the AR-
DBD (Claessens et ai. 1996). A situation that was reflected in transient transfection 
experiments with an ARE-II driven reporter gene. The functional C3(1) ARE is not specific. 
Studies with probasinfC3(l) swapped half-sites indicated that the right half site (5'-
AGAACC-3' of probasin ARE-2 prevents GR-DBD binding. Comparison of the probasin 
ARE-2 sequence with all other known functional ARE sequences revealed that the AR 
specific binding affinity of probasin ARE-II can not be attributed to a single nucleotide. More 
detailed mutational experiments are needed to identify the mechanism determining the 
observed specificity of AR-DBD binding. 
LNCaP prostate cells 
The research on regulatory elements involved in androgen-regulated and prostate-specific 
expression of the PSA gene has benefitted from the availability of the LNCaP prostate cancer 
cell line, that endogenously expresses both AR and PSA (Horoszewicz et ai. 1983). Initially 
this cell line was not easy to transfect and it was a challenge to find the proper culture and 
transfection conditions. Once the initial problems were overcome, the LNCaP cell line made 
a very suitable model system. The LNCaP cell line harbors one unfavorable property, the 
AR gene in the LNCaP cell line contains a point mutation in the LBD which renders this 
receptor responsive not only to androgens but also to estrogens, progestins and several anti-
androgens (Veldscholte et ai. 1990). For comparison it is very important to have additional 
human prostate cells available, expressing both AR and PSA. Hopefully, the recently 
developed cell line PC346C can fulfil this requirement (Romijn, personal communication, 
Dubbink et ai. 1996). 
III vivo applicatiou of PSA regulatory regions 
The 6 Kb PSA promoter is the first human promoter, shown to direct prostate specific 
gene expression in transgenic mice. Out of the two rat promoters tested in transgenic mice 
for prostate specificity [C3(1), and probasin] (Allison et ai. 1989, Buttyan & Slawin 1993, 
Greenberg et a!. 1994), only the 426 bp rat probasin promoter fragment directed transgene 
expression almost exclusively to the prostate (Greenberg et ai. 1994). Transgene expression 
(ventral and dorsolateral prostate) did not strictly follow the expression pattern of the 
endogenous rat probasin gene, which is selectively expressed in dorsolateral prostate. This 
indicates that additional regulatory regions surrounding or present in the pro basin gene are 
needed for the tissue specific expression as observed for the endogenous gene. 
Because of its strict prostate specific activity in transgenic mice, it can be argued that the 
6 kb promoter contains most, if not all elements important for regulation of expression of the 
endogenous PSA gene in human tissues. These results strongly support the application of the 
PSA promoter in gene therapy of prostate cancer. Because the endogenous PSA gene is 
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expressed in the vast majority of prostate cancers, it is likely that all transcription factors and 
co-activators needed to drive a transgene PSA promoter are present. However, although 
difficult to judge, expression of the 6 Kb PSA promoter driven transgene in the mouse 
prostate did not look very high. Therefore, it might be beneficial to attempt to develop 
modified derivatives of the PSA promoter directing higher expression levels. To this end, the 
most important components directing prostate specific activity of the PSA promoter need to 
be determined. The 440 bp core enhancer seems a very attractive start point to identify such 
elements. Furthermore, since neither of the three ARE sequences in the PSA promoter is 
completely identical to the consensus sequence, substitution of these AREs by the consensus 
ARE might result in an even higher, prostate specific activity of the PSA promoter or PSA 
promoter derivatives. 
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SUMMARY 
In Western countries, adenocarcinoma of the prostate is the most frequently diagnosed 
tumor in men, and the second leading cause of male cancer death. Although early 
diagnosis, which can lead to successful surgical interference, is improving, a large 
proportion of patients presents with disseminated disease. Furthermore, a considerable 
number of surgically treated patients returns with metastases. First line therapy of locally 
invasive or metastatic disease is generally endocrine therapy. Unfortunately, the effects of 
this type of therapy are only temporary, and after a variable period of time, a then hormone 
refractory tumor continues to grow. 
In the present study transcription factors involved in the development, growth and 
differentiation of the prostate were studied. These factors might also play a role in the 
initiation and progression of prostate cancer. The main focus is on androgen regulated gene 
expression. It was previously shown that the presence of a functional androgen receptor 
(AR), a member of the steroid hormone receptor family, and the appropriate androgenic 
hormones are essential for the development and maintenance of the prostate. Chapter I 
gives an overview of the current knowledge of the steroid hormone receptor family. 
Furthermore, androgen regulated and prostate specific gene expression are discussed. 
To identify and characterize prostate specific transcription factors involved in growth and 
differentiation of the prostate, two complementary experimental approaches were followed. 
The first approach, a search for novel members of known families of transcription factors, 
resulted in the identification of the human C/EBPo gene. The C/EBPo gene was assigned to 
the pericentromeric region of chromosome 8. C1EBPo was found to be the major C/EBP 
family member expressed in LNCaP prostate cells, however, C/EBPo expression appeared 
not to be prostate specific (Chapter II). 
The second experimental approach focussed on the regulation of prostate specific antigen 
(PSA) expression, the main subject of this thesis. PSA is a member of the human kallikrein 
gene family, further members of this family are the human glandular kallikrein (hGK-l) 
gene and the tissue kallikrein gene, KLK-l. The three genes are clustered in all area of 60 
Kb on chromosome 19qI3.2-13.4. PSA is expressed at high level in the luminal epithelial 
cells of the prostate, and at very low levels in other tissues. Expression of PSA is androgen 
regulated, this regulation is at least partially at the level of transcription initiation. 
Chapter III reports the identification of two AR binding sites in the proximal PSA 
promoter, identified by means of bandshift analysis with recombinant AR protein. At 
position -170 a high affinity AR binding site, ARE-I (AGAACAgcaAGTGCT) was found 
to be present; ARE-II (GGATCAgggAGTCTC) at position -394, is a low affinity AR 
binding site. Functional activity of these candidate androgen response elements or AREs 
was shown by transient transfection experiments in PSA and AR positive LNCaP prostate 
tumor cells. The proximal PSA promoter, including ARE-I and ARE-II, is more active in 
LNCaP cells than in the PSA negative prostate cell lines DUl45 and PC3 cells and in 
severalnou prostate cell lines. In LNCaP cells cotransfected with a glucocorticoid receptor 
(GR) expression plasmid, the pattern of PSA promoter activity induced by dexamethasone 
turned out to be identical to AR mediated activity. 
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In order to directly compare the functional activity of the AR and the closely related GR 
in prostate cells, a GR expression vector was stably integrated in AR positive LNCaP cells 
(Chapter IV). Interestingly, both AR and GR were found to upregulate expression of the 
endogenous PSA gene, but they were different in their growth stimulating properties of 
LNCaP sublines. These cell lines provide a novel system for comparison of AR and GR 
molecular and biological functions. 
Its relatively low activity suggested that the proximal PSA promoter is not sufficient to 
account completely for androgen regulation of the endogenous PSA gene. In order to detect 
additional, more distal control elements, DNaseI hypersensitive sites (DHSs) upstream of 
the PSA gene were mapped in chromatin from the prostate derived cell line LNCaP, grown 
in the presence and absence of the synthetic androgen R188!. In a region 3.8 to 4.8 Kb 
upstream of the transcription start site of the PSA gene, a cluster of three DHSs was 
detected. The middle DHS (DHSII, at approximately -4.2 Kb) showed strong androgen 
responsiveness in LNCaP chromatin, and was absent in chromatin from HeLa cells. Further 
analysis of the region encompassing DHSII provided evidence for the presence of a 
complex, androgen responsive and cell specific enhancer. In transiently transfected LNCaP 
cells, PSA promoter constructs containing this upstream enhancer region showed 
approximately 3000-fold higher activity in the presence than in the absence of R188!. The 
core region of the enhancer could be mapped within a 440 bp fragment. The enhancer 
showed synergistic cooperation with the proximal PSA promoter, and was found to be 
composed of at least three separate regulatory regions. In the center, a functionally active, 
high affinity AR binding site was identified (ARE-III: GGAACAtatTGTATC at position 
-4.2 Kb). Mutation of this element almost completely abolished PSA promoter activity. To 
study whether the activity of the upstream core enhancer showed cell specificity, luciferase 
(LUC) reporter gene constructs were co-transfected with an AR expression plasmid to a 
series of AR negative prostate and non-prostate cell lines. Transient transfection 
experiments in (PSA negative) PC3, DU145, Hep3B and COS cells did not reveal any 
activity of the PSA upstream core enhancer, although PC3 and DUI45 cell lines originate 
from the prostate. In addition to LNCaP cells, the PSA promoter is only active in T47D 
mannllary tumor cells. However, the androgen induced activity of the PSA promoter in 
T47D cell is much lower than the activity in LNCaP cells. In T47D cells, the PSA-LUC 
reporter gene activity could also be induced by the activated progesterone receptor, again 
indicating that the PSA promoter is not completely AR specific (Chapter V). 
Chapter VI describes the ill vivo characterization of the PSA promoter. A 6 Kb PSA 
promoter fragment, but not a proximal 632 bp PSA promoter fragment, was sufficient to 
direct prostate specific expression of the bacterial LacZ reporter gene in transgenic mice. 
For both constructs three transgenic strains were generated. Integration was assayed by 
PCR analysis on tail DNA, and confirmed and quantitated by Southern blotting. LacZ 
expression was tested by RT-PCR, ill situ hybridization, and p-galactosidase assay on 
whole tissues and tissue sections. First of all, lysates were prepared from 26 different 
tissues, and tested for p-galactosidase activity in a solution assay. In none of the mouse 
strains with the proximal (632 bpi PSA construct activity of the reporter gene could be 
detected. In contrast, all three strains with integration of the 6 Kb PSA promoter-LacZ 
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fragment showed expression of the trans gene, which was completely prostate specific. The 
level of expression was comparable in all three transgenic strains, and independent of the 
number of integrated copies. Expression was absent in salivary glands, where many 
members of the mouse kallikreins are expressed at a high level, and in male and female 
mammary cells. Out of the different prostate lobes, reporter gene expression was 
exclusively found in the lateral prostate. Whole mount X-gal assay, followed by 
examination of staining in tissue sections, and ill situ hybridization with a specific probe 
showed exclusive expression of the reporter gene in the luminal epithelial cells, like the 
endogenous PSA gene in the human prostate. The p-galactosidase assays could be 
confirmed by RT-PCR with reporter gene specific primers. Transgene expression was 
undetectable until 8 weeks after birth. Castration of transgenic mice rapidly led to down-
regulation of p-galactosidase expression, which could be restored within 40 h by 
dihydrotestosterone supplementation. Both the developmental expression pattern and the 
hormone manipulation experiment indicated androgen regulation of the trans gene, as found 
in human LNCaP cells. The results obtained strongly indicate prostate specificity of the 6 
Kb PSA promoter in normal cells, and suggest that the 6 Kb promoter contains most, if not 
all elements important for regulation of expression of the endogenous PSA gene in human 
tissues. The strict prostate specificity of the 6 Kb PSA promoter fragment strongly supports 
its applicability in gene therapy of human prostate cancer. Furthermore, this fragment can 
be employed to direct oncogene expression to the prostate, to generate new mouse prostate 
cancer models. 
The results as described in the previous chapters are reviewed in the light of recent 
literature data in Chapter VII. Additionally, future directions for research are proposed in 
this chapter. 
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SAMENVATTING 
Adenocarcinoom van de prostaat is de rueest voorkomende tumor bij manneD in westerse 
landen, en de op een na meest frequente oorzaak van kankersterfte. Ondauks de mogeJijkbeden 
tot vroege diagnose, met meer kans op succesvol chirurgisch ingrijpen, zijn er veel patienten 
waarbij de ziekte reeds is uitgezaaid op het moment van diagnose. Daarnaast worden bij een 
substantieel deel van de patienten die chirurgisch behandeld werden, na verloop van djd toch 
metastasen waargenomen. Op dit moment is endocriene therapie de meest loegepaste 
behandeling bij gemetastaseerd prostaat-carcinoom. Helaas is het effect van deze vorm van 
therapie slechls tijdelijk, en na verloop van tijd groeit er een dan hormoon onafuankelijke 
tumor verder. 
Het in dit proefschrift beschreven onderzoek richt zich op de identificatie van 
transcriptiefactoren die betrokken zijn bij de ontwikkeling, groei en differentiatie van de 
prostaat. Deze factoren spelen mogelijk ook een rol bij het ontstaan en de progressieve groei 
van prostaattumoren. Uit eerder onderzoek is reeds bekend dat de androgeenreceptor (AR) , 
een lid van de familie van steroidhormoonreceptoren en bepaalde androgenen onmisbaar zijn 
voor de ontwikkeling en het instandhouden van de prostaat. In Hoofdstuk I wordt een overzicht 
gegeven van de huidige kennis van de familie van steroidhormoomeceptoren en met name van 
de structuur, de interactie met andere transcriptiefactoren en co-activatoren, en alternatieve 
mogelijkbeden van activatie van de receptor. Daarnaast worden een aantal aspecten van 
androgeen gereguleerde en prostaatspecifieke genexpressie behandeld. 
Twee complementaire strategieen werden gevolgd in de poging om prostaatspecifieke 
transcriptiefactoren te identificeren. De eerste aanpak, die onderzoek naar een nieuw, prastaat 
specifiek lid van een bekende familie van transcriptiefactoren behelst, resulteerde in de 
identificatie en karakterisering van het humane C/EBPI\ gen. Het gen werd gelokaliseerd nabij 
het centromeer van chromosoom 8. CIEBPI\ is het lid van de familie van C/EBP genen dat het 
hoogst tot expressie komt in LNCaP prostaatcellen. Helaas bleek C/EBPI\ expressie niet 
prostaat specifiek (Hoofdstuk In. 
De tweede experimentele benadering richlle zich op onderzoek naar de regulatie van de 
expressie van prostaalspecifiek anligeen (PSA), het hoofdlhema van dit proefschrift. PSA is 
een lid van de familie van humane kallikreine genen. Andere leden van deze fanlilie zijn het 
hGK-I gen en hel KLK-I gen. Deze drie humane kallikreine genen liggen gec1usterd in een 
gebied van 60 Kb op chromosoom 19q13.2-13.4. PSA komt haag tot expressie in de luminale 
epitheliale cellen van de proslaat. De expressie is laag of at\vezig in andere weefsels. Het 
expressieniveau van PSA wordl gereguleerd door androgenen, en deze regulatie vind op zijn 
minst gedeeUelijk plaals op het niveau van Iranscriptie. 
Hoofdstuk III beschrijft de idenlificatie van Iwee AR bindingsplaalsen in de proximale 
promotor van het PSA gen mbv bandshift analyse mel recombinant AR eiwit. Op posilie -170 
bevindl zich een bindingsplaals met hoge affinileil voor de AR, ARE-I 
(AGAACAgcaAGTGCT); ARE-II (GGATCAgggAGTCTC) op posilie -394, is een 
bindingsplaats mel een lage afftnileit. De functionele aClivileil van deze kandidaat androgeen-
responsieve elementen of AREs werd bewezen mbv transiente transfectie-experimenten in 
PSA- en AR-positieve LNCaP proslaat lumorcellen. Het proximale PSA promotor gebied, 
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inclusief ARE-I en ARE-II, is actiever in LNCaP cellen dan in de PSA negatieve prostaat 
cellijnen DUI45 en PC3 en in een aantal niet-prostaat cemjnen. In LNCaP cellen transient 
gecotransfecteerd met een glucocorticoid receptor (GR) expressieplasmide, is het patroon van 
dexamethason gelnduceerde activiteit van de PSA promotor gelijk aan de activiteit tot stand 
gebracht door de geactiveerde AR. 
Om de eigenschappen van de AR en de GR meer direct met elkaar te kunnen vergelijken 
werden, dmv stabiele integratie van een GR expressie plasmide, LNCaP sUblijnen gegenereerd, 
die niet aileen de AR maar ook GR constitotief tot expressie brengen (Hoofdstuk IV). Zowel 
de AR als de GR bleek in staat de expressie van het endogene PSA gen te induceren, maar er 
bleek een verschi! in hun groeistimulerende effect op LNCaP sUblijnen. Deze cemjnen vormen 
een nieuw bruikbaar systeem voor de vergelijking van de moleculaire en biologische functies 
van de AR en de GR. 
De relatief lage activiteit van de proximale PSA promotor suggereerde dat niet aile 
informatie die nodig is voor de androgeen gereguleerde expressie van het endogene PSA gen 
hierin aanwezig is. Om additionele, meer distaal gelegen regulerende gebieden te identificeren 
is gezocht naar DNase I hypergevoelige gebieden (DHS) in de chromatinestructour voor het 
endogene PSA gen in de LNCaP cemjn, gekweekt met en zonder het synthetische androgeen 
R1881. In een gebied 3,8 tot 4,8 Kb voor de transcriptiestartplaats van het PSA gen, werd een 
cluster van drie DHS gevonden. De middelste DHS (DHSII, op ongeveer - 4,2 Kb) laat sterke 
gevoeligheid voor androgenen zien in LNCaP cell en, terwijl deze DHS niet aantoonbaar is in 
chromatine van HeLa cellen. Verdere analyse van het gebied rond DHSII gaf aanwijzingen 
voor de aanwezigheid van een complexe, androgeengevoelige en celspecifieke "enhancer". In 
transient getransfecteerde LNCaP cellen zijn PSA promotorconstructen die dit gebied omvatten 
ongeveer 3000 maal meer actief in de aanwezigheid dan in de afwezigheid van R1881. De kern 
van dit "enhancer tl gebied wordt gevormd door een 440 bp fragment. De !lkern-enhancer" 
werkt synergistisch samen met de proximate PSA promotor en bestaat uit tenminste drie 
afzonderlijke regulerende elementen. In het centrum werd een functioneel actieve 
bindingsplaats met sterke affmiteit voor de AR gevonden (ARE-III: GGAACAtatTGTATC op 
positie -4.2 Kb). Mutatie van dit element verhinderde bijna volledig de activiteit van de PSA 
promotor. Om mogelijk prostaatspecifieke activiteit van de Ilieuwe enhancer te onderzoeken 
werden een aantal AR negatieve prostaat en niet-prostaat afgeleide cemjnen gecotransfecteerd 
met reportergen constructen en een AR expressieplasmide. Transiente transfectie in (PSA 
negatieve) PC3, DUI45, Hep3B en COS cellen vertoonde geen activiteit van de PSA "kern-
enhancer". De PSA promotor bleek naast in LNCaP cellen aIleen in T47D borst tumorcellen 
actief te zijn. De door androgenen gelnduceerde activiteit van de PSA promotor in T47D cellen 
is echter veellager dan in LNCaP cellen. In T47D cellen kan de activiteit van het PSA-LUC 
reportergen ook gelnduceerd worden door de geactiveerde progesteronreceptor, een nieuwe 
indicatie dat de PSA promotor niet geheel AR specifiek is. 
Hoofdstok VI beschrijft de ill vivo analyse van de PSA promotor. Een 6 Kb, maar niet het 
proximale 632 bp fragment van de PSA promotor bleek prostaat specifieke expressie van het 
bacteriele LacZ reportergen in transgene muizen te kunnen induceren. Voor beide constructen 
werden drie onafhankelijke transgene lijnen ontwikkeld. Integratie van het transgen werd 
bepaald dmv PCR op DNA gelsoleerd uit de staart, en bevestigd en gekwantificeerd dmv 
178 
Samenvatting 
Southern blot analyse. LacZ expressie werd bestudeerd dmv RT -PCR, ill situ hybridizatie, en 
een p-galactosidase test op weefsels en coupes. Als eerste werd van 26 weefsels Iysaat gemaakt 
en vervolgens werd de p-galactosidase-activiteit in deze Iysaten bepaald. In geen van de 
transgene muizen met het proximale (632 bp) PSA construct kon LacZ activiteit worden 
aangetoond. Daarentegen kon in aUe transgene lijllen met integratie van het 6 Kb PSA 
promotor-LacZ fragment expressie van het transgellworden aangetoond. Deze expressie bleek 
specifiek voor de prostaat. Het expressieniveau was vergelijkbaar in aile drie de transgene 
lijnen en was onafhankelijk van het aantal geintegreerde kopieell van het transgen. Expressie 
van het transgen was afwezig in de speekselklier, een orgaan waar vee! leden van de muize 
kallikreine familie hoog tot expressie komen. Ook in mannelijke en vrouwelijke borstklier 
cellen kon geen transgen expressie worden aangetoond. Expressie van het reportergen bleek 
aileen aantoonbaar in de laterale prostaat, een van de vier lob ben van de muize prostaat. De 
resultaten konden worden bevestigd dmv RT -PCR met primers specifiek voor het transgen 
eDNA. X-gal kleuring van de hele prostaat, gevolgd door analyse van weefselcoupes, en 
daarnaast in situ hybridizatie toonden exclusieve expressie van het reportergen in de lumillale 
epithelilale ceUen aan, identiek aan expressie van het endogene PSA gen in de humane 
prostaat. Expressie van het transgen kon niet worden aangetoond in muizen jonger dan 8 
weken. Castratie van transgene muizen had een sterke afuame van p-galactosidase activiteit tot 
gevolg, welke hersteld kon worden door toediening van dihydrotestosteron gedurende 40 UUf. 
Zowel het patroon van transgen expressie tijdens de ontwikkeling, alsmede het castratie-
experiment duiden op een regulering door androgenen regulering van het transgen, zoals ook 
gevonden voor het endogene PSA gen. De verkregen resultaten laten duidelijk de prostaat 
specifieke activiteit van de 6 Kb PSA promotor in normale cellen zien, en suggereren dat de 
6 Kb promotor de meeste, zo niet aUe elementen bevat, die nodig zijn voor de regulering van 
expressie van het endogene PSA gen in humane weefsels. De strikte prostaat specificiteit van 
de 6 Kb promotor is een sterke aanwijzing dat dit grote promotor fragment, of afgeleiden 
ervan, toegepast kunnen worden in gentherapie voor humaan prostaatkanker. Daarnaast kan 
dit fragment gebruikt worden voor de expressie van specifieke oncogenen bij de ontwikkeling 
van nieuwe muize modellen voor prostaatkanker (Hoofdstuk VI). 
In het afsluitende Hoofdstuk VII worden de resultaten die beschreven zijn in de voorafgaande 
hoofdstukken besproken in het licht van recente literatuurgegevens. Tevens worden in dit 
hoofdstuk de mogelijkheden voor toekomstig onderzoek beschreven. 
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